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CHAPTER 1
SYNTHESIS OF FUNCTIONALIZED GPI ANCHORS
1.1 Introduction
The anchoring of membrane proteins and glycoproteins to the cell surface by
glycosylphosphatidylinositol (GPI) anchors, a structurally diverse class of complex
glycolipids, is ubiquitous among eukaryotic species.1 The discovery of this membraneprotein binding mechanism – a surprising alternative to the classic Singer-Nicolson
model2 – spanned the 1970s and 1980s, and culminated in the full characterization of
the Trypanosoma brucei variant surface glycoprotein (VSG) GPI anchor in 1988 by
Ferguson and co-workers.3 Over the ensuing two decades, more than 30 unique GPIs
were identified, which can be categorized into two classes. One class consists of nonprotein-anchoring GPIs that are often found in protozoan parasites and contain the core
structure 1.1 (Figure 1.1): Manα1→4GlcNH2α1→6-myo-inositol-1-OPO3-lipid.4-5 The
other class, which this dissertation will focus on, is comprised of protein-anchoring GPIs
in mammals and other lower eukaryotes, which exhibit the core structure 1.2: NH2EtOPO3-6Manα1→2Manα1→6Manα1→4GlcNH2α1→6-myo-inositol-1-OPO3-lipid.1,6-7

Figure 1.1. Core structures of GPIs

2
The primary function of GPI anchors of type 1.2 is to localize extracellular
molecules, namely membrane proteins/glycoproteins, to the cell surface. This process
involves covalent attachment of the protein C-terminus to the phosphoethanolamine unit
at the non-reducing end of the GPI and insertion of the phosphatidylinositol lipid chains
into cell membrane, thereby creating a “molecular bridge” between the protein and
membrane.3 Other biological processes that GPIs have been implicated in include cell
recognition and adhesion,8 signal transduction,9-10 pathogenic infections,11 and
involvement in enzymatic reactions on the cell surface.12 GPI-anchored proteins and
glycoproteins are also functionally diverse, ranging from enzymes such as alkaline
phosphatase (APase) and acetylcholinesterase (AChE) to cellular markers such as the
human CD14 and CD52 antigens.13 To date, more than 250 eukaryotic membrane
proteins have been established as GPI-anchored,13-14 a number that will certainly
continue to grow considering that a recent study estimated that 0.5–1% of proteins
encoded in the eukaryotic genome are anchored to the cell surface by GPIs.15
Despite significant advances in understanding the biosynthesis, structure, and
function of GPI anchors, many aspects of these molecules remain a mystery. For
example, the anchoring of membrane proteins could seemingly be accomplished by
simpler covalent lipid modifications; the considerable structural complexity of GPIs is
suggestive of additional biological responsibilities beyond providing a stable anchoring
system for proteins. While evidence for some ancillary GPI functions exists, additional
biological studies are required to better understand the various roles of GPIs on the cell
surface. In addition, the correlations between specific structural features/diversity of
GPIs and function are essentially unknown. Answering these questions necessitates

3
structure-activity relationship (SAR) studies aimed at probing the significance of GPI
structural features, such as type of sugar unit, stereo- and regiochemistry of glycosidic
bonds, lipid modifications, and additional sugar branching or phosphoethanolamine
units. Furthermore, the scope of GPI anchoring has not been rigorously studied. To
investigate all of these issues, it is necessary to have access to homogeneous and
structurally well-defined GPIs, GPI analogs, and functionalized GPIs. However, due to
the issues of structural microheterogeneity and the natural scarcity of these molecules,
it is nearly impossible to obtain sufficient quantities of GPIs from natural sources,
making the study of GPI anchorage quite difficult. To address this problem, chemical
synthesis, although challenging and time-consuming, has become the primary means
for obtaining pure samples of GPIs. While several complex GPI structures have been
synthesized, the development of new synthetic methodologies is necessary for the
preparation of uniquely functionalized GPIs aimed at studying various aspects of the
GPI anchoring process.
The remainder of the introduction will serve as a review of various aspects of GPI
anchors. The first section will provide a historical perspective on GPI anchors, including
the key studies that led to their discovery. The structural properties of GPIs will then be
discussed, including the first characterization of a GPI by Ferguson and subsequent
identification of various structurally diverse GPIs. Next, GPI anchors will be evaluated in
a purely biological context. These sections will survey GPI biosynthesis and function.
Finally, the state-of-the-art in GPI chemical synthesis will be reviewed prior to a full
report of the synthetic studies conducted for this dissertation.
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1.1.1 Discovery of GPI Anchors
The lipid bilayer of the cell membrane functions as a permeability barrier that
prevents the free extracellular/cytoplasmic exchange of water-soluble molecules, such
as ions and proteins. Nearly all biological processes that occur on the cell surface
involve membrane proteins, which function by associating with the lipid bilayer and
facilitating signal transmission, metabolite transportation, and other vital cellular
activities. Early on, protein–membrane binding was primarily attributed to the insertion
of hydrophobic protein domains into the lipid bilayer,2 and little credence was afforded to
the notion that a covalently linked lipid moiety could be solely responsible for the
anchoring of proteins to the membrane. However, evidence for the latter anchoring
mechanism accumulated rapidly in the 1970s and 1980s, when various lipid-modified
prokaryotic and eukaryotic proteins were characterized.16 For example, protein Spalmitoylation17 (addition of a C16 fatty acid) and N-myristoylation18 (addition of a C14
fatty acid) are modifications of cysteine and N-terminal glycine residues, respectively,
that can contribute to protein-membrane binding. Another type of membrane-anchoring
protein lipidation that was identified during this time was the covalent attachment of
complex glycosylated phospholipids, later designated GPI anchors, to the C-terminus
carboxyl group of various membrane proteins, a discovery that was “most unusual and
unexpected.”16
The concept of membrane protein anchoring by phosphatidylinositol (PI) was
independently cultivated by Low19-21 and Ikezawa22-23 in the late 1970s. Their work
centered on the ability of a class of PI-cleaving bacterial phospholipases, termed
phosphatidylinositol-specific phospholipases C (PI PLC), to release the membrane-
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bound enzyme APase from various tissues. Actually, PI PLC were first shown to release
APase from Bacillus anthracis toxins in the early 1960s,24-27 but the significance of
these results was overlooked until Low, Ikezawa, and others extensively studied purified
PI PLC and found that they released a variety of membrane proteins, also including 5’nucleotidase and AChE.28 These observations led to the conclusion that certain proteins
were covalently linked to PI, a property that enabled membrane binding by insertion of
the PI lipid chains. Furthermore, the release of a protein by PI PLC could be used as a
convincing marker that PI was involved in membrane anchoring, although the converse
was not necessarily true, as some PI-anchored proteins were later shown to be
resistant to PI PLC cleavage.28
The nature of the protein-PI linkage remained unclear for several years, but was
unraveled from 1980-1985 as a result of characterization data accumulated for a
number of PI-anchored proteins. Studies on Torpedo electric organ AChE,29 human
erythrocyte AChE,30 rat brain and thymocyte Thy-1,31-32 and T. brucei VSG33-36
demonstrated that for all of these PI-PLC-positive membrane proteins, a glycosylated
phosphatidylinositol structure was attached to the C-terminus amino acid via a
phosphoethanolamine unit. Structural data obtained from these experiments confirmed
the presence of various fragments of the GPI structure, including myo-inositol,
phosphate, ethanolamine, and an oligosaccharide composed of glucosamine and
mannose. Although the precise structure of a GPI anchor had not yet been determined,
a consensus for the general structure and distribution of GPI anchors materialized in
1985.14
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1.1.2 Structure of GPI Anchors
The first fully characterized GPI anchor was that of the T. brucei VSG, achieved
in 1988 by Ferguson and co-workers using a combination of NMR spectroscopy, MS,
chemical modification, and exoglycosidase digestion.3 Since then, more than 30
different GPI anchors derived from various eukaryotic cells and species have been
identified.1,6 To date, all GPI anchors contain the conserved core described by structure
1.2

(Figure

1.1):

NH2EtO-PO3-6Manα1→2Manα1→6Manα1→4GlcNH2α1→6-myo-

inositol-1-OPO3-lipid.
The phosphoethanolamine-protein bridge exists in the form of an amide bond that
links the GPI anchor to the C-terminal amino acid carboxyl group. This connection was
confirmed by testing for dansylation of the ethanolamine NH2-group during Edman
degradation, which only occurred after removal of the protein’s C-terminal amino acid.33
The presence of non-acetylated glucosamine, which is present in all GPIs but rarely in
other eukaryotic glycoconjugates, was identified by its unique propensity to undergo
deamination by nitrous acid.36 This reaction also released PI and inositol phosphate,
which was evidence for the glucosamine-inositol linkage.3 Moreover, 1H NMR studies
showed that the glucosamine-inositol glycosidic bond was located at the inositol 6-Oposition and exhibited α stereochemistry. The remainder of the conserved glycan portion
was determined to be a linear trimannose, also bearing α-configured anomeric centers.
The phosphatidylinositol group is composed of D-myo-inositol derivatized at the 1-Oposition with a phosphoglycerolipid backbone containing an sn-1,2-dilipid-3-phosphate
stereochemical configuration. These assignments were aided by the action of enzymes
that hydrolyze these specific moieties.35,37
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GPI anchors exhibit a high degree of structural diversity, as summarized for
various GPIs in Table 1.1 (adapted from Bertozzi13 and Ikezawa38). The tetrasaccharide
core can contain additional carbohydrate chains and phosphoethanolamine groups. The
trimannose segment commonly exhibits additional carbohydrate branching at the Man-III
2-O-position and Man-I 3- and 4-O-positions. The former location typically is decorated
with additional mannose residues in the form of a Manα1→2 linkage, while the latter two
locations may contain a variety of sugars, including galactose, galactosamine, and sialic
acid in the form of monosaccharides or oligosaccharides. The core glucosamine residue
is rarely modified, but has been observed to carry a unique 2-aminoethylphosphonate
group (similar to a phosphoethanolamine group but bearing a P-C bond) at the 6-Oposition

in

the

Trypanosoma

cruzi

NETNES

GPI

anchor.

Additional

phosphoethanolamine side chains are also found frequently at the Man-I 2-O-position
and Man-II 6-O-position in higher eukaryotes. There is also wide variation in the
composition of the lipid chains, which may be linked to the glycerol moiety via an ether or
ester bond or contain unsaturation. The presence of unsaturation in the lipid chains of
GPIs may have a pronounced impact on biological function. A recent study by Ferguson
on highly purified T. cruzi GPI anchors indicated that their potent proinflammatory activity
is dependent on unsaturated fatty acids, rather than saturated fatty acids, at the sn-2
position of the glycerolipid.39 This finding demonstrates the importance of synthesis and
SAR studies aimed at evaluating the importance of structural diversity among GPI
anchors.
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1.1.3 Biosynthesis of GPIs and Their Attachment to Proteins
The highly conserved core structure of GPI anchors (1.2) described in section
1.1.2 is shared among a wide range of species. This fact suggests that a generally
conserved GPI biosynthetic pathway exists in nature.6,40 Studies on the parasitic
trypanosomes, which express large amounts of isolable GPIs, provided the first
information regarding GPI biosynthesis. Trypanosome membranes were incubated with
radiolabeled uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) and guanosine
diphosphate-mannose (GDP-Man), which allowed GPI biosynthetic intermediates to be
observed, thus elucidating the biosynthetic pathway.41-42 Subsequent studies on
mammal and yeast GPIs confirmed the features of this process that were conserved or
species-specific.
As outlined in Figure 1.2, GPI biosynthesis starts with the transfer of a GlcNAc
residue from UDP-GlcNAc to PI to form GlcNAc-PI on the cytoplasmic surface of the
endoplasmic reticulum (ER), which is followed by de-N-acetylation of GlcNAc and then
addition of a palmitoyl group to the inositol 2-O-position.6 Inositol 2-O-palmitoylation
depends on and is stimulated by the presence of acyl coenzyme A (acyl-CoA).43
However, the attachment of a palmitoyl group is not necessary for subsequent
biosynthetic steps. For example, GPI biosynthesis in the bloodstream form of T. brucei
does not require inositol acylation.44 Thereafter, the biosynthetic intermediate is
translocated to the lumen side of the ER, where the first mannose (Man-I) is added to
glucosamine by GPI mannosyltransferase I (PIG-M), with dolicholphosphomannose
(Dol-P-Man) as the mannosyl donor. Subsequently, the second and third mannoses
(Man-II and Man-III) are sequentially added by GPI mannosyltransferases II (PIG-V)
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and III (PIG-B), respectively.

In some cases, after Man-II is attached, a

phosphoethanolamine moiety is added to the 2-O-position of Man-I.7

It was also

observed in T. brucei that the inositol residue can be deacylated and re-acylated once
the first mannose is added,44-45 suggesting that inositol palmitoylation is reversible.46
For most GPIs, the last biosynthetic step is the addition of a phosphoethanolamine unit
to the Man-III 6-O-position with phosphatidylethanolamine as the donor, though
sometimes additional carbohydrate chains and/or phosphoethanolamine moieties may
be added to the core glycan at this stage as well.7 Once a phosphoethanolamine unit is
added to the 6-O-position of Man-III, the GPI anchor may undergo attachment to target
proteins.

Figure 1.2. An outline of GPI biosynthesis

The attachment of GPIs to proteins also takes place in the ER lumen through a
process known as GPI transamidation (Figure 1.3),47-49 which is catalyzed by a multisubunit transmembrane enzyme called GPI transamidase.

Both the GPIs and the

proteins destined for GPI attachment are anchored to the ER membrane, with the latter
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being anchored via a hydrophobic peptide sequence at the C-terminus. This sequence
is also the GPI attachment signal that is responsible for regulating GPI transamidation50
and is essential for the target proteins to be recognized and coupled to GPIs by GPI
transamidase.

Though the GPI attachment signal is required for nascent proteins

destined for GPI addition, its exact sequence can vary in different proteins.51-54 During
GPI transamidation, the C-terminal signal peptide is deleted and substituted by a GPI,
thus GPIs are always linked to the polypeptide C-terminus.50 The proteins to be GPIlinked contain another signal peptide located at the N-terminus, which directs nascent
proteins to the ER but is not deleted during the transamidation process.50 After GPIs are
attached to proteins, the palmitoyl group at the inositol 2-O-position is usually removed55
for the purpose of quality control of GPI-linked proteins. This process may also facilitate
the transportation of GPI-linked proteins from the ER to the Golgi apparatus.56 However,
it is observed that some GPI-anchored proteins may retain the palmitoyl group on the
inositol residue, as observed with the GPI anchors of procyclic acidic repetitive protein
(PARP) of T. brucei, the human CD52 antigen, and human AChE.57-66 After the GPIlinked proteins are transported to the Golgi, GPIs may be further modified through a socalled “fatty acid remodeling” process,67-69 the details of which are not well established.
Finally, the GPI-anchored proteins are delivered onto the cell surface via the trans-Golgi
network.
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Figure 1.3. Attachment of proteins to mature GPIs to form GPI-anchored proteins

1.1.4 Biological Functions of GPI Anchors
As discussed, the primary role of GPIs is to provide a stable membrane
anchoring device for cell surface proteins and glycoproteins.1 Despite this apparent
function, the questions of why certain proteins are GPI-anchored and why GPIs exhibit
such a complex structure remain largely unanswered. Investigation of the various
biological roles of GPIs on the cell surface has led to a better – although still murky –
understanding of the significance of GPI anchoring and GPI structure.
Some unique properties of GPIs can be particularly useful for the functioning of
GPI-anchored proteins and glycoproteins. For example, GPIs are thought to associate
with lipid rafts, which are membrane microdomains that contain high concentrations of
glycosphingolipids, cholesterol, and other lipidated biomolecules. Lipid rafts are
relatively small and discrete domains where various processes such as vesicle
transportation and signal transduction may occur.13 It is hypothesized that the presence
of GPIs in lipid rafts may help the sorting and localization of some GPI-anchored
proteins.70-71 For instance, GPI-linked proteins are selectively delivered onto the apical
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surface in polarized mammalian cells.72 In addition, the lateral mobility of GPIs in cell
membranes and the clustered existence of GPI-linked proteins in lipid rafts can facilitate
reactions on the cell surface. For example, many bacterial toxins use GPIs or GPIanchored proteins/glycoproteins on the host cell surface to assist their aggregation and
subsequent formation of porous oligomers that automatically insert into the cell
membrane to kill the host cell.73-74 Furthermore, GPIs and GPI-anchored molecules can
be released relatively easily from the cell membrane, which can facilitate their shedding,
shuffling, and turnover processes. This release process, mediated by endogenous PI
PLC that cleave the lipid moiety of the GPI, has been suggested as a mechanism for
the selective regulation of GPI-anchored proteins.75-76 Finally, GPI anchors may have an
impact on the structure of the proteins to which they are attached. A variety of studies,
including circular dichroism (CD), 2D NMR spectroscopy, molecular modeling, and
Förster resonance energy transfer (FRET), have confirmed this hypothesis, although
the effects of GPI-induced structural/conformational changes are unclear.77-80
GPIs have been implicated in a number of other biological processes as well.
The involvement of GPI anchors in signal transduction between the cell exterior and
internal signaling molecules has been observed in some systems.13 Notably, the
enzyme-mediated release of water soluble inositol phosphoglycans (IPGs) from GPIanchored molecules can have inhibitory or stimulatory effects on various cellular
activities.81 In addition, GPI metabolites can serve as secondary messengers involved in
certain hormonal pathways,82 possibly including insulin mediation.83 Other processes
that GPI anchors may be involved in include cellular adhesion/recognition, bacterial
toxin binding, and prion disease pathogenesis.13 The involvement of GPI anchors in
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these proposed functions is controversial and requires additional studies, which would
benefit greatly from access to pure and structurally defined synthetic GPI derivatives.

1.1.5 Chemical Synthesis of GPI Anchors
Obtaining homogeneous GPI anchors for biological studies is a challenging task.
Like other natural glycoconjugates, each GPI anchor may be comprised of
heterogeneous glycoforms,84 a phenomenon known as microheterogeneity. This
heterogeneity can be further compounded by variations in the lipid chains, such as
differences in chain length and the presence of unsaturated bonds.1 The separation of
such naturally occurring complex GPI mixtures is practically impossible. Furthermore,
the low abundance of these molecules in most species prevents their isolation in
sufficient amounts. Thus, it is extremely difficult to obtain homogeneous GPIs and GPIanchored proteins or glycoproteins from living cells. Consequently, the chemical
synthesis of GPIs has drawn much attention from the synthetic community.
The first total synthesis of a GPI anchor, specifically a diastereomer of the
natural membrane GPI anchor of T. brucei, was completed by Murakata and Ogawa in
1991.85-86 Since then, numerous GPIs have been synthesized, including the GPIs of T.
brucei by Ley,87-88 rat brain Thy-1 by Fraser-Reid89-90 and Schmidt,91 S. cerevisiae and T.
gondii by Schmidt,92-94 P. falciparum by Fraser-Reid95 and Seeberger,96-97 human sperm
CD52 by Guo,98-100 and T. cruzi by Nikolaev.101 These syntheses and other reports on
the synthesis of partial/core structures of GPIs were covered in extensive reviews by
Gigg102 and Guo.103 In this section, general strategies for the synthesis of GPI anchors
and their components will be discussed.
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1.1.5.1 Retrosynthetic Analysis of GPIs
GPI synthesis involves several different areas of chemistry, including lipid,
phosphate, inositol, and carbohydrate chemistry. While this combination of chemistries
poses a considerable synthetic challenge, other issues complicate GPI synthesis as
well. For example, the preparation of suitably differentiated and enantiomerically pure or
enriched myo-inositol derivatives is difficult due to the presence of six secondary
hydroxyl groups and the meso-symmetric nature of the compound, respectively. In
addition, stereoselective assembly of the glycans and regioselective introduction of the
desired side chains requires careful planning. Furthermore, characterization of GPI
intermediates by NMR spectroscopy, particularly if they exist as isomeric mixtures, can
be difficult as well. These combined challenges render GPI synthesis a demanding task.
As described in section 1.1.3, nature uses an iterative biosynthetic process to
construct GPI anchors.7 Living systems use a series of glycosyltransferases to elongate
the PI-linked glycan in a linear fashion. In the context of chemical synthesis, a
convergent strategy offers a much more efficient and versatile approach. In terms of
efficiency, a linear strategy involves a large number of chemical manipulation steps on
valuable complex intermediates, whereas a convergent synthesis allows for a key
coupling of two fragments to produce a highly elaborated GPI intermediate. A
convergent approach also offers more flexibility in what types of fragments are used for
the key coupling reactions, which provides an opportunity for the preparation of small
libraries of related GPI derivatives for bioactivity studies. These advantages clearly
support the use of a convergent strategy, which has been used in preference to a
biomimetic approach in nearly all reported GPI syntheses.
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A typical GPI retrosynthetic analysis used by our group is shown in Scheme 1.1.
The first disconnection is often a phosphorylation reaction between fully protected GPIs
of type A and a phosphate precursor B that is used to install one or more
phosphoethanolamine units, including at the conserved Man-III 6-O-position and
sometimes at other positions. This is often chosen as the final functionalization step
because the stability of phosphate esters and their protecting groups (e.g., cyanoethoxy)
to a wide range of glycosylation and functional group manipulation conditions is not
guaranteed. Thus, the reaction conditions available for use with phosphates present can
be quite limited. In addition, the presence of phosphates can significantly alter physical
properties relating to solubility and separation. For instance, in the simplest case,
monophosphorylation of a GPI generates a 1:1 mixture of diastereomers originating at
the stereogenic phosphorus atom. These mixtures, which are often inseparable,
complicate

the

characterization

of

intermediates

by

NMR

spectroscopy,

phosphorylation reactions are usually left until the final stages of the synthesis.

Scheme 1.1. Typical retrosynthesis of GPI anchors

so
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In many GPI syntheses, structure A is prepared by a key glycosylation reaction
between trimannoside glycosyl donor C and pseudodisaccharide glycosyl acceptor D
(or derivatives thereof). This allows for a highly convergent synthesis that hinges on the
formation of an α-mannosidic bond, which is a favorable process. Trimannoside
fragment C, which is usually built using three suitably protected monomers, contains an
orthogonal protecting group at the Man-III 6-O-position for later phosphorylation. In
addition, any side chains present in the target GPI can be incorporated into the structure
of C. In our lab, pseudodisaccharide D is formed via sequential glucosaminylation and
phospholipidation of a differentially protected inositol derivative. Guo found that
installation of phospholipid E to inositol was best performed at this point in the synthesis
– rather than at a later stage – to enhance convergency and prevent an interesting but
debilitating cyclization reaction between the GPI azido group and the nascent
phosphite.99 However, most GPI syntheses reported to date have successfully used
late-stage phospholipidation of inositol on an advanced intermediate, so this is not
always a problem. Specific approaches to each of the building blocks in Scheme 1.1, as
well as strategies for their assembly, will be discussed in the following sections.

1.1.5.2 Synthesis of Differentially Protected and Optically Pure Inositols
myo-Inositol, commonly referred to as inositol in this text, is a meso-symmetric
cyclohexanehexol compound that widely occurs in nature in both free and derivatized
form. The incorporation of inositol building blocks in natural product synthesis is a
demanding prospect for two reasons. First, the selective functionalization of inositol
requires the differentiation of six secondary alcohols. Therefore, the regioselective
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protection and deprotection of inositol derivatives is a broadly studied area in bioorganic
chemistry. This topic was recently reviewed by Sureshan and Shashidhar.104 The
second challenging aspect of inositol synthesis lies in the symmetrical nature of the
molecule. Derivatization of any symmetrical position of inositol will produce chirality and
result in the formation of a racemic mixture (Figure 1.4). Given the ubiquity of inositol
derivatives in nature, many methods have been developed for the preparation of
optically pure or enriched inositols. These methods fall into three categories: (1)
conversion of naturally occurring inositol derivatives into the desired structures; (2)
chemical or enzymatic resolution of synthetic inositol racemates; (3) de novo synthesis
of inositol derivatives from chiral pool starting materials. This section will focus on
selected methods that address the preparation of building blocks commonly used in GPI
synthesis, namely 1,2-O- and 1,2,6-O-differentiated inositols.

Figure 1.4. Desymmetrization of myo-inositol by derivatization

A useful and common starting point for many reported GPI syntheses involves
the cyclohexylidenation of commercially available and inexpensive myo-inositol
(Scheme 1.2).105 This reaction produces an approximate 1:1:1 mixture of regioisomeric
diols 1.3, 1.4, and 1.5. The most GPI-relevant 1,6-O-differentiated product 1.5 can be
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isolated using sequential recrystallization and column chromatography. The eventual
resolution of racemate 1.5 has been achieved both chemically and enzymatically. The
former method involves derivatization with a temporary chiral resolving reagent, such as
(1S)-(-)-camphanic chloride, which produces a separable diastereomeric mixture. After
purification of the desired diastereomer, the chiral auxiliary is cleaved to afford an
enantiomerically pure inositol derivative. This method has been commonly used in the
synthesis of GPI anchors by several groups, including those of Fraser-Reid,90 Ley,88
Martin-Lomas,106 Ogawa,107 Schmidt,93 and others. The other strategy, developed by
Gou et al.,108 employed an enzymatic enantioselective resolution of (±)-1.5 (Scheme
1.2). After stannylene acetal-directed regioselective addition of a butanoyl group to the
inositol 6-O-position, the racemic product (±)-1.6 was subjected to porcine pancreas
lipase (PPL) digestion, which enantioselectively cleaved the ester bond. After
separation of enantiomerically enriched products (-)-1.7 and (-)-1.8 by column
chromatography, the latter was deacylated using NaOMe to give the desired enantiomer
(+)-1.7. We have employed both chemical and enzymatic resolution in this research
(see section 1.2.3). Because the 1-O- and 6-O-positions are already differentiated from
the remaining hydroxyl groups in (+)-1.7, it is an ideal substrate for the preparation of
1,6-O-differentiated inositols for GPI synthesis, particularly due to the ability of its 6-Oposition to undergo a highly regioselective stannylene acetal-directed allylation reaction,
which is shown in Scheme 1.3.
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Scheme 1.2. Enzymatic resolution of a 1,6-O-differentiated inositol racemate

The preparation of 1,2,6-O-differentiated inositols, which are required for the
synthesis of GPIs containing a palmitoyl group at the inositol 2-O-position, are more
difficult to prepare. Guo developed a strategy for the conversion of both enantiomers of
1.7 to the same 1,2,6-O-differentiated inositol 1.12,109 thus eliminating the major
disadvantage of enantiomeric resolutions by increasing the maximum theoretical yield
from 50% to 100% (Scheme 1.3). Route A commenced with a regioselective allylation of
(+)-1.7 to provide 6-O-allyl inositol 1.9, which then underwent para-methoxybenzylation
and acid catalyzed selective removal of the trans-cyclohexylidene ring. The resulting
diol 1.10 was then benzylated and treated with acid for a prolonged period to remove
the more stable cis-cyclohexylidene ring, resulting in diol 1.11. Finally, regioselective
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benzylation of the 3-O-position provided 1.12. Route B describes a similar pathway to
1.12 from the other enantiomer (-)-1.7, with analogous reactions in a different order.

Scheme 1.3. Synthesis of a 1,2,6-O-differentiated inositol derivative

De novo synthesis of inositol derivatives from chiral pool starting materials offers
an efficient alternative to chemical/enzymatic resolution, in which half of the material is
typically lost. Our lab has made extensive use of Fraser-Reid’s method for the
preparation of gram-scale amounts of benzyl-protected inositol derivatives from
commercially available methyl α-D-glucopyranoside (Scheme 1.4).110 This strategy
centers on an application of the Ferrier rearrangement, which was used to transform
enol acetate 1.17 to polyhydroxylated cyclohexanone 1.18. After a stereoselective
reduction of the ketone and deacetylation, product 1.20 can be converted into a number
of 1,2-O- or 1,2,6-O-differentiated inositol building blocks.
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Scheme 1.4. De novo synthesis of inositol derivatives from methyl glucopyranoside

The Bertozzi lab developed a de novo synthesis of highly discriminated inositols
starting from commercially available and optically pure tartrate derivative 1.21 (Scheme
1.5).111

Key

steps

for

this

strategy

included

various

substrate-controlled

diastereoselective reactions and a ring-closing metathesis step catalyzed by Grubbs’
catalyst. A final selective para-methoxybenzyl (PMB) ether cleavage provided 1,2,3,6O-differentiated inositol 1.27. This de novo method required only 8 steps and proceeded
in an impressive 25% overall yield.

Scheme 1.5. De novo synthesis of inositol derivatives from a tartrate derivative
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The procedures described above constitute a small sample of the available
methods104 for preparing discriminated inositol derivatives. However, these strategies
meet the demands of most GPI syntheses, which require 1,6-O- and 1,2,6-Odifferentiated inositol building blocks in optically pure form.

1.1.5.3 Synthesis of the Pseudodisaccharide Fragment
As outlined in the GPI retrosynthesis (Scheme 1.1), one of the key glycosylation
components used in our GPI syntheses is pseudodisaccharide D. Construction of this
intermediate (Scheme 1.6) requires the stepwise functionalization of a 1,6-Odifferentiated inositol building block. In our lab, α-glycosylation of the 6-O-position with a
glucosaminyl donor is followed by selective deprotection of the 1-O-position. Next, the
desired phospholipid is installed at this site, and then the glucosamine 4-O-position is
exposed to set up for the key glycosylation reaction. Alternatively, phospholipidation can
be performed after the key glycosylation, as in most reported GPI syntheses.

Scheme 1.6. General outline for the synthesis of pseudodisaccharide D

To generate the required α-glycosidic bond between a glucosaminyl donor and
an inositol acceptor, several factors, such as substrate structure, protecting group
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effects, and reaction conditions, must be considered. Of utmost importance for allowing,
and ideally magnifying, formation of the 1,2-cis configured α-product is the presence of
a non-participating N-protecting group at the glucosamine 2-position. Therefore,
commonly

employed

amine

protecting

groups

such

as

phthalimido

(Phth),

tetrachlorophthalimido (TCP), and various carbamates (i.e., Fmoc and Troc) cannot be
used. While non-participating N-protecting groups are limited, the azido group has
become the standard choice for GPI synthesis, as it satisfies the non-participating
requirement, is stable to a range of reaction conditions, is not sterically bulky, and can
be selectively removed under a variety of mild conditions. The preparations of different
1,4-O-differentiated glucosaminyl donors from a variety of starting materials, including
anhydromannose,112-113 D-glucal,109,114 glucosamine hydrochloride,115 and others116
have been achieved using a number of methods. Our lab typically relies on elaboration
of glucosamine hydrochloride to the desired building block, and we make use of Wong’s
copper-catalyzed diazo transfer reaction117 to install an azido group at the 2-position.
The glycosyl donor leaving group, activation conditions, solvent, and temperature
can also affect the stereochemical outcome of the reaction. Among the various
glucosaminyl donors employed in this reaction have included glycosyl fluorides,
bromides, and trichloroacetimidates. Several glucosamine-inositol glycosylation reaction
examples are summarized in Table 1.2. In most cases, α-stereoselectivity is moderate,
and the factors leading to an increase of the α-anomer are not entirely clear. However,
some modifications, such as using Et2O as the solvent or using Lemieux conditions118
for glycosyl bromide activation, can improve stereoselectivity.
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Table 1.2. Stereochemical outcomes for several glucosamine-inositol glycosylations

Donor

Acceptor

BnO OBn/Lipid
OBn
HO
OBn
PMBO
1.31

AllO
BnO

OBn
O
N3 F
1.38

Promoter

Solvent

Yield

AgClO4

Et2O

α: 63%
β: 22%

Bu4NBr

CH2Cl2

α: 63%

TMSOTf

Et2O

α: 85%
β: 0%

TMSOTf

Et2O/
CH2Cl2

α: 46%
β: 25%

TMSOTf

CH2Cl2

α: 65%
β: 19%
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With the fully protected psuedodisaccharide D completed, options include
elongation of the glycan chain from the glucosamine 4-O-position or installation of the
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phospholipid moiety at the inositol 1-O-position. Most research groups have utilized the
former method, opting to install the phospholipid at a late stage. However, as pointed
out above, late stage phospholipidation performed on a fully elaborated GPI
intermediate can result in an unwanted cyclization reaction.99 Therefore, we typically
proceed with selective deprotection/phosphorylation of the inositol 1-O-position prior to
glycan advancement as the preferred assembly sequence for GPI synthesis.
Phospholipidation of inositol, as well as later attachment of the phosphoethanolamine
group(s), can be achieved using one of several available phosphorylation methods.

1.1.5.4 Phosphorylation Methods in GPI Synthesis
Many phosphorylation methods have been developed for the introduction of
phosphates into synthetic nucleotides, GPI anchors, inositols, and other types of natural
products. These methods can be classified by the oxidation state of the phosphorus
atom in the reagent used. One category of reagents makes use of pentavalent
phosphorus derivatives, such as POCl3 and tetrabenzyl pyrophosphate, which have
been used extensively in nucleotide synthesis. The other category is composed of
trivalent phosphorus reagents, which can be activated under mild conditions to undergo
substitution reactions, the products of which can be easily oxidized to phosphates. Two
reagents in the latter category, phosphoramidites and H-phosphonates, have found
widespread use in GPI synthesis (Scheme 1.7).123-125
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Scheme 1.7. Commonly used methods for GPI phosphorylation

Phosphoramidites of type 1.41 are activated by mild acids such as 1H-tetrazole,
which protonates the diisopropylamino group. Then, displacement of diisopropylamine
by an alcohol to form an intermediate phosphite 1.42 occurs. This usually fast reaction
is followed by addition of an oxidant such as tert-butyl hydroperoxide (t-BuOOH) or
meta-chloroperbenzoic acid (mCPBA), which converts the trivalent phosphite to a
pentavalent phosphate 1.43. If the three substituents around phosphorus are different,
then the phosphorus atom will be chiral, and the reaction will result in the formation of
an enantiomeric or diastereomeric mixture (depending on whether chirality exists in the
substituents). If one of the substituents is a protecting group that is later removed to
form a phosphate mono- or diester, the phosphorus atom will lose its stereogenic
property. In the context of GPI synthesis, the formation of diastereomeric mixtures is a
disadvantage because it complicates characterization and purification. In addition to this
setback, purification of these phosphorylations can be cumbersome due to the large
excess (usually 5–10 equiv) of phosphorylating reagent required. However, the speed
and efficiency of the phosphoramidite method, coupled with the ability to prepare fully
protected phosphates, have made it applicable to GPI synthesis.
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H-Phosphonates of type 1.44 are trivalent phosphorus species that when in
solution are in equilibrium with their tautomeric pentavalent form 1.45. The latter is
reactive and may be activated toward nucleophilic attack by treatment with pivaloyl
chloride in dry pyridine, which results in the formation of a highly reactive mixed
anhydride 1.46. In the presence of a nucleophilic alcohol, the anhydride undergoes
attack, forming H-phosphonate intermediate 1.47 along with loss of pivalic acid.
Oxidation of the intermediate with water and iodine gives the desired phosphate diester
1.48. Unlike the phosphoramidite method, usage of H-phosphonates does not generate
a chiral phosphorus atom, and therefore problematic diastereomeric mixtures do not
arise in GPI synthesis. However, this method produces unprotected phosphate diesters,
which can complicate purification and prevent the use of various chemistries at later
stages. Both phosphorylation strategies have been successfully used for attaching
phospholipids and phosphoethanolamine groups to synthetic GPI intermediates.

1.1.5.5 Synthesis of the Trimannose Fragment
The conserved core of GPI anchors contains a trimannose fragment, identified as
structure C in the retrosynthesis (Scheme 1.1). If not modified beyond the conserved
core, the trimannose fragment is fairly straightforward to construct from suitably
protected monomers, particularly due to the relative ease of forming α-mannosidic bonds.
Scheme 1.8 depicts Guo’s preparations of each mannose monomer and their assembly
to form a typical non-modified trimannose fragment of type C.100 The central mannose
building block, Man-I, must be 1,6-O-differentiated for the purposes of accepting the
Man-II anomeric center at the 6-O-position and acting as a latent glycosyl donor for the
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later key glycosylation reaction. Starting from methyl α-D-mannopyranoside, four steps,
including a selective hydrolysis–acetylation of the 1-O- and 6-O-positions of 1.49 to
provide 1.50, were required to obtain Man-I glycosyl acceptor 1.52. Man-II must be 1,2O-differentiated, preferably with an orthogonal acyl protecting group at the 2-O-position
to enable neighboring group participation and thus α-stereoselectivity in glycosylation
reactions. This was accomplished using intermediate 1,2-orthoester 1.55, which can be
selectively opened with trimethylsilyl chloride (TMSCl) to form 2-O-acetyl protected
glycosyl chloride 1.56. The Man-III building block, like Man-I, requires 1,6-Odifferentiation, so intermediate 1.50 was useful in both preparations. Thus, 1.50 was
converted to the desired Man-III glycosyl bromide 1.57 in a single step by usage of
HBr/HOAc. Assembly of the trisaccharide started with a silver triflate (AgOTf)-promoted
glycosylation of Man-I acceptor 1.52 with Man-II donor 1.56. This provided αdimannoside 1.58, which was subjected to deacetylation with NaOMe to provide alcohol
1.59. The final glycosylation also made use of AgOTf to activate Man-III glycosyl
bromide 1.57, resulting in α-anomer 1.60. The Man-III 6-O-position protecting group was
then swapped for a tert-butyldimethylsilyl (TBS) ether to ensure later compatibility with
the inositol 2-O-palmitoyl acyl group.
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Scheme 1.8. Typical synthesis of a trimannose fragment of structure C

As described in Table 1.1, the trimannose core of different GPIs is structurally
diverse and often contains additional sugar chains or phosphoethanolamine units or
both located at various points along the glycan. Obviously, the synthesis of a modified
trimannose fragment in this case would require additional positions carrying
mono/oligosaccharides or orthogonal protecting groups for latent functionalization. For
example, the VSG GPI anchor of T. brucei contains an oligogalactose moiety at the
Man-I

3-O-position;

the

rat

brain

Thy-1

GPI

anchor

has

GlcNAc

and

phosphoethanolamine units at the Man-I 4-O- and 2-O-positions, respectively; both the
Thy-1 GPI anchor and the human lymphocyte CD52 GPI anchor contain additional
mannose residues at the Man-III 2-O-position. Therefore, appropriate protecting group
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tactics must be employed in the synthesis and assembly of the mannose monomers, as
summarized in Scheme 1.9. In the synthesis of the T. brucei VSG GPI anchor, Ley and
co-workers synthesized 1,3,6-O-differentiated Man-I building block 1.67 so that an
oligogalactosyl group could be installed at the 3-O-position prior to mannosylation at the
6-O-position. Fraser-Reid employed 1,2,4,6-O-differentiated Man-I building block 1.71 in
the synthesis of the rat brain Thy-1 GPI anchor, which allowed for the incorporation of
GlcNAc and phosphoethanolamine groups. Preparation of such highly discriminated
building blocks is laborious but essential for the synthesis of GPI anchors containing
modified trimannose cores.

Scheme 1.9. Syntheses of modified trimannose building blocks
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1.1.5.6 Assembly of GPI Anchors
There are multiple possible sequences for the assembly of GPIs from their
corresponding subunits, and several factors must be taken into account when planning
the synthesis. First, late-stage manipulations of valuable and complex intermediates
should be minimized. When handling samples of high molecular weight on a small scale,
isolated yields are generally lower, even for robust and straightforward protecting group
manipulations. In addition, if a reaction fails on a complex substrate, it is difficult to
amend the overall strategy and restart the synthesis. Second, time-consuming,
inefficient, or difficult fragment preparations or bond formations should be accomplished
at an early stage. For example, preparation of the glucosamine-inositol fragment is an
arduous task and should be completed early on to streamline synthetic efficiency. Third,
appropriate protecting group usage must be carefully planned. Sites on the GPI core
structure that require functionalization should contain protecting groups that have welldocumented orthogonality to all other protecting groups in the intermediate. Chemistries
used to install or remove orthogonal protecting groups must be compatible with
permanent functionalities in GPI intermediates.
Given the considerations laid out above, it is not surprising that most GPI
syntheses reported to date have employed convergent strategies, such as the assembly
shown in Scheme 1.1, that minimize late-stage reactions and protecting group
manipulations. The first total synthesis of a GPI anchor, completed by Ogawa,85-86 made
use of a moderately convergent plan, although several glycan elongation steps were
performed in a linear fashion on complex intermediates (Scheme 1.10). Ogawa’s GPI
assembly commenced with the convergent coupling of psuedotrisaccharide acceptor
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1.73 and digalactosyl fluoride donor 1.74. This step served to install a digalactose
moiety that is observed at the Man-I 3-O-position in the T. brucei GPI anchor. NaOMe
was

then

used

to

remove

the

Man-I

6-O-acetyl

group,

resulting

in

pseudopentasaccharide 1.75. To elongate the GPI core glycan at this site, sequential
mannosylation reactions were performed using monosaccharide building blocks 1.56
and 1.76, which formed the advanced GPI intermediate 1.77. This compound then
underwent a series of manipulations to install the remaining functionalities and remove
all of the protecting groups, affording the target GPI anchor. The use of linear assembly
necessitated a multitude of late-stage transformations, which decreased the overall
efficiency of this otherwise incredible first total synthesis of a GPI anchor. Also of note is
the successful installation of the phospholipid on a fully elaborated GPI.

Scheme 1.10. Ogawa’s synthesis of the T. brucei GPI anchor
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In 1994, Schmidt reported a highly convergent synthesis of a S. cerevisiae GPI
anchor, which contains a unique ceramide phospholipid and an additional mannose
residue at the Man-III 2-O-position (Scheme 1.11).92 The key reaction in this synthesis
was

a

glycosylation

between

tetramannosyl

trichloroacetimidate

1.78

and

pseudodisaccharide 1.79. These components reacted in the presence of trimethylsilyl
trifluoromethansulfonate (TMSOTf) to form α-pseudohexasaccharide 1.80, which was
designed

as

a

versatile

intermediate,

bearing

two

sites

for

installation

of

phosphoethanolamine groups and orthogonal protection at the inositol 1-O-position for
attaching the ceramide phospholipid. Like Ogawa, Schmidt successfully performed the
phospholipidation reaction at a later stage. This synthesis was highlighted by efficiency
due to a convergent strategy, highly stereoselective Schmidt glycosylation reactions,
and a versatile design for accessing variously modified S. cerevisiae GPI derivatives.

Scheme 1.11. Schmidt’s synthesis of the S. cerevisiae GPI anchor
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Fraser-Reid published the synthesis of a fully phosphorylated GPI anchor of the
rat brain Thy-1 antigen in 1995,89,119 which carried additional mannose and
galactosamine residues attached to the GPI core structure (Scheme 1.12). The
construction of GPI precursor 1.85 hinged on the application of their n-pentenyl
glycoside methodology to the convergent assembly of several advanced building blocks.
Thus, pseudodisaccharide 1.82 coupled with n-pentenyl disaccharide 1.81, furnishing αpseudotetrasaccharide 1.83 after treatment with thiourea to remove the Man-I 6-Ochloroacetyl (ClAc) group. This positioned the authors to attach n-pentenyl trimannoside
1.84 to the GPI core 1.83, which produced the fully protected GPI intermediate 1.85. At
this point, several steps were used to sequentially introduce phosphoethanolamine
groups to the Man-III 6-O- and Man-I 2-O-positions. Fraser-Reid capped this highly
convergent synthesis with a late-stage phospholipidation of the inositol residue.

Scheme 1.12. Fraser-Reid’s synthesis of the rat brain Thy-1 GPI anchor
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Ley and co-workers designed a strategy for the synthesis of the T. brucei GPI
anchor similar to those described above (Scheme 1.13).88 While Ogawa had previously
synthesized a version of this molecule, Ley enhanced its preparation by improving
convergence and making use of several methodologies developed in their lab. For
example, a racemic inositol intermediate was desymmetrized using a chiral
bis(dihydropyran) derivative, and butanediacetals were used extensively as protecting
groups in the synthesis. In terms of assembly, a key glycosylation took place between
pseudodisaccharide 1.82 and pentasaccharide thioglycoside 1.86, which made use of
Ley’s butanediacetal protecting groups and was activated by N-iodosuccinimide
(NIS)/trifluoromethanesulfonic

acid

(TfOH).

The

resulting

fully

protected

GPI

intermediate 1.87 was poised for the remaining phosphorylation and global deprotection
reactions.

Scheme 1.13. Ley’s synthesis of the T. brucei GPI anchor
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The GPI syntheses described above all relied on late-stage installation of a
phosphoglycerolipid to the inositol 1-O-position. While apparently this route was
successfully applied in these cases, Guo uncovered an interesting problem with this
strategy in the synthesis of the human sperm CD52 GPI anchor.99 The sperm CD52 GPI
anchor contains an additional palmitoyl group at the inositol 2-O-position, and Guo’s
initial plan involved early palmitoylation and late-stage installation of the phospholipid.
However, upon attempting the latter reaction on fully elaborated GPI 1.88, a novel
cyclophosphoramidation reaction occurred between the glucosamine 2-azido group and
the nascent inositol 1-O-phosphite, forming 1.89 (Scheme 1.14).

Scheme 1.14. Cyclic phosphoramidate formation observed by Guo

Because this unexpected reaction did not occur in previous GPI syntheses, it
was concluded that the coexistence of the palmitoyl and trimannose groups forced the
intermediate into a conformation such that this intramolecular reaction was favored. To
circumvent this problem, Guo performed the phospholipidation at an earlier stage
(Scheme 1.15). Therefore, pseudodisaccharide 1.90, containing a palmitoyl group at the
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inositol 2-O-position, underwent a smooth phospholipidation at the 1-O-position followed
by Pd-catalyzed deallylation to give 1.91. This product reacted with trimannose
thioglycoside

1.92

in

the

presence

of

NIS/TfOH

to

form

the

desired

α-

pseudopentasaccharide 1.93, which could be transformed into the target molecule in
only a few more steps. Guo’s modified sequence for GPI assembly prevented a deadend cyclization reaction while also improving convergency.

Scheme 1.15. Guo’s synthesis of the human sperm CD52 antigen GPI anchor

Although convergent synthesis is the most efficient and practical way to construct
GPI anchors, linear assembly is suitable for solid phase synthesis. Seeberger and coworkers synthesized an analog of the P. falciparum GPI anchor for testing as an antimalarial candidate. After completing a solution phase preparation of the target
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molecule,97 their linear strategy was translated to use in an automated synthesizer
(Scheme 1.16A).126 First, a tetramannose was constructed on the surface of an
octenediol-functionalized Merrifield resin 1.94 in an iterative fashion using mannosyl
donors 1.95-1.98. The tetramannose n-pentenyl glycoside 1.99 was then released from
the resin using Grubbs’ catalyst, and solution phase elaboration of this molecule led to a
partial GPI structure lacking a phosphoglycerolipid. Martín-Lomas also employed solid
phase synthesis to construct a GPI analog (Scheme 1.16B).127 Starting from solid
supported pseudodisaccharide 1.100, the entire glycan was built up in a stepwise
fashion on the solid phase. After release from the acid sensitive resin with trifluoroacetic
acid (TFA), pseudopentasaccharide 1.104 was transformed into a GPI partial structure.
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Scheme 1.16. Linear assembly of GPIs using solid phase synthesis
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As demonstrated by the groups of Seeberger and Martín-Lomas, solid phase
synthesis was effective for synthesizing GPI partial structures. However, solution phase
preparation of the challenging glucosamine-inositol pseudodisaccharide was still
required in both cases. Furthermore, the phosphoglycerolipid was omitted from the
target structure in each synthesis, which points to a limitation of this method. Therefore,
traditional solution phase synthesis combined with a highly convergent strategy
currently represents the strongest route to synthetic GPI anchors.
In 2006, Nikolaev and co-workers published the first synthesis of a GPI anchor
containing unsaturated lipid chains (Scheme 1.17),128 which bears direct relevance to
the research presented in this chapter. Up to the point of Nikolaev’s publication, all GPI
syntheses applied the benzyl group for global hydroxyl protection; however, this
strategy is clearly incompatible with unsaturated lipids, because Pd-catalyzed
hydrogenation is required to remove the benzyl groups as a final step. To address this
issue, Nikolaev employed benzoyl esters for permanent protection despite the presence
of an acylglycerolipid in the PI moiety, which appears to be incompatible with the
conditions required for deacylation. The authors noted their hypothesis that upon global
deprotection with NaOMe in MeOH, benzoyl-protected intermediates 1.105 and 1.106
could form micelles, thus mostly preventing methanolysis of the ester-linked lipid chains.
However, their reported deacylation steps gave ≤ 40% yield of products 1.107 and
1.108, thus this effect was quite limited, if operative at all. At best, the hypothesis of
micellar protection of the fatty acid linkages could not take place unless the intermediate
was at least partially deprotected (therefore containing a polar region), and as a result
lipid cleavage would occur indiscriminately at the start of the reaction.
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Scheme 1.17. Nikolaev’s synthesis of GPI anchors bearing unsaturated lipids

Although Nikolaev’s work does represent the first successful synthesis of a GPI
anchor using esters for permanent hydroxyl protection, this strategy should not be relied
on for future work. Ideally, such a risky and low-yielding deprotection step on a valuable
and complex substrate should be avoided. The research presented in section 1.2 takes
aim at the essentially unsolved issue of synthesizing functionalized GPI anchors.

1.2 Results and Discussion
1.2.1 Background and Project Design
To probe the significance of GPI structure and diversity, and to better understand
the scope and mechanism of GPI anchoring, it is necessary to have access to pure and
structurally defined samples of GPIs, GPI analogues, and functionalized GPIs.
Advances in chemical synthesis have enabled the preparation of GPI anchors by
several research groups, including ours, but limitations associated with current hydroxyl
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group protection strategies in carbohydrate/GPI synthesis prevent the inclusion of
certain combinations of important functional groups in the target molecule.
As described in section 1.1.5, GPI synthesis involves the elaboration of suitably
protected building blocks, including monosaccharide, inositol, lipid, and phosphate
precursors, into a fully protected GPI intermediate (Figure 1.5). Such an intermediate
contains several types of protecting groups: an azido group is always used to mask the
glucosamine 2-position; a 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butylcarbonyl (Boc)
group is commonly used to protect the primary amine of the phosphoethanolamine
group; the phosphates at either end of the GPI are protected usually with a benzyl or
cyanoethoxy group. Finally, the global/permanent protecting group, abbreviated as ‘PG’
in Figure 1.5, is employed to mask all of the nonfunctionalized hydroxyl groups in the
intermediate. The choice of global protecting group at the outset of a synthesis is an
important decision for several reasons. First, it will affect what other types of protection
and deprotection reactions may be used throughout the synthesis. Second, protecting
groups can dramatically impact reactivity and stereoselectivity in glycosylation reactions.
Finally, the identity of the global protecting group will determine what conditions are
required to effect a global deprotection reaction, which is the final synthetic step needed
to afford the target GPI. Ideally, the global deprotection reaction will be high yielding and
specific for only the protecting groups, leaving the entire desired structure intact.

43

Figure 1.5. Global protecting group considerations in GPI synthesis

Two primary strategies exist for permanent hydroxyl protection in carbohydrate
synthesis. Most commonly used is the benzyl ether, which is simple to install and is
stable to a wide range of reaction conditions used in carbohydrate/GPI synthesis. In
addition, usage of the benzyl ether has the advantage of a very mild global deprotection,
which is accomplished using palladium-catalyzed hydrogenolysis. To date, all but one
reported GPI synthesis have made use of the benzyl group for permanent hydroxyl
protection. The primary setback to this strategy is that potentially reducible or catalystpoisoning functional groups, such as alkenes, alkynes, thiols, and sulfides, are
incompatible

with

hydrogenolysis

global

deprotection,

thus

preventing

their

incorporation into the target molecule. In the context of synthesizing naturally occurring
GPI anchors, this is problematic because many GPIs contain unsaturated fatty acid
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lipids, a property that is biologically important39 yet disallows the usage of benzyl ethers
for protection. Furthermore, alkenes, alkynes, thiols, and sulfides are broadly useful
functional groups. Alkenes are one of the most versatile functional groups in organic
chemistry and can be converted to numerous other structures. Alkynes are similarly
versatile, and also have the ability to participate in the copper-catalyzed [3+2]
cycloaddition “click” reaction, which is a high yielding and very chemoselective reaction
that has found extensive use in all areas of chemistry and chemical biology.129 Thiols
can also participate in useful chemoselective reactions such as native chemical
ligation130 (NCL) and thiol-ene chemistry. A thioether bond is present in biotin, which is
an exceptionally useful molecule due to its high binding affinity for the protein avidin, a
property that allows biotinylated molecules to be separated with high efficiency from
very complex mixtures. These examples illustrate the limitations of using the benzyl
group for permanent protection.
An alternative to the standard benzyl ether protection strategy is usage of ester
protection such as acetyl and benzoyl groups, which would be compatible with the
aforementioned functional groups. However, ester global deprotection is typically
carried out using NaOMe, which would clearly be problematic for other acyl groups
present in the target molecule. As summarized in Table 1.1, all known GPI anchors
contain at least one acyl-linked lipid. In addition, peptides and glycopeptides, which are
conjugated to GPI anchors and other carbohydrates in nature, may be sensitive to
treatment with NaOMe. Another potential disadvantage to this strategy is that glycosyl
donors bearing multiple electron-withdrawing ester groups are termed “disarmed,” and
can be less reactive in glycosylation reactions.131 Despite these apparent limitations,
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Nikolaev and co-workers employed the benzoyl group for permanent protection to
achieve the first synthesis of GPI anchors containing unsaturated lipid chains, as
described above (Scheme 1.17).101 Although the target molecules were obtained, the
global deacylation reactions proceeded in unacceptable yields, likely due cleavage of
the ester-linked lipid chains. Therefore, usage of acyl-based permanent hydroxyl
protection is not particularly amenable to GPI synthesis.
Given the clear limitations of benzyl ether and ester global protection strategies
in the synthesis of functionalized GPI anchors and other carbohydrates, I sought to
develop a complementary strategy using the PMB group for permanent hydroxyl
protection. Certainly, PMB ethers have found extensive use as orthogonal protecting
groups in carbohydrate synthesis, and, to a lesser extent, as global protecting groups in
simple systems such as glycosylation with monosaccharides.132 However, one of my
goals for this project was to legitimize PMB groups as candidates for permanent
hydroxyl protection in complex and challenging syntheses. More importantly, I wished to
access biologically relevant functionalized GPI anchors that simply could not be
synthesized using current protecting group strategies. It was anticipated that PMB
ethers, which can be cleaved under either acidic (e.g. 5-10% TFA) or oxidative
conditions [e.g. ceric ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ)], would provide the flexibility necessary for the incorporation of a
wide range of functional groups in the target GPIs.
The target molecules for this project are depicted in Figure 1.6. Initially, I set out
to prepare GPI anchors bearing unsaturated lipid chains as a proof-of-concept for the
PMB protection strategy. Thus, GPI anchors 1.109 and 1.110, each containing the core
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GPI structure and a diacyloleoyl phospholipid, were designed as natural product targets.
A variable phosphorylation site at the Man-I 2-O-position was included because the
presence of an additional phosphoethanolamine unit at this site is the most commonly
observed GPI structural modification in higher eukaryotes.

Figure 1.6. Target molecules accessible using the PMB protection strategy

Compounds 1.111 and 1.112 in Figure 1.6 represent biofunctionalized GPI
anchors that will be incorporated into biological studies aimed at probing the scope and
mechanism of the anchoring process, as well as at evaluating GPIs for potential
therapeutic development. ‘Clickable’ GPI anchor 1.111 contains a short linker and
alkyne functionality at the Man-I 2-O-position. Click tags are useful for appending
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virtually any type of molecule to a substrate. For example, alkynyl GPIs, like other
alkynyl sugars,133 could be useful in a range of biological studies, from fluorescent tag
labeling and cell surface visualization experiments to carrier protein conjugation for
vaccine development. This utility centers on the versatility of the alkyne functional group,
which is small, biologically inert, and able to undergo click reactions as described above.
The fourth target GPI anchor 1.112 is quite similar in structure to 1.111, but instead
carries a biotin moiety at the 2-O-position. As mentioned above, biotinylated molecules
can be isolated from extremely complex mixtures by using commercially available
streptavidin products, which make use of the incredibly strong binding between the
tetrameric protein avidin and biotin (KD = ~10-15 mol/L).134 Biotinylated GPI anchors may
prove to be extremely useful for the study of GPIomics, which is the large-scale profiling
of GPIs and GPI-anchored molecules in cells.
The common thread that ties target molecules 1.109-1.112 together is their
inaccessibility by traditional synthetic strategies. The unique – but exceptionally useful –
functional group combinations present in the target GPIs necessitated the development
of a new global protecting group strategy, for which the PMB group was chosen.

1.2.2 Retrosynthesis
The retrosynthetic analysis for target GPI anchors 1.109-1.112 is outlined in
Scheme 1.18. To assemble these targets, I elected to use a convergent approach, the
benefits of which were described in section 1.1.5. This strategy was centered on the use
of two common PMB-protected intermediates, pseudodisaccharide 1.114 and
trimannose thioglycoside 1.115, which could be applied to the synthesis of all four target
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GPIs as follows: pseudodisaccharide 1.114 could undergo phospholipidation at the free
inositol 1-O-position by using any freshly prepared phosphoramidite, thus allowing
flexibility in what type of phosphoglycerolipid was installed in the GPI. After removal of
the glucosamine 4-O-TBS group, the resulting product could participate in a key
glycosylation reaction with trimannoside 1.115, or a derivative thereof, to produce fully
PMB-protected GPI intermediate 1.113. With orthogonal protecting groups at the Man-III
6-O-position (PG1) and Man-I 2-O-position (PG2), compound 1.113 could undergo
phosphorylation and/or functionalization at either position. Finally, removal of all
protecting groups would result in the formation of the target compounds. The two
common intermediates, 1.114 and 1.115, would be formed from their corresponding
suitably protected monomers 1.116-1.120.

Scheme 1.18. Retrosynthesis of target GPI anchors
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Several considerations were made in the planning of this synthesis. First, due to
the sensitivity of PMB groups to acidic conditions, care was taken in selecting the
primary glycosylation method. Various donors/activation conditions were evaluated
throughout the course of this project, including glycosyl fluorides, trichloroacetimidates,
and

thioglycosides.

The

Schmidt

glycosylation,135

which

makes

use

of

trichloroacetimidate donors and catalytic TMSOTf for activation, consistently gave the
best results. Second, the PMB group also required the identification and employment of
protecting groups and reaction conditions with truly orthogonal properties, which turned
out to be quite challenging in some cases. Finally, the functionalization site was chosen
based on positions of modification in natural GPI anchors. Initially, the Man-I 3-Oposition was used for functionalization, but eventually this was shifted to the Man-I 2-Oposition due to a crippling side reaction (see section 1.2.6). Both of these positions are
commonly modified in naturally occurring GPI anchors, and therefore no significant
changes in the conformation or global structure of the GPI backbone were expected as
a result of shifting the site of derivatization.
The following sections will describe the preparations – both failed and successful
– of monomer building blocks 1.116-1.120, including inositol, glucosamine, and
mannose

derivatives,

and

their

conversion

into

common

key

intermediates

pseudodisaccharide 1.114 and trimannose 1.115. Then, separate sections will be used
to detail the completion of each target molecule from the common intermediates. Finally,
future directions for this research, both in terms of synthesis and biological studies, will
be laid out.
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1.2.3 Synthesis of Inositol Building Block 1.116
The preparation of differentially protected and optically pure inositol compounds
in the context of GPI synthesis is discussed in section 1.1.5.2. For the purpose of
synthesizing a suitable PMB-protected inositol derivative, I first explored the conversion
of optically enriched diol (+)-1.7 to a useful building block by using a route similar to that
previously employed by Guo for the synthesis of benzyl-protected inositols.109 Guo’s
strategy involved initial differentiation of the 1-O- and 6-O-positions, then installation of
the permanent benzyl groups. My attempt to develop an analogous preparation is
shown in scheme 1.19. First, a highly regioselective stannylene acetal-directed allylation
of the 6-O-position provided compound 1.9 in 80% yield, thus successfully
differentiating the 1-O- and 6-O-positions. Here, in the synthesis of benzyl-protected
inositols (route A), an orthogonal PMB group was installed at the 1-O-position to provide
1.121. This was followed by replacement of the cyclohexylidene ketals with benzyl
groups by sequential treatment with AcCl/MeOH and NaH/BnBr to furnish inositol 1.122.
For such a preparation to translate successfully to the synthesis of an analogous PMBprotected inositol 1.124, a 1-O-position protecting group (PG) would have to be
identified that satisfied the following requirements: 1) PG must withstand treatment with
strong acid (AcCl/MeOH); 2) PG must withstand treatment with strong base
(NaH/PMBCl); 3) PG must be orthogonal to All, PMB, TBS, and N3 groups; 4) PG must
not be susceptible to migration from the inositol 1-O-position to the 2-O-position under
acidic or basic conditions. After exploring a variety of protecting groups, it was
concluded that none met these criteria, and I was forced to redesign the inositol
preparation.
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Scheme 1.19. Failed inositol preparation

Rather than immediately differentiate the 1-O- and 6-O-positions, I decided to
attempt differentiation after protecting the remaining hydroxyl groups as PMB ethers
(Scheme 1.20). This route also provided an opportunity to investigate a chemical
resolution of the inositol racemic mixture rather than enantiomeric resolution. Thus, the
racemic mixture of diol (±)-1.5 was subjected to allylation of the 1-O- and 6-O-positions,
resulting in bis(allylether) (±)-1.125. Then, the cyclohexylidene ketals were removed
with

HCl-promoted

methanolysis,

and

the

intermediate

tetraol

was

para-

methoxybenzylated to provide (±)-1.126. Deallylation of this product was quite lowyielding using standard reagents such as PdCl2 (< 50%). However, the desired diol (±)1.127 was obtained in 85% yield when Cha’s deallylation protocol136 using
cyclohexylmagnesium chloride and titanium isopropoxide was used. At this point, 1,6-Odifferentiation was required, and I preferred to protect the 1-O-position regioselectively,
thus leaving the 6-O-position free for anchoring to a chiral resolving reagent. Although
the similar diol (±)-1.7 undergoes stannylene-acetal directed allylation at the 6-Oposition, I predicted that this regioselectivity would fortuitously swap for substrate (±)-
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1.127 because of the neighboring axial substituent, which often increases nucleophilicity.
On the other hand, the selectivity observed for substrate (±)-1.7 most likely is a result of
a steric effect of the molecule resulting from the rigid nature of the cyclic ketal protecting
groups.109 In the reaction, the regioselectivity fortunately did favor the desired 1-Oposition in a 4:1 ratio (determined by HPLC), which allowed compound (±)-1.128 to be
obtained in 72% yield. This enantiomeric mixture was then reacted with the chiral
resolving agent (1S)-(-)-camphanic chloride. The resulting mixture of diastereomers
could be separated by semi-preparative HPLC, providing enantiomerically pure (-)1.129 in 46% yield (maximum 50%). The chiral auxiliary was then saponified in
excellent yield to give the desired inositol derivative 1.116.

Scheme 1.20. Preparation of inositol derivative 1.116

Because compound 1.116 and its enantiomer were generated in this procedure,
the desired isomer had to be identified. To make this assignment, I performed the same
procedures outlined in scheme 1.20 on enantiomerically enriched (+)-1.7, which allowed
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access to an authentic sample of 1.116. Comparison of optical rotation values between
the authentic and unknown samples confirmed the identity of the desired enantiomer.
The efficiency of the chemical resolution procedure described in scheme 1.20 compared
favorably to Gou’s enzymatic resolution,108 which is commonly used in our lab to obtain
enantiomerically enriched inositol derivatives. The chemical procedure required 2 steps
(relating to the resolution) and gave a 44% overall yield (maximum 50%), whereas the
enzymatic procedure required 3 steps and gave a 25% overall yield. However, the
overall efficiency of the chemical procedure was dampened by the need for HPLC
purification.

1.2.4 Synthesis of Glucosamine Building Block 1.117
The glucosamine moiety in GPI anchors contains an α-glycosidic bond to the 6O-position of inositol. Achieving a highly stereoselective α-glycosylation reaction
between these two subunits has been a rather difficult task in most GPI syntheses, as
summarized in Table 1.2. While the presence of a non-participating protecting group at
the 2-position is absolutely necessary to form a 1,2-cis glycosidic bond, other factors
affecting stereoselectivity are not very predictable. PMB-protected glucosaminyl donor
building blocks were designed to contain a non-participating azido group at the 2position and an orthogonal TBS group masking the 4-O-position for later removal and
glycan chain extension.
I prepared both glucosaminyl fluoride and trichloroacetimidate building blocks for
the purpose of optimizing the glycosylation reaction with inositol acceptor 1.116. Both
syntheses followed nearly identical paths, beginning with commercially available
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glucosamine hydrochloride. Synthesis of the trichloroacetimidate donor 1.117 is shown
in Scheme 1.21. First, Wong’s copper-catalyzed diazotransfer reaction117 was used to
install a non-participating azido group at the 2-position. Without purification, the
intermediate was peracetylated using acetic anhydride in pyridine to provide 1.130 in
82% yield. The anomeric acetate was then replaced with an allyl ether using allyl
alcohol and promoter tin(IV) chloride. After the resulting product 1.131 was deacetylated
with NaOMe, the intermediate triol was reacted with para-anisaldehyde dimethyl acetal
in the presence of catalytic camphor sulfonic acid (CSA), which resulted in the formation
of 4,6-O-para-methoxybenzylidene-protected derivative 1.132. PMB protection of the 3O-position was followed by regioselective reductive ring opening of the paramethoxybenzylidene ring, providing alcohol 1.34 in 71% yield. The newly exposed 4-Oposition hydroxyl group was then capped with TBSOTf to provide 1.135 in 85% yield.
Removal of the anomeric allyl ether was inefficient using PdCl2, but a two step
protocol137 involving Ir(I)-catalyzed isomerization of the allyl ether to a vinyl ether, and
subsequent hydrolysis of the vinyl ether to a hydroxyl group with Hg(II) provided
hemiacetal 1.136 in 85% yield. Conversion of the hemiacetal to trichloroacetimidate
1.117 took place upon treatment with trichloroacetonitrile and 1,8-diazobicycloundec-7ene (DBU).
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Scheme 1.21. Preparation of glucosamine derivative 1.117

1.2.5 Synthesis of Common Pseudodisaccharide 1.114
The crucial step to forming common intermediate 1.114 was the glycosylation
reaction between inositol acceptor 1.116 and a glucosaminyl donor. Various conditions
using glycosyl fluorides and trichloroacetimidates were screened, and the results are
shown in Table 1.3. I first evaluated glucosaminyl fluoride 1.137 (entries 1-3) because
similar benzyl-protected fluoride donors required only mild activation conditions in their
successful application in previous GPI syntheses. However, as reflected in entry 1,
these PMB-protected glycosyl donors were quite unreactive. When performing this
reaction at room temperature with any activator and stirring for days, either no reaction
or only trace amounts of product 1.138 were observed. It was found, however, that upon
heating the reaction to reflux in Et2O, donor 1.137 reacted completely, although only
moderate yields of the desired product were obtained when using Cp2HfCl2/AgOTf (22%)
and Yb(OTf)3/CaCO3 (40%) as promoters (entries 2-3).
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Table 1.3. Reaction conditions and results of glucosamine-inositol glycosylation

TBSO
PMBO

OPMB
O

1.117 or N3
1.137

X

+

PMBO OPMB
OPMB
HO
OPMB
AllO
1.116

See Table 1.3

TBSO
PMBO

OPMB
O
OPMB
N3 PMBO
OPMB
O
OPMB
AllO
1.138

Yield
(α+β)

α:β
ratio

Any activator/solvent, ambient temp,
days

NR/trace

-

F
(1.137)

Cp2HfCl2, AgOTf, MS, Et2O refluxing,
overnight

22%

1:1

F
(1.137)

Yb(OTf)3, CaCO3, MS, Et2O refluxing,
overnight

40%

2:1

Entry

X

1

F
(1.137)

2
3

Conditions

4

OC(NH)CCl3 TMSOTf (cat.), MS, CH2Cl2, 0 ºC, 10 min
(1.117)

84%

1:1.6

5

OC(NH)CCl3 TMSOTf (cat.), MS, Et2O, 0 ºC, 10 min
(1.117)

86%

1.2:1

The low yields of product 1.138 when using glucosaminyl fluoride donors were
attributed to a side reaction that accounted for a significant portion of the mass balance
(Scheme 1.22). Upon heating, donor 1.137 underwent ring flip and activation,
generating oxocarbenium cation 1.139, which possessed the proper conformation to
undergo formation of 1,6-anhydro sugar 1.140. This was a result of cleavage of the 6-OPMB group and subsequent attack of the liberated primary alcohol on the electrophilic
anomeric center. In the event, a significant amount of inositol acceptor 1.116 was
consumed because it reacted with the newly formed PMB cation, thus resulting in the
formation of fully-protected inositol derivative 1.141.
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Scheme 1.22. Glucosaminyl fluoride side reaction

Given the ineffectiveness of the glycosyl fluoride donor under numerous
conditions, I then turned my attention to usage of trichloroacetimidate donor 1.117
(Table

1.3,

entries

4-5).

I

expected

that

the

high

reactivity

of

glycosyl

trichloroacetimidates at low temperatures would suppress the side reaction discussed
above. Under standard Schmidt glycosylation conditions, usage of 0.1 equiv TMSOTf at
0 °C in CH2Cl2, I was fortunate to observe formation of the desired pseudodisaccharide
1.138 in 84% yield. However, the α:β ratio (1:1.6) favored the undesired β-anomer. This
figure was somewhat improved by changing the solvent to diethyl ether, which resulted
in an 86% yield and generated the α-anomer in slight excess (α:β ratio 1.2:1). The two
stereoisomers could be purified at this stage by semi-preparative HPLC, or alternatively
by using silica gel column chromatography following the subsequent deallylation step.
Removal of the inositol 1-O-allyl ether was accomplished using the one-pot Ir(I)/Hg(II)
method, which provided common intermediate pseudodisaccharide 1.114 in 96% yield
(Scheme 1.23). This versatile PMB protected intermediate was ready for immediate
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phospholipidation at the inositol 1-O-position and later glycosylation at the glucosamine
4-O-position, thus allowing for the preparation of a diverse set of GPI anchors.

Scheme 1.23. Deallylation to form common intermediate psuedodisaccharide 1.114

1.2.6 Synthesis of Man-I Building Block 1.118
The Man-I building block was particularly important for this synthesis because I
chose this unit as the functionalization site, where alkyne- or biotin-containing groups
would be attached. As discussed previously, Man-I is extensively modified in various
naturally occurring GPIs. In fact, additional carbohydrate or phosphoethanolamine
groups have been observed at every position of Man-I. My initial plan involved using the
3-O-position as the functionalization site because I predicted that the monomer
preparation would be straightforward and that late-stage functionalization would be
easiest due to the higher nucleophilicity of the equatorial 3-O-hydroxyl group. Therefore,
I set out to synthesize a 1,3,6-O-differentiated mannoside.
In the first generation synthesis of the Man-I building block, I designed glycosyl
fluoride 1.147 as the target (Scheme 1.24). I expected that diol 1.147 would undergo
selective glycosylation at the primary 6-O-position by the Man-II glycosyl donor, leaving
the 3-O-position discriminated for later functionalization and the anomeric fluoride ready
for the later key glycosylation. Thus, mannose peracetate 1.142 was subjected to
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regioselective deacetylation with benzylamine,138 and the resulting hemiacetal 1.143
was converted in excellent yield to glycosyl fluoride 1.144 using diethylaminosulfur
trifluoride (DAST). The planned pathway to 1.147 was interrupted when an unexpected
reaction occurred during deacetylation. Upon treatment of fluoride 1.144 with
NaOMe/MeOH, a mixture of fluoroglycoside 1.145 and methyl glycoside 1.146 were
obtained from the reaction mixture (stereochemistry predicted, not determined
experimentally). The undesired latter product likely resulted from displacement of the αconfigured anomeric fluoride by the 2-O-position alkoxide, which formed an intermediate
1,2-anhydro sugar that could be opened by methoxide to give 1.146.139 Given this
unforeseen reaction, and the low reactivity observed for other PMB-protected glycosyl
fluorides, I opted to redesign the Man-I building block.

Scheme 1.24. Failed preparation of Man-I glycosyl fluoride

In the second generation Man-I synthesis, I targeted thioglycoside 1.152
(Scheme 1.25) to allow for versatility in the anomeric leaving group later on, as
thioglycosides can be directly activated under numerous conditions or be converted into
other glycosyl donors. Again, the preparation was started from mannose peracetate
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1.142, which underwent boron trifluoride-promoted glycosylation with toluenethiol to
give 1.148 in 85% yield over two steps. After deacetylation, the intermediate tetraol was
selectively protected at the 6-O-position using the bulky reagent para-methoxytrityl
chloride (PMTrtCl). Next, product 1.149 was regioselectively allylated at the 3-Oposition via a stannylene acetal intermediate. The desired compound 1.150 was purified
from the reaction mixture in a low but unoptimized 38% yield. The remaining hydroxyl
groups at the 2-O- and 4-O-positions were protected as PMB ethers to give 1.151, and
then the very acid-labile 6-O-PMTrt group was selectively removed using AcOH,
furnishing the desired thioglycoside 1.152 in 85% yield over two steps.

Scheme 1.25. Preparation of second generation Man-I building block

Unfortunately, the second generation Man-I building block turned out to cripple
the GPI synthesis at a later stage. After elaboration of 1.152 to the desired trimannosyl
trichloroacetimidate donor 1.153, I was poised to attempt the key glycosylation reaction
with phospholipidated pseudodisaccharide fragment 1.154 (Scheme 1.26). Under
various reaction conditions, none of the desired pseudopentasaccharide 1.155 was
formed. Instead, the entirety of the glycosyl donor was consumed by an intramolecular
reaction. Upon activation with catalytic TMSOTf to form oxocarbenium cation 1.156, the
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2-O-PMB group was cleaved, liberating a secondary hydroxyl group that collapsed
down on the neighboring electrophilic anomeric center, resulting in the formation of 1,2anhydro sugar 1.157.

Scheme 1.26. Second generation Man-I building block disables synthesis

Because no attempted modifications of the glycosylation conditions could
circumvent this side reaction when using trimannosyl donor 1.153, I was again forced to
redesign the Man-I building block. To do so, the site of functionalization was changed
from the Man-I 3-O-position to the 2-O-position. In this case, the orthogonal allyl ether
protecting group replaced the troublesome 2-O-PMB group, which should enable a
successful key glycosylation. Also, because GPIs naturally contain substituents at the 2O-position, no significant conformational changes were expected. Therefore, I
developed a preparation of the third generation Man-I building block 1.118 (Scheme
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1.27). The expedient synthesis began with a reported conversion of mannose
peracetate 1.142 to 4,6-O-para-methoxybenzylidene-protected diol 1.159.140 Stannylene
acetal-directed regioselective protection of the 3-O-position with a PMB group left the 2O-position to be masked as an allyl ether. This two step sequence gave 1.161 in 68%
yield. Finally, regioselective reductive opening of the para-methoxybenzylidene ring
afforded the desired Man-I building block 1.118 in 82% yield.

AcO
AcO
AcO

OAc
O
1.142

Bu 2SnO;
PMBCl, DMF

PhSH, BF3 ,OEt2
OAc

CH 2Cl2, MS

OAc
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O
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AcO
1.158 SPh

OH
O
NaH, AllBr
O
O
PMBO
1.160 SPh 68%, 2 steps

PMP

NaOMe, MeOH;

PMP

anisaldehyde
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OAll
O
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O
PMBO
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PMBO
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OAll
O
1.118 SPh

Scheme 1.27. Preparation of third generation Man-I building block 1.118

1.2.7 Synthesis of Man-II Building Block 1.119
For the Man-II monomer, a 1,2-O-differentiated mannose derivative, preferably
bearing a participating protecting group at the 2-O-position, was required. To this end,
1,2-orthoesters are very useful intermediates and were applied in the synthesis of ManII building block 1.119 (Scheme 1.28). Thus, from mannose peracetate 1.142 a reported
method141 was used to obtain orthoester intermediate 1.163. Deacetylation with NaOMe
formed a triol intermediate that was converted to PMB-protected orthoester 1.164 in
76% yield over two steps. Next, a regioselective orthoester ring opening was carried out
using acetic acid/H2O. The desired hemiacetal 1.165 was generated in 70% yield, while
the remainder of the mass balance was attributed to the regioisomeric anomeric acetate.
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Compound 1.165 was then transformed into glycosyl trichloroacetimidate 1.119 by
treatment with trichloroacetonitrile and DBU.

Scheme 1.28. Preparation of Man-II building block 1.119

1.2.8 Synthesis of Man-III Building Block 1.120
The 1,6-O-differentiated Man-III building block 1.120 was synthesized from
mannose peracetate 1.142 using the procedure shown in Scheme 1.29. First, 1.142
was converted to allyl glycoside 1.166 by BF3-promoted glycosylation with allyl alcohol.
Subsequent deacetylation and para-methoxytritylation of the primary alcohol afforded
triol 1.167 in 66% yield over two steps. Next, installation of PMB groups at the 2-, 3-,
and 4-O-positions resulted in fully protected intermediate 1.168. The PMTrt was then
replaced with a TBS group in two steps, including acidic hydrolysis of the 6-O-PMTrt
group to give 1.169 in 94% yield, and treatment of this product with TBSCl to furnish
1.170 in 88% yield. Hydrolysis of the anomeric allyl ether with PdCl2 efficiently produced
hemiacetal 1.171, which was converted to glycosyl trichloroacetimidate 1.120, again
using trichloroacetonitrile and DBU.
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Scheme 1.29. Preparation of Man-III building block 1.120

1.2.9 Synthesis of Common Trimannose 1.115
The synthesis of common intermediate 1.115 from mannose monomers 1.118,
1.119, and 1.120 was a straightforward process (Scheme 1.30), in large part due to the
relative ease of forming α-mannosidic bonds. To construct each glycosidic bond, the
Schmidt glycosylation was applied, which did not affect the numerous PMB groups
present in the coupling partners. The first glycosylation was between Man-I acceptor
1.118 and Man-II donor 1.119. Upon treatment of these substrates with catalytic
TMSOTf, exclusively α-glycosylation took place, forming disaccharide 1.172, which after
a quick purification by column chromatography was subjected to deacetylation with
K2CO3/MeOH. The resulting disaccharide alcohol 1.173 was formed in 66% yield over
two steps and was ready for elongation at the Man-II 2-O-position. Thus, 1.172 was
reacted with Man-III trichloroacetimidate 1.120 in the presence of TMSOTf. When
CH2Cl2 was used as the solvent, the desired trimannose 1.115 was generated in an α:β
ratio of 5:1. The stereoselectivity was improved to α-only by switching the solvent to
Et2O. Under these conditions, common intermediate 1.115 could be obtained in 76%
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yield. The configurations of all three anomeric centers were established as α by the
anomeric JCH coupling constants (see experimental). Of note here is that no anhydro
sugar derivative of 1.120 (as a result of PMB loss, e.g. Scheme 1.26) was observed.
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Scheme 1.30. Synthesis of common intermediate trimannose 1.115

As outlined in the retrosynthesis (section 1.2.2), common intermediates 1.114
and 1.115 were designed to be applicable to the synthesis of all four target GPI anchors.
With both PMB-protected intermediates successfully synthesized, I then turned to the
assembly of the target GPIs, which will be discussed individually in the following three
sections.

1.2.10 Synthesis of GPIs with Unsaturated Lipid Chains 1.109 and 1.110
Two of the synthetic targets for this project were variably phosphorylated GPI
anchors bearing unsaturated lipid chains, 1.109 and 1.110. Both targets contained
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diacyloleoyl phosphoglycerolipids attached to the inositol 1-O-position. For the
phospholipidation

reaction

of

pseudodisaccharide

1.114,

I

chose

to

use

phosphoramidite 1.179 as the reactive phosphate precursor, and thus prepared it from
optically pure glycerol derivative 1.174 (Scheme 1.31). First, the free primary alcohol
was protected by a tert-butyldiphenylsilyl (TBDPS) group, and then the isopropylidene
was removed with acetic acid, providing diol 1.176 in 66% yield over two steps. The
unsaturated lipid chains were then installed in 96% yield in an acylation reaction using
oleic acid, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDCI), and
catalytic 4-(dimethylamino)pyridine (DMAP). The resulting compound 1.177 was then
subjected to desilylation with tetrabutylammonium fluoride (TBAF) to give alcohol 1.178
in

96%

yield.

This

intermediate

was

reacted

with

bis(diisopropylamino)(2-

cyanoethoxy)phosphine in the presence of diisopropylammonium tetrazolide to provide
phosphoramidite 1.179 in 85% yield. The sensitive phosphoramidite reagent was
purified quickly by a triethylamine-neutralized silica gel column and characterized by 1H
and 31P NMR spectroscopy.

Scheme 1.31. Preparation of phospholipid precursor 1.179
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The phospholipidation of pseudodisaccharide 1.114 by phosphoramidite 1.179
was accomplished using 1H-tetrazole as a mild acidic promoter (Scheme 1.32). This
resulted in the formation of trivalent phosphite intermediate 1.180, which was
chemoselectively oxidized to pentavalent phosphate 1.181 by direct addition of tBuOOH to the reaction mixture at low temperature. Previous studies in our lab showed
that a temperature of -40 °C was required to prevent oxidation of other alkenes present
in the substrate. In this case, the double bonds in the unsaturated lipid chains were
unaffected by the oxidation event. Excess t-BuOOH was scavenged with dimethyl
sulfide prior to warming and quenching the reaction. After work-up and quick column
purification, the crude product 1.181 was taken forward to the next step, removal of the
glucosamine 4-O-TBS group. This reaction was unexpectedly difficult, as a number of
commonly used desilylation reagents failed to produce the desired product 1.182.
Substrate 1.181 was unreactive toward standard conditions, TBAF buffered with acetic
acid. When stronger conditions were used, the starting material decomposed
unproductively. For example, unbuffered TBAF cleaved the base-labile cyanoethoxy
phosphate protecting group prior to cleaving the TBS group. More acidic reagents, such
as pyridine•HF, resulted in hydrolysis of multiple PMB groups prior to affecting the 4-OTBS. Finally, I found that commercially available triethylamine trihydrofluoride cleanly
effected the desired desilylation without compromising other protecting groups, although
reaction times were unfortunately quite long (5-7 days). The resulting product 1.182 was
obtained in a very acceptable 56% yield over three steps. Because this sample existed
as a ~1:1 mixture of diastereomers originating from the stereogenic phosphorus atom,
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semi-preparative HPLC was used to separate the two isomers. This was beneficial for
the characterization of 1.182 and subsequent complex intermediates.

Scheme 1.32. Phospholipidation of 1.114 to install unsaturated lipid chains

At this stage, pseudodisaccharide fragment 1.182 was ready for the key
glycosylation with the trimannose donor fragment. However, common trimannose
intermediate 1.115 required two alterations prior to glycosylation. First, the Man-I 2-Oallyl group had to be swapped for a different orthogonal protecting group, because later
removal of the allyl ether would likely conflict with the unsaturated lipid chains. Secondly,
direct activation of the trimannose thioglycoside under various conditions was disovered
to be ineffective or very low yielding. Given my success using Schmidt’s
trichloroacetimidate method, I decided to convert the anomeric thioether to a
trichloroacetimidate.

69
The adjustment of trimannose intermediate 1.115, shown in Scheme 1.33, began
with selecting a suitable 2-O-position protecting group that would be orthogonal to the
remainder of the molecule’s functional groups and also provide a suitable environment
for the key glycosylation reaction. I first evaluated neighboring group-participating
carbonates such as 2,2,2-triclhloroethoxycarbonyl (Troc) and Fmoc, but these
protecting groups were either difficult to install or were unstable to later reaction
conditions. In addition, these electron-withdrawing protecting groups would disarm the
trimannose donor, making for an unpredictable glycosylation reaction. I eventually
chose the triethylsilyl (TES) group to protect the 2-O-position, expecting that the Man-III
6-O-TBS and Man-I 2-O-TES groups could be selectively removed because the former
was protecting a primary alcohol, while the latter was protecting a relatively inaccessible
secondary alcohol. I hoped that this potential orthogonality might provide the ability to
variably phosphorylate or functionalize the GPI anchors. Thus, trimannose 1.115
underwent a 2-O-position protecting group swap at Man-I. Deallylation using standard
protocols was ineffective, so again Cha’s Ti(OiPr)4–Grignard reagent method was used
for the efficient removal of the Man-I 2-O-allyl group, which provided trimannose alcohol
1.183 in 82% yield. Installation of the TES group proceeded smoothly upon treatment
with TESOTf, resulting in compound 1.184 in 90% yield. Next, the thioglycoside
required converstion to a trichloroacetimidate, which was accomplished in two steps.
First, hydrolysis of the anomeric thioether with NIS, AgOTf, and hindered base tri-tertbutylpyrimidine (TTBP) gave hemiacetal 1.185 in 74% yield. Conversion of this
intermediate to the desired trimannose trichloroacetimidate 1.186 was carried out using
trichloroacetonitrile and DBU.
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Scheme 1.33. Adjustment of trimannose 1.115 for the key glycosylation

With both key glycosylation components in hand, I carried out the pivotal reaction
using

standard

Schmidt

conditions

(Scheme

1.34).

Phospholipidated

pseudodisaccharide acceptor 1.182 and trimannose donor 1.186 were treated with a
catalytic amount of TMSOTf at 0 °C, and TLC showed nearly complete consumption of
the acceptor in less than 10 minutes. After careful workup and purification, the desired
α-pseudopentasaccharide 1.187 was obtained in 64% yield, while no β-isomer was
detected. Configurations of anomeric positions were established as α by coupled

13

C

NMR JCH values (125 MHz): 101.80 (JCH = 176 Hz, Man-1), 99.66 (JCH = 175 Hz, Man1), 99.54 (JCH = 170 Hz, Man-1), 97.90 (JCH = 177 Hz, GlcN3-1).
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Scheme 1.34. Key glycosylation reaction

Attention was then turned to installation of phosphoethanolamine groups in the
PMB-protected GPI intermediate 1.187 (Scheme 1.35). To do so with optimal flexibility, I
hoped

to

remove

the

Man-III

6-O-TBS group selectively

with

triethylamine

trihydrofluoride. However, this reaction proceeded without useful regioselectivity, and
both silyl groups were removed after overnight treatment with Et3N•3HF to provide diol
1.188 in 70% yield. Given this result, I expected to only be able to access the fully
phosphorylated GPI 1.110, an unfortunate yet acceptable occurrence. Therefore, the
synthesis proceeded to the phosphorylation of 1.188 using phosphoramidite 1.189 as
the phosphoethanolamine precursor. After approximately 1 hour reaction time in the
presence of 1H-tetrazole, TLC showed one major product, so chemoselective oxidation
with t-BuOOH, work-up, and sequential purifications using silica gel and size-exclusion
LH-20 columns were performed. Upon analysis, the product was determined to be
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singly phosphorylated GPI intermediate 1.190, which was isolated in 50% yield (61%
based on recovered starting material). Using 2D NMR spectroscopy, specifically
correlation spectroscopy (COSY), I confirmed that phosphorylation occurred selectively
at the primary Man-III 6-O-position alcohol. This fortunate result meant that I would be
able to access both target GPIs 1.109 and 1.110. Given the limited amount of material
available at this stage in the synthesis, ~50-100 μg of 1.190 were taken forward to
attempt the second phosphorylation reaction. Using the same conditions, but employing
a larger excess of 1.189 and a longer reaction time (overnight), fully phosphorylated
GPI intermediate 1.191 was formed, as detected by matrix-assisted laser desorption
ionization (MALDI) MS. Given the high reactivity of phosphoramidite reagents,
regioselectivity was not expected at this stage. However, the relatively low
nucleophilicity of the Man-I 2-O-position was not surprising; this secondary hydroxyl
group was also unreactive in late-stage acylation reactions (see Scheme 1.40).
The final phase of synthesizing GPIs 1.109 and 1.110 involved developing a
suitable global deprotection procedure (Scheme 1.36). With fully elaborated and
protected GPI intermediates 1.190 and 1.191 available, I focused on their conversion to
the target molecules. Global deprotection required three sets of reaction conditions: (1)
reductive, to convert the glucosamine azido group to an amine; (2) basic, to remove the
Fmoc and cyanoethoxy protecting groups; (3) acidic or oxidative, to remove the global
PMB protecting groups. For azide reduction, use of a heterogeneous catalyst such as
Lindlar’s catalyst was avoided in order to align with the overall strategy to use global
deprotection conditions that would allow for the most flexibility in functional group
incorporation (i.e., a thiol or sulfide could poison Lindlar’s catalyst). Thus, I decided to
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Scheme 1.35. Regioselective installation of phosphoethanolamine groups

use the combination of activated zinc and acetic acid, a very mild set of conditions for
selective azide reduction. For removal of the base-labile Fmoc and cyanoethoxy groups,
a low concentration of the non-nucleophilic base DBU could be used to quickly effect
deprotection of the phosphates and the phosphoethanolamine primary amino groups.
For PMB removal, oxidative conditions (e.g., DDQ or CAN) were ineffective, but a low
concentration of TFA satisfactorily hydrolyzed all PMB groups. Thus, after extensive
optimization of reaction concentrations, times, and sequence, a three-step, one-pot
reaction was developed that could efficiently remove all of the protecting groups in
under 4 hr: 1) zinc-mediated reduction of the azide for 2 h; 2) after filtration and
evaporation, removal of the base-labile Fmoc and cyanoethoxy groups by treatment
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with DBU for 1 h; 3) direct addition of 20% TFA to quench the DBU and give a final
concentration of 10% TFA, which removed all PMB groups in only 30 min. The reaction
mixture was then co-evaporated with toluene several times to remove volatile TFA, and
purification was accomplished using a Sephadex LH-20 size exclusion column. Using
this deprotection sequence, target GPI 1.109 was obtained in 81% yield after global
deprotection

and

purification,

and

was

subsequently

characterized

by

NMR

spectroscopy and MALDI MS. Fully phosphorylated GPI 1.110 was also successfully
obtained using this global deprotection, and the microscale sample was characterized
by MALDI MS.
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Scheme 1.36. Global deprotection to afford GPIs bearing unsaturated lipid chains
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1.2.11 Synthesis of Clickable GPI 1.75
To commence the synthesis of alkyne-containing ‘clickable’ GPI anchor 1.111, a
diacylstearoyl glycerolipid was installed at the free inositol 1-O-position of common
intermediate 1.114 (Scheme 1.37). The phosphorylating reagent, phosphoramidite
1.192, was prepared in a manner identical to that shown for compound 1.179 in
Scheme 1.31, and with similar yields. The phospholipidation reaction proceeded
smoothly with 1H-tetrazole as the promoter and after oxidation of intermediate
phosphite 1.193 to a phosphate, compound 1.194 was isolated as a ~1:1 mixture of
diastereomers originating from the stereogenic phosphorus atom. I again employed
triethylamine trihydrofluoride to remove the glucosamine 4-O-TBS group. The
desilylation reaction was clean but comparably slow, requiring stirring for 7 days at room
temperature. The desired phospholipidated pseudodisaccharide 1.195 was obtained in
54% yield over three steps, and separation of the two diastereomers was completed at
this stage using semi-preparative HPLC.

Scheme 1.37. Phospholipidation of 1.78 to install saturated lipid chains
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I first attempted the key glycosylation reaction by directly activating trimannose
thioglycoside 1.115 in the presence of acceptor 1.195. Because the donor contained an
allyl ether protecting group at the Man-I 2-O-position, an orthogonal thioether activation
protocol was necessary. Thus, in lieu of the standard NIS/AgOTf combination, I made
use of para-toluenesulfenyl chloride (p-TolSCl), AgOTf and TTBP, a reagent system
developed by Crich.142-143 These conditions did result in the formation of desired
pseudopentasaccharide 1.197, but in only ~20% yield, prompting me to evaluate
alternative glycosylation methods. Because of prior success using the Schmidt
glycosylation, trimannose thioglycoside 1.115 was converted to trichloroacetimidate
1.196 in two steps (Scheme 1.38). First, the p-TolSCl/AgOTf/TTBP reagent system
used in combination with wet CH2Cl2 was applied to hydrolyze the substrate, providing
the corresponding intermediate hemiacetal in 68% yield (BRSM). Treatment of this
intermediate with trichloroacetonitrile and DBU gave glycosyl imidate 1.196, which was
then tested in the key glycosylation reaction. Usage of 0.1 equivalents of TMSOTf in
Et2O at 0 °C effected a successful activation of imidate 1.196, which reacted with
acceptor 1.195 efficiently to provide only the α-linked pseudopentasaccharide 1.197.
After work-up and without purification, 1.197 was treated with triethylamine
trihydrofluoride in CH3CN-THF overnight, which resulted in clean removal of the Man-III
6-O-TBS group. Purification at this stage gave GPI alcohol 1.198 in 81% yield over two
steps, including the key glycosylation reaction. This intermediate was fully characterized
using 1D/2D NMR spectroscopy and MS, and the mannosidic bonds were established
as α by coupled

13

C NMR JCH values (125 MHz): 101.09 (JCH = 167 Hz, Man-1), 99.79

(JCH = 174 Hz, Man-1), 99.79 (JCH = 174 Hz, Man-1), 97.94 (JCH = 177 Hz, GlcN3-1).

77

Scheme 1.38. Key glycosylation reaction

At this point, GPI intermediate 1.198 was ready for addition of

a

phosphoethanolamine group to the Man-III 6-O-position, for which phosphoramidite
1.189 was again used as the phosphorylating reagent (Scheme 1.39). The reaction was
fast, quantitatively forming a phosphite intermediate in ~1 hr. After cooling the reaction
mixture to -40 °C, t-BuOOH was used to chemoselectively oxidize the phosphite to
phosphate 1.199 in situ without affecting the Man-I 2-O-allyl group. The phosphorylation
process proceeded in 81% yield and, as previously, generated a ~1:1 mixture of
diastereomers

that

were

separated

by

semi-preparative

HPLC

to

facilitate

characterization. Next, removal of the Man-I 2-O-allyl group of 1.199 was realized by
using the aforementioned Ir(I)/Hg(II) protocol, which afforded secondary alcohol 1.200 in
90% yield (of note: a stoichiometric amount of the iridium catalyst was required, and the
isomerization reaction could not be monitored by TLC).
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Scheme 1.39. Phosphorylation and deallylation

Installation of the alkyne ‘click tag’ and global deprotection to afford target GPI
1.111 are shown in Scheme 1.40. Functionalization of the Man-I 2-O-position proved to
be a formidable task, likely a result of poor nucleophilicity, which was also encountered
at this site in the synthesis of GPIs bearing unsaturated lipid chains (Scheme 1.35).
Initially, direct esterification of 1.200 was attempted by using an alkyne-containing
carboxylic acid (e.g., pentanoic acid) and standard coupling conditions such as EDCI
and 1-hydroxybenzotriazole (HOBt) or DMAP. However, even upon heating, the desired
acylation products were not observed. Difficulty was also encountered when attempting
to use acid chlorides. Fortunately, I found that the substrate could undergo succinylation
in 67% yield when employing a large excess of succinic anhydride, DMAP, and
molecular sieves. Addition of a succinate “linker” to the GPI provided a carboxylic acid
handle in intermediate 1.201, thus allowing me to perform a much more facile
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Scheme 1.40. Alkyne functionalization and deprotection to afford ‘clickable’ GPI

amidation reaction to install the desired alkyne functionality. Accordingly, the GPI
carboxylic acid 1.201 was treated with propargyl amine under standard amide bondforming conditions (EDCI/HOBt). This reaction successfully attached the ‘clickable’
alkyne functional group, furnishing fully protected GPI 1.202 in 75% yield. For the global
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deprotection sequence, I employed the three-step, one-pot protocol developed
previously: (1) zinc-mediated reduction of the azide for 1 h; (2) after filtration and
evaporation, removal of the base-labile Fmoc and cyanoethoxy groups by treatment
with DBU for 1 h; (3) direct addition of 20% TFA to quench the DBU and give a final
concentration of 10% TFA, which removed all PMB groups in 30 min. After coevaporation of the reaction mixture with toluene to remove volatile TFA, the crude
material was purified using a Sephadex LH-20 size exclusion column. This protocol
again proved effective, as the desired ‘clickable’ GPI anchor 1.111 was obtained in 85%
yield over the three deprotection steps. Characterization of the target molecule was
accomplished using 1D/2D NMR spectroscopy and MALDI MS.

1.2.12 Synthesis of Biotinylated GPI 1.112
After establishing a successful synthesis of clickable GPI 1.111, the structurally
analogous biotinylated GPI 1.112 could be prepared expediently from a common
intermediate, GPI carboxylic acid 1.201 (Scheme 1.41). Reaction of this compound with
a commercially available biotin derivative, PEG3-biotin-amine 1.203, in the presence of
EDCI and HOBt provided fully protected GPI 1.204 in 70% yield. Finally, the three-step,
one-pot global deprotection and subsequent purification described above were used to
convert 1.204 into the target biotinylated GPI 1.112. An isolated yield of this compound
was not obtained due to a decomposition reaction that is discussed further in section
1.4. However, initial characterization of the final product using MALDI MS showed a
single species corresponding to the desired compound, with no peaks relating to the
starting material or intermediates.
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Scheme 1.41. Biotin functionalization and deprotection to afford biotinylated GPI

1.3 Conclusions
In this work, a new global protecting group strategy was developed to enable the
synthesis of uniquely and usefully functionalized GPI anchors. By employing the acidlabile PMB group for permanent hydroxyl protection, a variety of functional groups that
are incompatible with current protection strategies (benzyl, acetyl, benzoyl) could be
incorporated into the target molecule, such as alkenes, alkynes, thiols and sulfides. To
demonstrate the utility and feasibility of this methodology, four functionalized GPI
anchors were synthesized, including GPIs bearing unsaturated lipid chains (1.109 and
1.110), an alkyne-containing ‘clickable’ GPI (1.111), and a biotinylated GPI (1.112).
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These syntheses were highlighted by several features: (1) Employing a convergent
assembly to increase efficiency and allow for easy customization of coupling partners;
(2) Incorporation of several PMB-orthogonal protecting groups for late-stage selective
functionalization; (3) Usage of the Schmidt glycosylation, which provided a relatively
mild means for stereoselective glycosidic bond formation; (4) Development of a highly
efficient three-step, one-pot global deprotection protocol that proceeded in 80-85% yield.
While the use of PMB protection greatly expands the accessibility of variously
modified GPIs, the sensitivity of PMB groups to acid/oxidation complicated certain
strategies and reactions. For example, I observed anydro sugar formation as a result of
PMB cleavage in two key glycosylation reactions, which required redesign of the
glycosyl donors. In addition, the choice of methods and reagents was limited in some
cases, such as in the removal of the hindered glucosamine 4-O-TBS group, where more
powerful desilylation reagents hydrolyzed PMB groups in the substrate. Furthermore, a
number of strategic alterations were required to accommodate the use of PMB groups.
For instance, the preparation of a suitable PMB-protected inositol derivative
necessitated an overhaul of the synthetic route used in most GPI syntheses. However,
despite some PMB-borne challenges and setbacks in this work, an efficient and robust
strategy for the construction of functionalized GPIs was eventually developed. By
demonstrating the practicality of global PMB protection in GPI synthesis, which is a
difficult and complex task, this strategy should also be broadly applicable in the
synthesis of other functionalized oligosaccharides.
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1.4 Future Work
Future work for this project will initially involve revisiting the synthesis of the
‘clickable’ and biotinylated GPI anchors. I observed that upon prolonged PMB
deprotection with TFA (overnight), the Man-I 2-O-ester bond of these molecules was
slowly cleaved. Furthermore, the same decomposition reaction occurred when the GPIs
were stored for extended periods (months) at -4 °C (Scheme 1.42). Because the
phosphatidylinositol ester-linked lipid chains remained intact during these processes, it
became clear that the Man-I 2-O-ester bond was particularly labile, and would clearly
not be a suitable linker for GPIs to be used in biological studies.

Scheme 1.42. Observed GPI decomposition

Instead, a new ‘clickable’ GPI anchor 1.205 containing a much more stable Man-I
2-O-ether linkage will be synthesized (Scheme 1.43). The pentynyl ether will be
installed during monomer preparation. It will act as a protecting group for the Man-I 2-Oposition and as a latent click functionality. In addition, this design should not only
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provide a much more stable functionalized GPI but greatly improve the efficiency of the
synthesis by removing three late-stage steps in the original synthesis (deallylation,
succinylation, amidation). Conversion of 1.205 to biotinylated GPI anchor 1.206 using
Cu-catalyzed [3+2] cycloaddition should be straightforward. This work will allow access
to cell-stable functionalized GPI anchors, and I do not expect any problems to arise
from this strategic modification.

Scheme 1.43. Redesigned stable GPIs

As soon as a sufficient quantity of biofunctionalized GPIs 1.205 and 1.206 are
prepared, their incorporation into various biological studies will be considered. The
versatility of these two compounds, arising from the alkyne and biotin tags, should allow
for their application to a broad range of studies. Although the details of such studies
have not yet been established, several planned projects include:
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1. Probing cell-surface GPIomics: By incubating GPI-deficient cell lines with the
synthetic biotinylated GPI anchor 1.206, the cell’s intact GPI anchoring
biosynthetic machinery will attach proteins/glycoproteins destined for GPI
anchorage to the phosphoethanolamine unit of 1.206. Isolation of the biotinylated
GPI-anchored proteins with a streptavidin column and proteomic analysis of the
resulting mixture will aid in profiling GPI-anchored molecules.

2. Visualization of GPIs on the cell surface: By ‘clicking’ a fluorescent label to
1.205 and other derivatives, GPI distribution on the cell surface may be
determined, and structure-dependent localization of GPIs may also be studied.

3. GPI-based vaccine development: Carbohydrate-based vaccines are usually
presented on carrier proteins such as BSA or KLH, a task that could be
accomplished by conjugating GPI-alkynes such as 1.205 to azide-modified
carrier proteins. Because GPIs are essential to various antigenic species, such
as the human sperm and lymphocyte CD52 antigens, it would be interesting to
identify GPI-containing epitopes for vaccine development.

These projects represent potential future applications of the biofunctionalized GPI
anchors synthesized in this work, and I expect these compounds to be useful in
designing other biological studies as well.
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1.4 Experimental
General Methods
Materials were obtained from commercial sources without further purification unless
otherwise noted. Anhydrous solvents were obtained either commercially or from an
MBRAUN alumina column solvent purification system. Molecular sieves were flamedried under hi-vacuum and used immediately after cooling. All reactions were carried
out in oven-dried glassware under argon unless otherwise noted. Analytical TLC was
performed on Whatman silica gel 60 Å plates (thickness 0.25 mm) and detected by UV
lamp, charring with phosphomolybdic acid in EtOH, or charring with 5% H2SO4 in EtOH.
Column chromatography was performed using Dynamic Adsorbents flash silica gel (3263 μm). 1H NMR spectra were recorded at 400 or 500 MHz with the chemical shifts
reported in ppm (δ) relative to CHCl3 (7.26 ppm), tetramethylsilane (0.00 ppm), or
CH3OH (3.30 ppm).
13

13

C NMR spectra were recorded at 100 or 125 MHz relative to the

C signal of CDCl3 (77.23 ppm) or CD3OD (49.3 ppm). 31P NMR spectra were recorded

at 160 MHz relative to the

31

P signal of phosphoric acid (0.00 ppm). Coupling constants

(J) are reported in hertz (Hz). Mass spectrometry was performed using either a Bruker
Daltonics Ultraflex MALDI TOF MS or Waters LCT Premier XE high resolution ESI MS.
Optical rotation values were recorded using a Rudolph Research Analytical Autopol III
automatic polarimeter. Microscale sample measurements were made using a Mettler
Toledo AX205 DeltaRange balance (for max 81 g, d = 0.01 mg).
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Preparation of Compounds
(±)-1,6-di-O-Allyl-myo-inositol (1.207)

To a solution of (±)-1.125 (9.00 g, 21.4 mmol) in anhydrous CH2Cl2/MeOH (2:1, 150 mL)
stirring under an Ar atmosphere at rt was added acetyl chloride (1.0 mL) dropwise. After
3 h, the reaction was quenched with triethylamine and concentrated in vacuum. The
crude material was purified by silica gel column chromatography to give (±)-1.207 (5.55
g, 98%) as a white solid. NMR (500 MHz, CD3OD): δ 5.94-5.84 (m, 2 H), 5.23 (dd, J =
2.0, 17.5 Hz, 1 H), 5.17 (dd, J = 1.5, 17 Hz, 1 H), 5.06 (dd, J = 1.0, 10.5 Hz, 1 H), 5.01
(dd, J = 1.5, 10.5 Hz, 1 H), 4.22 (ddd, J = 6.0, 12.5, 19.5 Hz, 2 H), 4.11 (dd, J = 5.5, 13
Hz, 1 H), 4.02-3.99 (m, 2 H), 3.53 (t, J = 9.5 Hz, 1 H), 3.47 (t, J = 9.5 Hz, 1 H), 3.22-3.19
(m, 1 H), 3.17 (dd, J = 3.0, 10 Hz, 1 H), 3.14 (t, J = 9.0 Hz, 1 H). 13C NMR (CD3OD, 125
MHz): δ 137.11, 136.53, 117.06, 116.54, 82.08, 81.17, 76.09, 75.27, 74.17, 73.13,
72.22, 71.11. HR ESI MS: calcd. for C12H20O6Na [M+Na]+ m/z, 283.1158; found,
283.1152. To identify the desired enantiomer of compound 1.116, an analogous route
was developed starting with optically active inositol (+)-1.7, which was prepared using a
known enzymatic resolution procedure.108 Optical rotation for the correct enantiomer of
1.207 generated by authentication route: [α]D25 = -21o (c 1.0, CH3OH).
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(±)-1,6-di-O-Allyl-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.126)

To a solution of (±)-1.207 (5.30 g, 20.3 mmol) in anhydrous DMF (100 mL) stirring under
Ar at 0 ºC was slowly added NaH (60% dispersion in mineral oil, 3.65 g, 91.4 mmol).
After stirring for 30 min, p-methoxybenzyl chloride (10.3 mL, 98.3 mmol) was added
dropwise. The reaction was stirred overnight at rt, then quenched with MeOH, diluted
with EtOAc, and poured into water. The aqueous layer was extracted 3x with EtOAc,
after which the combined organic layer was washed with brine, dried over Na2SO4, and
concentrated in vacuum. The residue was purified by silica gel column chromatography
to give (±)-1.126 (11.0 g, 73%) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.35-7.25 (m,
8 H), 6.89-6.84 (m, 8 H), 6.04-5.97 (m, 1 H), 5.96-5.88 (m, 1 H), 5.31 (dd, J = 1.0, 17 Hz,
1 H), 5.29 (dd, J = 1.0, 17.5 Hz, 1 H), 5.19-5.15 (m, 2 H), 4.75-4.84 (m, 6 H), 4.60 (d, J
= 11.5 Hz, 1 H), 4.55 (d, J = 11 Hz, 1 H), 4.39 (dd, J = 5.5, 12 Hz, 1 H), 4.31 (dd, J = 6.0,
12.5 Hz, 1 H), 4.13-4.05 (m, 2 H), 4.00-3.95 (m, 2 H), 3.86 (t, J = 9.0 Hz, 1 H), 3.83 (s, 3
H), 3.81 (s, 3 H), 3.80 (s, 6 H), 3.38 (t, J = 9.5 Hz, 1 H), 3.32 (dd, J = 2.0, 10 Hz, 1 H),
3.18 (dd, J = 1.5, 9.5 Hz, 1 H).

13

C NMR (CDCl3, 125 MHz): δ 159.38, 159.34, 159.19,

135.83, 135.32, 131.50, 131.45, 131.41, 130.90, 129.91, 129.75, 129.63, 129.38,
116.72, 116.64, 113.99, 113.73, 83.71, 81.75, 81.63, 80.94, 80.89, 75.81, 75.69, 74.78,
74.19, 73.81, 72.64, 71.89, 55.51. HR ESI MS: calcd. for C44H52O10Na [M+Na]+ m/z,
763.3458; found, 763.3448. Optical rotation for the correct enantiomer of 1.126
generated by authentication route: [α]D25 = -9.0o (c 1.0, CHCl3).
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(±)-2,3,4,5-tetra-O-(p-Methoxybenzyl)-myo-inositol (1.127)

To a solution of (±)-1.126 (10.5 g, 14.2 mmol) and titanium(IV) isopropoxide (9.20 mL,
31.2 mmol) in THF (100 mL) was slowly added cyclohexylmagnesium chloride (2.0 M
solution in THF, 85 mL) via a dropping funnel under an Ar atmosphere at rt. After 2 h,
the reaction was poured into 0.5 N HCl and the aqueous layer was extracted 3x with
Et2O. The combined organic layer was washed with brine, dried over Na2SO4, and
concentrated in vacuum. The resulting residue was purified by silica gel column
chromatography to obtain (±)-1.127 (7.9 g, 85%) as a syrup. 1H NMR (500 MHz,
CDCl3): δ 7.30-7.26 (m, 8 H), 6.89-6.85 (m, 8 H), 4.98 (d, J = 11.0 Hz, 1 H), 4.88 (d, J =
11.0 Hz, 1 H), 4.87 (d, J = 10.5 Hz, 1 H), 4.77 (d, J = 10 Hz, 1 H), 4.69 (d, J = 11 Hz, 1
H), 4.68 (d, J = 11.5 Hz, 1 H), 4.63 (d, J = 11.5 Hz, 1 H), 4.59 (d, J = 11.5 Hz, 1 H),
3.99-3.95 (m, 2 H), 3.83 (s, 3 H), 3.82 (s, 6 H), 3.81 (s, 3 H), 3.77 (t, J = 9.5 Hz, 1 H),
3.44 (dd, J = 2.0, 9.5 Hz, 1 H), 3.37-3.33 (m, 1 H), 3.28 (t, J = 9.0 Hz, 1 H). 13C NMR
(CDCl3, 125 MHz): δ 159.48, 131.12, 129.94, 129.75, 129.67, 129.52, 114.18, 114.10,
114.05, 114.01, 82.94, 81.44, 81.37, 77.14, 75.65, 75.22, 74.71, 74.12, 73.08, 72.33,
55.52. HR ESI MS: calcd. for C38H44O10Na [M+Na]+ m/z, 683.2832; found, 683.2834.
Optical rotation for the correct enantiomer of 1.127 generated by authentication route:
[α]D25 = +7.0o (c 1.0, CHCl3).
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(±)-1-O-Allyl-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.128)

A mixture of (±)-1.127 (7.00 g, 10.6 mmol) and dibutyltin oxide (2.90, 11.7 mmol) in
anhydrous toluene (150 mL) was refluxed with azeotropic removal of water using a
Dean-Stark apparatus for 2 h. After concentration in vacuum, the residue was dissolved
in anhydrous DMF (100 mL) and cooled to 0 ºC, after which cesium fluoride (8.2 g, 54
mmol) and allyl bromide (4.6 mL, 54 mmol) were added to the solution. After stirring
overnight under an Ar atmosphere at rt, the reaction mixture was diluted with EtOAc,
washed with brine, dried over Na2SO4, and concentrated in vacuum. After passing the
crude products through a silica gel plug, the two regioisomers were separated by
preparative HPLC (Waters Nova-Pak Silica 6 μm, 300 x 19 mm, eluent 33% EtOAc in
hexanes, 10 mL/min, tR = 13.4 min) to give the desired product (±)-1.128 (5.39 g, 72%)
as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.33-7.25 (m, 8 H), 6.90-6.85 (m, 8 H),
5.94-5.86 (m, 1 H), 5.28 (dd, J = 1.5, 17 Hz, 1 H), 5.20 (dd, J = 1.0, 10 Hz, 1 H), 4.85
(d, J = 10.5 Hz, 1 H), 4.84 (d, J = 11 Hz, 1 H), 4.80-4.73 (m, 4 H), 4.63 (d, J = 11 Hz, 1
H), 4.57 (d, J = 11 Hz, 1 H), 4.10-3.97 (m, 5 H), 3.83 (s, 3 H), 3.81 (s, 6 H), 3.81 (s, 1 H),
3.35 (dd, J = 2.5, 9.5 Hz, 1 H), 3.34 (t, J = 9.0 Hz, 1 H), 3.09 (dd, J = 2.0, 10.0 Hz, 1 H).
13

C NMR (CDCl3, 125 MHz): δ 159.43, 159.37, 159.26, 134.84, 131.38, 131.24, 130.81,

129.94, 129.70, 129.64, 129.41, 117.50, 114.08, 114.02, 113.98, 113.79, 83.44, 81.43,
81.19, 80.08, 75.68, 75.19, 73.82, 73.17, 72.94, 72.77, 71.32, 55.52. HR ESI MS: calcd.
for C41H48O10Na [M+Na]+ m/z, 723.3145; found, 723.3110. Optical rotation for the
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correct enantiomer of 1.128 generated by authentication route: [α]D25 = -8.5o (c 1.0,
CHCl3).

(-)-1-O-Allyl-6-O-[(1S)-camphanoyl]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol
(1.129)

To a solution of (±)-1.128 (5.10 g, 7.27 mmol), triethylamine (2.0 mL, 15 mmol), and 4(dimethylamino)pyridine (300 mg) in anhydrous CH2Cl2 (100 mL) under an Ar
atmosphere at 0 ºC was added (1S)-(-)-camphanic chloride (freshly prepared 1.0 M
solution in anhydrous CH2Cl2, 12.9 mL) dropwise. After stirring for 1 h, the reaction was
poured into water and extracted 3x with CH2Cl2, after which the combined organic layer
was washed with saturated aqueous NaHCO3, brine, dried over Na2SO4, and
concentrated in vacuum. The residue was then subjected to silica gel column
chromatography, which gave a 1:1 mixture of diastereomers. Preparative HPLC (Waters
Nova-Pak Silica 6 μm, 300 x 19 mm, eluent 25% EtOAc in hexanes, 10 mL/min, tR =
21.4 min) was used to separate the diastereomers, affording optically pure 1.129 (2.97
g, 46%) as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.35-7.32 (m, 2 H), 7.27-7.25 (m,
2 H), 7.21-7.18 (m, 4 H), 6.89-6.81 (m, 8 H), 5.83-5.76 (m, 1 H), 5.71 (t, J = 10 Hz, 1 H,
6-O-position shifted downfield after acylation, confirming regiochemistry of previous
step), 5.24 (dd, J = 1.5, 17 Hz, 1 H), 5.15 (dd, J = 1.5, 10.5 Hz, 1 H), 4.76 (m, 4 H), 4.70
(d, J = 10 Hz, 1 H), 4.62 (d, J = 10.5 Hz, 1 H), 4.61 (d, J = 11 Hz, 1 H), 4.54 (d, J = 11.5
Hz, 1 H), 4.09 (t, J = 10 Hz, 1 H), 4.03 (t, J = 1.5 Hz, 1 H), 3.97 (dd, J = 5.0, 12.5 Hz, 1
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H), 3.86-3.83 (m, 4 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.52 (t, J = 9.5 Hz, 1 H),
3.34 (dd, J = 2.5, 9.5 Hz, 1 H), 3.29 (dd, J = 2.0, 10.0 Hz, 1 H), 2.36 (ddd, J = 1.0, 4.0,
10 Hz, 1 H), 1.78-1.91 (m, 2 H), 1.59-1.64 (m, 1 H), 1.10 (s, 3 H), 1.06 (s, 3 H), 0.96 (s,
3 H).

13

C NMR (CDCl3, 125 MHz): δ 178.94, 166.94, 159.46, 159.38, 159.29, 159.21,

134.35, 131.19, 131.01, 130.92, 130.65, 129.92, 129.75, 129.45, 129.04, 117.30,
114.02, 113.96, 113.87, 113.81, 91.53, 81.35, 81.24, 80.65, 78.01, 75.68, 75.06, 74.74,
73.74, 72.82, 72.37, 70.82, 55.54, 55.51, 55.14, 54.55, 31.12, 29.18, 16.85, 9.93. [α]D25
= -11º (c 1.0, CHCl3). HR ESI MS: calcd. for C51H60O13Na [M+Na]+ m/z, 903.3932; found,
903.3889.

(-)-1-O-Allyl-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.116)

O

O
O

PMBO OPMB
OPMB
O
OPMB
AllO
(-)-1.129

1M NaOH
MeOH, THF

PMBO OPMB
OPMB
HO
AllO
OPMB
(-)-1.116

To a solution of (-)-1.129 (400 mg, 0.45 mmol) in anhydrous THF (4 mL) was added a
2.0 M solution of NaOH in MeOH (4 mL) at rt. After stirring at rt for 3 h, the reaction was
neutralized with AcOH. After concentration, the residue was dissolved in EtOAc, and the
resulting organic layer was washed with brine 3x, dried over Na2SO4, and concentrated
in vacuum. The residue was purified by silica gel column chromatography to give
optically pure (-)-9 (302 mg, 95%) as a white solid. The product was confirmed as the
correct enantiomer by comparison of optical rotation with a standard compound, which
was prepared from optically active (+)-1.7108 using an identical route. (-)-1.116: [α]D25 = -

93
7.5º (c 1.0, CHCl3), authentic standard: [α]D25 = -8.5º (c 1.0, CHCl3). All spectroscopic
data for (-)-1.116 are identical to those obtained for (±)-1.128.

Allyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranoside (1.131)

To a mixture of 1.130117 (3.80 g, 10.2 mmol), allyl alcohol (2.0 mL, 29 mmol), and MS 4
Å (1.0 g) in anhydrous CH2Cl2 stirring under Ar at 0 ºC was slowly added SnCl4 (1.0 M
solution in dry CH2Cl2, 30.0 mL). After the reaction stirred overnight at rt, additional
SnCl4 (1.0 M solution in dry CH2Cl2, 30.0 mL) was added and stirring continued for
another 48 h (total ~72 h). After filtration through celite to remove MS, the reaction was
quenched by pouring into cold, saturated aqueous NaHCO3, which was extracted 3x
with CH2Cl2. The combined organic layer was then washed with saturated aqueous
NaHCO3 and brine, dried over Na2SO4, and concentrated in vacuum. The residue was
purified by silica gel column chromatography to give α,β-mixture 1.131 (3.0 g, 81%) as a
syrup. NMR data is consistent with those reported in the literature144 (1H NMR and HR
ESI MS spectra are included in the supplemental information). HR ESI MS: calcd. for
C15H21N3O8Na [M+Na]+ m/z, 394.1226; found, 394.1231.
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Allyl 2-azido-2-deoxy-4,6-O-(p-methoxybenzylidene)-D-glucopyranoside (1.132)
CH(OMe)2
AcO
AcO

OAc
O

1.131 N3

OAll

NaOMe

PMP

MeO

MeOH

CSA, DMF

O
O
HO

O

OAll

1.132 N3

After a solution of 1.131 (2.6 g, 7.0 mmol) in 33 mL of 0.05 M NaOMe in methanol was
stirred at rt for 30 min, it was neutralized to pH 6-7 using Amberlyst H+ resin. The
solution was filtered off and concentrated to afford a white powder (1.75 g), which was
directly used for the next step. After the crude triol was dissolved in anhydrous DMF (40
mL), p-anisaldehyde dimethyl acetal (1.6 mL, 9.1 mmol) and camphor sulfonic acid (160
mg, 0.70 mmol) were added. The reaction was stirred for 12 h under an Ar atmosphere
at rt while periodically removing MeOH under reduced pressure. After dilution with
EtOAc, the organic layer was washed with saturated aqueous NaHCO3 and brine, dried
over Na2SO4, and concentrated in vacuum. The residue was purified by silica gel
column chromatography to obtain α,β-mixture 1.132 (1.94 g, 77%, 2 steps) as a syrup.
1

H NMR (500 MHz, CDCl3) of β anomer: δ 7.42-7.40 (m, 2 H), 6.92-6.89 (m, 2 H), 6.00-

5.93 (m, 1 H), 5.50 (s, 1 H), 5.37 (dd, J = 1.5, 17 Hz, 1 H), 5.27 (dd, J = 1.0, 10 Hz, 1 H),
4.46 (d, J = 8.0 Hz, 1 H, 1-position), 4.41 (dd, J = 5.0, 12.5 Hz, 1 H), 4.32 (dd, J = 5.5,
11 Hz, 1 H), 4.18 (dd, J = 6.0, 12.5 Hz, 1 H), 3.81 (s, 3 H), 3.77 (t, J = 10 Hz, 1 H), 3.64
(dt, J = 2.0, 9.5 Hz, 1 H), 3.53 (t, J = 9.5 Hz, 1 H), 3.43 (dd, J = 8.0, 9.5 Hz, 1 H), 3.413.36 (m, 1 H), 2.82 (d, J = 2.0 Hz, 1 H).

13

C NMR (CDCl3, 125 MHz) of β anomer: δ

160.56, 133.34, 129.48, 127.83, 118.49, 113.98, 102.15, 101.66, 80.80, 72.24, 70.98,
68.70, 66.62, 66.39, 55.55. [α]D25 of β anomer = -53º (c 1.0, CHCl3). HR ESI MS: calcd.
for C17H22N3O6 [M+H]+ m/z, 364.1509; found, 364.1511.
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Allyl 2-azido-2-deoxy-3-O-(p-methoxybenzyl)-4,6-O-(p-methoxybenzylidene)-Dglucopyranoside (1.133)

To a solution of 1.132 (1.70 g, 4.67 mmol) in anhydrous DMF (40 mL) stirring under Ar
at 0 ºC was slowly added NaH (60% dispersion in mineral oil, 0.92 g, 5.9 mmol). After
stirring for 30 min, p-methoxybenzyl chloride (0.62 mL, 5.9 mmol) was added dropwise.
The reaction was stirred overnight at rt, then quenched with MeOH, diluted with EtOAc,
and poured into water. The aqueous layer was extracted 3x with EtOAc, after which the
combined organic layer was washed with brine, dried over Na2SO4, and concentrated in
vacuum. The residue was purified by silica gel column chromatography to give α,βmixture 1.133 (2.20 g, 97%) as a syrup. 1H NMR (500 MHz, CDCl3) of β anomer: δ 7.437.41 (m, 2 H), 7.32-7.30 (m, 2 H), 6.94-6.87 (m, 4 H), 6.00-5.92 (m, 1 H), 5.55 (s, 1 H),
5.37 (dd, J = 1.5, 17.5 Hz, 1 H), 5.26 (dd, J = 1.5, 10.5 Hz, 1 H), 5.34 (d, J = 11 Hz, 1 H),
4.74 (d, J = 11 Hz, 1 H), 4.40 (d, J = 8.0 Hz, 1 H, 1-position), 4.39-4.37 (m, 1 H), 4.33 (d,
J = 4.5, 10.5 Hz, 1 H), 4.17 (dd, J = 6.0, 12.5 Hz, 1 H), 3.84 (s, 3 H), 3.81 (s, 3 H), 3.79
(t, J = 10 Hz, 1 H), 3.69 (t, J = 9.5 Hz, 1 H), 3.46 (dd, J = 8.0, 9.5 Hz, 1 H), 3.40-3.35 (m,
1 H).

13

C NMR (CDCl3, 125 MHz) of β anomer: δ 160.34, 159.64, 133.48, 130.18,

129.88, 127.56, 118.39, 114.03, 113.88, 101.63, 101.54, 81.77, 78.86, 74.80, 70.92,
68.77, 66.47, 66.34, 55.55, 55.51. [α]D25 of α anomer = +12º (c 1.0, CHCl3). HR ESI MS:
calcd. for C25H30N3O7 [M+H]+ m/z, 484.2084; found, 484.2097.
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Allyl 2-azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-D-glucopyranoside (1.134)

To a mixture of 1.133 (630 mg, 1.3 mmol), NaBH3CN (818 mg, 13 mmol), and MS 4 Å
(100 mg) in anhydrous THF (10 mL) stirring under Ar at 0 ºC was added dry hydrogen
chloride (1.0 M solution in Et2O) dropwise until a pH of ~1 was reached. After 1 h, the
reaction was filtered through celite to remove MS. The filtrate was then diluted with
EtOAc and washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, and
concentrated in vacuum. The residue was purified by silica gel column chromatography
to give α,β-mixture 1.134 (448 mg, 71%) as a syrup. 1H NMR (500 MHz, CDCl3) of β
anomer: δ 7.27-7.25 (m, 2 H), 7.34-7.32 (m, 2 H), 6.92-6.88 (m, 4 H), 5.99-5.91 (m, 1 H),
5.35 (dd, J = 1.5, 17 Hz, 1 H), 5.23 (dd, J = 1.5, 10.5 Hz, 1 H), 4.85 (d, J = 11 Hz, 1 H),
4.72 (d, J = 11 Hz, 1 H), 4.54 (d, J = 11.5 Hz, 1 H), 4.49 (d, J = 11.5 Hz, 1 H), 4.39 (dd,
J = 5.5, 13 Hz, 1 H), 4.33 (d, J = 8.0 Hz, 1 H, 1-position), 4.14 (dd, J = 6.5, 13 Hz, 1 H),
3.82 (s, 6 H), 3.70 (d, J = 5.0 Hz, 2 H), 3.61 (t, J = 9.0 Hz, 1 H), 3.42-3.37 (m, 2 H), 3.25
(t, J = 9.0 Hz, 1 H), 2.64 (s, broad, 1 H).

13

C NMR (CDCl3, 125 MHz) of β anomer: δ

159.72, 159.61, 133.69, 130.44, 130.08, 129.95, 129.67, 118.03, 114.25, 114.11,
101.23, 82.39, 74.97, 74.05, 73.62, 72.47, 70.56, 70.22, 65.91, 55.52. [α]D25 of β
anomer = -35º (c 1.0, CHCl3). HR ESI MS: calcd. for C25H31N3O7Na [M+Na]+ m/z,
508.2060; found, 508.2065.
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Allyl 2-azido-4-O-(tert-butyldimethylsilyl)-2-deoxy-3,6-di-O-(p-methoxybenzyl)-Dglucopyranoside (1.135)

TBSOTf (0.53 mL, 2.3 mmol) was added dropwise to a solution of 1.134 (900 mg, 1.8
mmol) and 2,6-lutidine (0.30 mL, 2.6 mmol) in anhydrous CH2Cl2 (20 mL) stirring under
Ar at 0 ºC. After 2 h, the reaction was diluted with CH2Cl2, washed with saturated
aqueous NaHCO3 and brine, dried over Na2SO4, and concentrated in vacuum. The
residue was purified by silica gel column chromatography to afford α,β-mixture 1.135
(920 mg, 85%) as a syrup. 1H NMR (500 MHz, CDCl3) of β anomer: δ 7.31-7.26 (m, 4
H), 6.90-6.87 (m, 4 H), 6.01-5.94 (m, 1 H), 5.36 (dd, J = 2.0, 17.5 Hz, 1 H), 5.24 (dd, J =
1.5, 10 Hz, 1 H), 4.83 (d, J = 10.5 Hz, 1 H), 4.65 (d, J = 10.5 Hz, 1 H), 4.60 (d, J = 12 Hz,
1 H), 4.46-4.41 (m, 2 H), 4.37 (d, J = 8.5 Hz, 1 H, 1-position), 4.17 (dd, J = 6.0, 13 Hz, 1
H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.73 (dd, J = 2.0, 11.0 Hz, 1 H), 3.56-3.51 (m, 2 H), 3.433.36 (m, 2 H), 3.20 (dd, J = 8.5, 9.5 Hz, 1 H), 0.86 (s, 9 H), 0.04 (s, 3 H), 0.00 (s, 3 H).
13

C NMR (CDCl3, 125 MHz) of β anomer: δ 159.41, 159.32, 133.86, 130.61, 130.57,

129.45, 129.40, 117.84, 114.01, 113.93, 101.28, 83.25, 76.73, 74.97, 73.28, 71.28,
70.48, 69.18, 67.00, 55.53, 55.50, 26.17, 18.22, -3.42, -4.49. [α]D25 of β anomer = +18º
(c 1.0, CHCl3). HR ESI MS: calcd. for C31H45N3O7NaSi [M+Na]+ m/z, 622.2924; found,
622.2927.
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2-Azido-4-O-(tert-butyldimethylsilyl)-2-deoxy-3,6-di-O-(p-methoxybenzyl)-Dglucopyranose (1.136)

A solution of [Ir(COD)(PMePh2)2]PF6 (72 mg, 80 μmol) in anhydrous THF (5 mL) was
stirred under H2 at rt until the color turned from red to colorless to pale yellow (15 min).
After the H2 atmosphere was exchanged with Ar, 1.135 (410 mg, 0.68 mmol, solution in
5 mL THF) was added slowly. TLC showed that isomerization was complete after
stirring at rt for 1 h. The reaction was concentrated in vacuum, then dissolved in
acetone/H2O (9:1, 10 mL) and treated with HgCl2 (950 mg, 3.5 mmol) and HgO (17 mg,
80 μmol). The mixture was stirred at rt under an Ar atmosphere for 15 min, then
concentrated and purified by silica gel column chromatography to give hemiacetal 1.136
(323 mg, 85%) as a syrup. 1H NMR (500 MHz, CDCl3, all signals): δ 7.32-7.26 (m, 8 H),
6.90-6.87 (m, 8 H), 5.36 (d, J = 3.5 Hz, 1 H, 1-position of α-anomer), 4.81 (d, J = 10.5
Hz, 1 H), 4.79 (d, J = 10.5 Hz, 1 H), 4.66-4.58 (m, 4 H, includes 1-position of β-anomer),
4.42 (d, J = 12 Hz, 2 H), 4.07-4.04 (m, 1 H), 3.81 (s, 12 H), 3.77 (dd, J = 9.0, 10.5 Hz, 1
H), 3.68-3.64 (m, 2 H), 3.53 (t, J = 8.5 Hz, 1 H), 3.50-3.42 (m, 5 H), 3.35-3.30 (m, 2 H),
3.18 (dd, J = 8.0, 10 Hz, 1 H), 0.85 (s, 9 H), 0.82 (s, 9 H), -0.02 (s, 6 H), -0.03 (s, 3 H), 0.05 (s, 3 H). 13C NMR (CDCl3, 125 MHz), all signals: δ 159.62, 159.58, 159.31, 159.29,
130.51, 130.02, 129.91, 129.85, 129.78, 129.46, 129.34, 114.11, 114.07, 113.94,
113.90, 96.52, 92.28, 83.02, 80.13, 76.38, 75.10, 75.04, 73.34, 73.23, 72.08, 71.93,
71.42, 69.18, 69.12, 68.06, 64.68, 55.53, 55.50, 26.12, 26.09, 18.18, 18.15, -3.39, -3.44,
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-4.43, -4.50. HR ESI MS: calcd. for C28H41N3O7NaSi [M+Na]+ m/z, 582.2611; found,
582.2604.

6-O-[2-Azido-4-O-(tert-butyldimethylsilyl)-2-deoxy-3,6-di-O-(p-methoxybenzyl)-αD-glucopyranosyl]-1-O-allyl-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.138)

DBU (1 drop) was added to a solution of hemiacetal 1.136 (320 mg, 0.57 mmol) and
trichloroacetonitrile (0.5 mL) in anhydrous CH2Cl2 (5 mL) stirring under an Ar
atmosphere at 0 ºC. After 1 h, the reaction mixture was concentrated in vacuum and
purified with a triethylamine-neutralized silica gel column to give 1.117 (335 mg, 83%).
A mixture of the resulting trichloroacetimidate 1.117 (310 mg, 0.44 mmol), acceptor
1.116 (180 mg, 0.26 mmol), and MS 4 Å (100 mg) in anhydrous CH2Cl2 (5 mL) was
stirred under an Ar atmosphere at rt for 1 h. After cooling to -10 ºC, TMSOTf (10 μl, 44
μmol) was added and the reaction was stirred for 10 min. Neutralization with
triethylamine was followed by filtration through celite to remove MS, concentration in
vacuum, and purification by silica gel column chromatography to give an α,β-mixture of
the pseudodisaccharide as a syrup. Preparative HPLC (Waters Nova-Pak Silica 6 μm,
300 x 19 mm, eluent 20% EtOAc in hexanes, 10 mL/min, α-tR = 16.1 min, β-tR = 17.8
min) showed an α/β ratio of 1.2:1, and purification using this method afforded pure
1.138 (143 mg, 44%) as a white solid. Alternatively, the α,β-mixture can be taken
directly to the next step and purified thereafter using silica gel column chromatography.
1

H NMR (500 MHz, CDCl3): δ 7.38-7.22 (m, 10 H), 7.12-7.10 (m, 2 H), 6.92-6.83 (m, 10
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H), 6.83-6.77 (m, 2 H), 6.00-5.92 (m, 1 H), 5.78 (d, J = 3.5 Hz, 1 H, 1-position), 5.30 (dd,
J = 2.0, 17.5 Hz, 1 H), 5.20 (d, J = 1.5, 10.5 Hz, 1 H), 4.94 (d, J = 11.5 Hz, 1 H), 4.86 (d,
J = 10 Hz, 1 H), 4.85 (d, J = 10.5 Hz, 1 H), 4.80-4.78 (m, 3 H), 4.74 (d, J = 10.5 Hz, 1 H),
4.67 (d, J = 10 Hz, 1 H), 4.62 (d, J = 11.5 Hz, 1 H), 4.57 (d, J = 11.5 Hz, 1 H), 4.43 (d, J
= 11.5 Hz, 1 H), 4.35 (d, J = 11.5 Hz, 1 H), 4.28 (t, J = 9.5 Hz, 1 H), 4.09 (t, J = 9.5 Hz,
1 H), 4.03-3.99 (m, 4 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.80 (s,
3 H), 3.79 (s, 3 H), 3.78 (t, J = 9.0 Hz, 1 H), 3.73 (t, J = 10.0 Hz, 1 H), 3.40 (t, J = 9.5 Hz,
1 H), 3.39-3.35 (m, 3 H), 3.33 (dd, J = 2.0, 11 Hz, 1 H), 3.22 (dd, J = 4.0, 10.5 Hz, 1 H),
0.80 (s, 9 H), 0.01 (s, 3 H), -0.03 (s, 3 H). 13C NMR (CDCl3, 125 MHz): δ 159.46, 159.33,
159.31, 159.19, 158.97, 134.64, 131.24, 131.20, 130.86, 130.81, 130.75, 129.90,
129.72, 129.46, 129.39, 129.15, 128.57, 117.11, 114.04, 113.92, 113.87, 113.81, 97.99,
82.22, 82.03, 81.31, 80.93, 80.39, 75.67, 75.63, 74.84, 74.29, 73.90, 73.07, 72.68,
72.59, 71.67, 70.97, 68.27, 64.22, 55.55, 55.54, 55.52, 26.33, 18.29, -3.49, -4.61. [α]D25
= +51º (c 1.0, CHCl3). HR ESI MS: calcd. for C69H87N3O16NaSi [M+Na]+ m/z, 1264.5753;
found, 1264.5693.

6-O-[2-Azido-4-O-(tert-butyldimethylsilyl)-2-deoxy-3,6-di-O-(p-methoxybenzyl)-αD-glucopyranosyl]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.114)

A solution of [Ir(COD)(PMePh2)2]PF6 (6 mg, 7 μmol) in anhydrous THF (2.5 mL) was
stirred under H2 at rt until the color turned from red to colorless to pale yellow (10 min).
After the H2 atmosphere was exchanged with Ar, 1.138 (88 mg, 70 μmol, solution in 2.5
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mL THF) was added slowly. TLC showed that isomerization was complete after stirring
at rt for 1 h. The reaction was concentrated in vacuum, then dissolved in acetone/H2O
(9:1, 5 mL) and treated with HgCl2 (95 mg, 0.35 mmol) and HgO (2 mg, 7 μmol). The
mixture was stirred at rt under an Ar atmosphere for 5 min, then concentrated and
purified by silica gel column chromatography to give pseudodisaccharide 1.114 (81 mg,
96%) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.33-7.28 (m, 8 H), 7.19-7.17 (m, 4 H),
6.90-6.80 (m, 12 H), 5.53 (d, J = 4.0 Hz, 1 H, 1-position), 4.96 (d, J = 11 Hz, 1 H), 4.91
(d, J = 10.5 Hz, 1 H), 4.87 (d, J = 10 Hz, 1 H), 4.80 (d, J = 11 Hz, 1 H), 4.76-4.62 (m, 6
H), 4.30 (s, 2 H), 4.04 (t, J = 9.5 Hz, 1 H), 3.97 (t, J = 9.0 Hz, 1 H), 3.97-3.95 (m, 1 H),
3.92-3.89 (m, 1 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 6 H), 3.80 (s, 6 H), 3.77 (t, J =
8.5 Hz, 1 H), 3.72 (t, J = 9 Hz, 1 H), 3.63-3.60 (m, 1 H), 3.46-3.41 (m, 3 H), 3.38 (t, J =
9.5 Hz, 1 H), 3.27 (dd, J = 2.0, 10.5 Hz, 1 H), 3.17 (d, J = 7.0 Hz, 1 H), 0.85 (s, 9 H),
0.02 (s, 3 H), 0.00 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 159.52, 159.36, 159.34,

159.20, 159.14, 131.21, 131.15, 130.93, 130.58, 130.52, 130.37, 129.95, 129.84,
129.61, 129.10, 129.04, 114.10, 113.97, 113.94, 113.91, 113.87, 98.15, 81.84, 81.36,
80.90, 80.83, 80.29, 77.12, 75.62, 74.99, 74.79, 74.60, 73.52, 73.02, 72.91, 72.51,
70.91, 68.14, 64.98, 55.53, 55.49, 26.28, 18.24, -3.44, -4.60. [α]D25 = +10º (c 1.0,
CHCl3). HR ESI MS: calcd. for C66H83N3O16NaSi [M+Na]+ m/z, 1224.5440; found,
1224.5420.
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Phenyl 2-O-allyl-3-O-(p-methoxybenzyl)-4,6-O-(p-methoxybenzylidene)-1-thio-α-Dmannopyranoside (1.161)

A mixture of 1.159145 (1.36 g, 3.48 mmol) and dibutyltin oxide (0.95 g, 3.8 mmol) in
anhydrous toluene (50 mL) was refluxed with azeotropic removal of water using a DeanStark apparatus for 4 h. After cooling to rt and concentration in vacuum, the residue was
dissolved in anhydrous DMF (20 mL) and cooled to 0 ºC, after which cesium fluoride
(1.22 g, 8.00 mmol) and p-methoxybenzyl chloride (1.0 mL, 7.3 mmol) were added to
the solution. After stirring overnight under an Ar atmosphere at rt, the reaction mixture
was filtered through celite into cold saturated aqueous NaHCO3 and EtOAc. The
organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuum.
The residue was purified by silica gel column chromatography to give 1.160 (a small
scale NMR tube acetylation was performed to confirm the regiochemistry of the product),
which was taken directly to the next step. To a solution of 1.160 in anhydrous DMF (30
mL) under Ar at 0 ºC was added NaH (60% dispersion in mineral oil, 350 mg, 8.7 mmol).
After stirring for 30 min, allyl bromide (0.73 mL, 8.7 mmol) was added dropwise and the
reaction was stirred for 1 h. The reaction was quenched with MeOH and diluted with
EtOAc. The organic layer was washed with brine, dried over Na2SO4, and concentrated
in vacuum. The residue was purified by silica gel column chromatography to give 1.161
(1.3 g, 68%, 2 steps) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.46-7.44 (m, 4 H), 7.347.29 (m, 5 H), 6.93-6.89 (m, 4 H), 5.97-5.89 (m, 1 H), 5.60 (s, 1 H), 5.53 (d, J = 1.0 Hz,
1 H, 1-position), 5.30 (dd, J = 2.0, 17.5 Hz, 1 H), 5.21 (dd, J = 1.5, 10.5 Hz, 1 H), 4.81 (d,

103
J = 11.5 Hz, 1 H), 4.66 (d, J = 11.5 Hz, 1 H), 4.31-4.16 (m, 5 H), 3.96-3.93 (m, 2 H),
3.87 (t, J = 10 Hz, 1 H), 3.83 (s, 3 H), 3.83 (s, 3 H).

13

C NMR (125 MHz, CDCl3): δ

160.21, 159.48, 134.81, 134.15, 131.73, 130.69, 130.39, 129.62, 129.37, 127.82,
127.65, 118.19, 114.02, 113.79, 101.74, 87.53, 79.22, 78.38, 75.97, 73.07, 72.77, 68.71,
65.67, 55.54. [α]D25 = +154º (c 1.0, CHCl3). HR ESI MS: calcd. for C31H34O7NaS
[M+Na]+ m/z, 573.1923; found, 573.1925.

Phenyl 2-O-allyl-3,4-di-O-(p-methoxybenzyl)-1-thio-α-D-mannopyranoside (1.118)

To a solution of 1.161 (550 mg, 1.0 mmol) in anhydrous CH2Cl2 (15 mL) stirring under
Ar at 0 ºC was added DIBAL-H (1.0 M solution in toluene, 2.0 mL, 2.0 mmol) dropwise
over 1 h. After stirring at 0 ºC for an additional hour, saturated aqueous Na-K-tartrate
was added and the mixture was stirred vigorously for 2 h. After separation of the two
phases, the organic layer was washed with brine, dried over Na2SO4, and concentrated
in vacuum. The residue was purified by silica gel column chromatography to give 1.118
(471 mg, 85%) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.46-7.44 (m, 2 H), 7.36-7.26
(m, 7 H), 6.93-6.88 (m, 4 H), 5.97-5.89 (m, 1 H), 5.52 (d, J = 1.5 Hz, 1 H, 1-position),
5.30 (dd, J = 1.5, 17.5 Hz, 1 H), 5.22 (dd, J = 2.0, 10.5 Hz, 1 H), 4.88 (d, J = 10.5 Hz, 1
H), 4.68 (s, 2 H), 4.59 (d, J = 11 Hz, 1 H), 4.16 (d, J = 6.0 Hz, 2 H), 4.13-4.09 (m, 1 H),
3.95 (t, J = 9.5 Hz, 1 H), 3.92 (dd, J = 2.0, 3.0 Hz, 1 H), 3.88 (dd, J = 3.0, 9.5 Hz, 1 H),
3.84 (s, 3 H), 3.83-3.76 (m, 2 H), 3.82 (s, 3 H).

13

C NMR (125 MHz, CDCl3): δ 159.60,

159.57, 134.87, 134.27, 132.02, 130.79, 130.47, 129.98, 129.85, 129.35, 127.86,
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118.20, 114.14, 114.12, 86.34, 79.91, 76.65, 75.21, 74.80, 73.45, 72.29, 72.00, 62.51,
55.54. [α]D25 = +18º (c 1.0, CHCl3). HR ESI MS: calcd. for C31H36O7NaS [M+Na]+ m/z,
575.2079; found, 575.2063.

3,4,6-tri-O-(p-Methoxybenzyl)-1,2-O-(1-methoxyethylidene)-β-D-mannopyranoside
(1.164)

After a solution of 1.163141 (2.00 g, 5.52 mmol) in 15 mL of 0.05 M NaOMe in methanol
was stirred at rt for 20 min, it was concentrated to afford a white powder (note:
Neutralization with Amberlyst H+ resin caused significant decomposition of the
orthoester, so the reaction was taken directly to the next step). To the crude triol in
anhydrous DMF (30 mL) stirring under Ar at 0 ºC was slowly added NaH (60%
dispersion in mineral oil, 1.10 g, 27.5 mmol). After stirring for 30 min, p-methoxybenzyl
chloride (2.30 mL, 22.0 mmol) was added dropwise. The reaction was stirred for 3 h
while warming to rt and then quenched with MeOH and diluted with EtOAc. The solution
was washed with brine, dried over Na2SO4, and concentrated in vacuum. The residue
was purified by silica gel column chromatography to give 1.164 (2.50 g, 76 %, 2 steps)
as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.32-7.30 (m, 2 H), 7.25-7.24 (m, 2 H), 7.147.12 (m, 2 H), 6.87-6.82 (m, 6 H), 5.32 (d, J = 2.5 Hz, 1 H, 1-position), 4.78 (d, J = 10.5
Hz, 1 H), 4.73 (d, J = 12 Hz, 1 H), 4.70 (d, J = 11.5 Hz, 1 H), 4.54-4.47 (m, 3 H), 4.34
(dd, J = 2.5, 4.0 Hz, 1 H), 3.83 (t, J = 9.5 Hz, 1 H), 3.80 (s, 6 H), 3.79 (s, 3 H), 3.68-3.65
(m, 3 H), 3.38 (dt, J = 3.5, 9.0 Hz, 1 H), 3.28 (s, 3 H), 1.72 (s, 3 H). 13C NMR (125 MHz,
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CDCl3): δ 129.95, 129.86, 129.46, 114.13, 114.01, 113.94, 97.76, 78.83, 75.10, 74.44,
74.19, 73.23, 72.25, 68.90, 55.51, 49.98, 24.62. [α]D25 = +12º (c 1.0, CHCl3). HR ESI
MS: calcd. for C33H40O10Na [M+Na]+ m/z, 619.2519; found, 619.2524.

2-O-Acetyl-3,4,6-tri-O-(p-methoxybenzyl)-D-mannopyranose (1.165)

To a round bottom flask containing 1.164 (2.30 g, 3.85 mmol) was added AcOH/H2O
(1:1, 20 mL). The poorly soluble substrate went into solution as the reaction was stirred
vigorously at rt over 3 h, after which the solution was diluted with CH2Cl2 and poured
into a separatory funnel containing cold, saturated aqueous NaHCO3. The aqueous
phase was extracted with CH2Cl2 two additional times, and the combined organic layers
were washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, and
concentrated in vacuum. The resulting residue was purified by silica gel column
chromatography to give hemiacetal 1.165 (1.57 g, 70%) as a glassy syrup, while the
minor product was identified as the regioisomer containing 1-O-acetyl and 2-OH
functional groups. 1H NMR (500 MHz, CDCl3): δ 7.27-7.25 (m, 4 H), 7.05-7.03 (m, 2 H),
6.86-6.81 (m, 6 H), 5.35 (dd, J = 2.0, 3.0 Hz, 1 H), 5.20 (d, J = 2.0 Hz, 1 H, 1-position),
4.75 (d, J = 10.5 Hz, 1 H), 4.63 (d, J = 11 Hz, 1 H), 4.54 (d, J = 12 Hz, 1 H), 4.46 (d, J =
10 Hz, 1 H), 4.44 (d, J = 12 Hz, 1 H), 4.35 (d, J = 10.5 Hz, 1 H), 4.04-4.00 (m, 1 H), 3.99
(dd, J = 3.0, 9.0 Hz, 1 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.68 (t, J = 10 Hz, 1
H), 3.66-3.60 (m, 2 H), 3.37 (d, J = 3.5 Hz, 1 H), 2.14 (s, 3 H).

13

C NMR (125 MHz,

CDCl3): δ 170.74, 159.50, 159.44, 130.73, 130.37, 130.17, 129.96, 129.95, 129.76,
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114.04, 113.99, 113.94, 92.75, 77.55, 74.96, 74.49, 73.24, 71.67, 71.41, 69.31, 69.03,
55.50, 55.48, 55.45, 21.40. HR ESI MS: calcd. for C32H38O10Na [M+Na]+ m/z, 605.2363;
found, 605.2392.

Allyl 6-O-(p-methoxytriphenylmethyl)-α-D-mannopyranoside (1.167)
OAc
AcO
NaOMe
O
AcO
AcO
1.166 OAll MeOH

PMTrtCl
pyridine

OH
PMTrtO
O
HO
HO
1.167 OAll

After a solution of allyl 1.166146 (2.45 g, 7.24 mmol) in 20 mL of 0.05 M NaOMe in
methanol was stirred at rt for 30 min, it was neutralized to pH 6-7 using Amberlyst H+
resin. The solution was filtered off and concentrated to afford a white powder, which
was directly used for the next step. After the crude tetraol was dissolved in pyridine (30
mL), p-methoxytrityl chloride (5.60 g, 18.1 mmol) was added and the reaction was
stirred at rt for 2 h, then concentrated in vacuum and purified by silica gel column
chromatography to afford 1.167 (2.30 g, 66%, 2 steps) as a white foam. 1H NMR (500
MHz, CDCl3): δ 7.45-7.43 (m, 4 H), 7.28-7.33 (m, 6 H), 7.24-7.21 (m, 2 H), 6.83-6.84 (m,
2 H), 5.95-5.87 (m, 1 H), 5.30 (dd, J = 1.5, 17 Hz, 1 H), 5.21 (dd, J = 1.5, 10.8 Hz, 1 H),
4.86 (d, J = 1.5 Hz, 1 H, 1-position), 4.19 (dd, J = 5.5, 13.5 Hz, 1 H), 3.99 (dd, J = 6.5,
13 Hz, 1 H), 3.93 (dd, J = 1.5, 3.5 Hz, 1 H), 3.84-3.83 (m, 1 H), 3.79 (s, 3 H), 3.74-3.71
(m, 2 H), 3.43 (dd, J = 4.5, 9.5 Hz, 1 H), 3.39 (dd, J = 4.5, 9.5 Hz, 1 H).

13

C NMR (125

MHz, CDCl3): δ 158.92, 144.37, 144.25, 135.39, 133.89, 130.57, 128.54, 128.20,
127.31, 117.84, 113.49, 98.86, 87.33, 71.86, 70.72, 70.58, 70.15, 65.05, 55.46. [α]D25 =
+17º (c 1.0, CHCl3). HR ESI MS: calcd. for C29H32O7Na [M+Na]+ m/z, 515.2046; found,
515.2054.
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Allyl 2,3,4-tri-O-(p-methoxybenzyl)-6-O-(p-methoxytriphenylmethyl)-α-Dmannopyranoside (1.168)

To a solution of 1.167 (2.10 g, 4.26 mmol) in anhydrous DMF (40 mL) stirring under Ar
at 0 ºC was slowly added NaH (60% dispersion in mineral oil, 756 mg, 18.9 mmol). After
stirring for 30 min, p-methoxybenzyl chloride (1.97 mL, 18.9 mmol) was added dropwise.
The reaction was stirred overnight at rt and then quenched with MeOH and diluted with
EtOAc. The solution was washed with saturated aqueous NaHCO3 and brine, dried over
Na2SO4, and concentrated in vacuum. The residue was purified by silica gel column
chromatography to give 1.168 (2.61 g, 73 %) as a white foam. 1H NMR (500 MHz,
CDCl3): δ 7.52-7.51 (m, 4 H), 7.37-7.33 (m, 4 H), 7.30-7.20 (m, 8 H), 6.87-6.79 (m, 8 H),
6.71-6.70 (m, 2 H), 5.93-5.85 (m, 1 H), 5.25 (dd, J = 1.5, 17 Hz, 1 H), 5.17 (dd, J = 1.0,
10.5 Hz, 1 H), 4.92 (d, J = 1.5 Hz, 1 H, 1-position), 4.76 (d, J = 12 Hz, 1 H), 4.65-4.63
(m, 2 H), 4.59 (d, J = 12 Hz, 1 H), 4.56 (d, J = 11 Hz, 1 H), 4.24 (dd, J = 4.5, 12.5 Hz, 1
H), 4.18 (d, J = 10 Hz, 1 H), 3.99 (dd, J = 6.0, 13 Hz, 1 H), 3.94 (t, J = 9.5 Hz, 1 H), 3.87
(dd, J = 3.0, 9.5 Hz, 1 H), 3.81 (s, 3 H), 3.78-3.80 (m, 2 H), 3.78 (s, 3 H), 3.78 (s, 3 H),
3.77 (s, 3 H), 3.47 (dd, J = 1.5, 9.5 Hz, 1 H), 3.24 (dd, J = 5.5, 9.5 Hz, 1 H).

13

C NMR

(125 MHz, CDCl3): δ 159.30, 158.67, 145.02, 144.84, 136.08, 134.20, 131.09, 130.95,
130.79, 130.71, 130.07, 129.50, 129.44, 128.91, 128.83, 127.95, 126.89, 117.45,
113.97, 113.78, 113.24, 97.02, 86.13, 80.23, 75.32, 75.03, 74.93, 72.53, 72.23, 67.77,
63.12, 55.50, 55.48, 55.39. [α]D25 = +13º (c 1.0, CHCl3). HR ESI MS: calcd. for
C53H56O10Na [M+Na]+ m/z, 875.3771; found, 875.3762.
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Allyl 2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranoside (1.169)

After a solution of 1.168 (2.40 g, 2.81 mmol) in AcOH/CH2Cl2/H2O (15:4:1, 20 mL) was
stirred at rt for 2.5 h, it was diluted with CH2Cl2 and poured into cold, saturated aqueous
NaHCO3. The organic layer was washed with saturated aqueous NaHCO3 and brine,
then dried over Na2SO4. After concentration in vacuum, the residue was purified by
silica gel column chromatography to give 1.169 (1.53 g, 94%) as a syrup. 1H NMR (500
MHz, CDCl3): δ 7.29-7.28 (m, 4 H), 7.24-7.22 (m, 2 H), 6.88-6.85 (m, 6 H), 5.86-5.78 (m,
1 H), 5.20 (dd, J = 2.0, 17.5 Hz, 1 H), 5.15 (dd, J = 1.5, 10.5, 1 H), 4.85 (d, J = 10.5 Hz,
1 H), 4.79 (d, J = 1.5 Hz, 1 H, 1-position), 4.71 (d, J = 12 Hz, 1 H), 4.61 (d, J = 12, 1 H),
4.57-4.55 (m, 3 H), 4.10 (dd, J = 5.0, 13 Hz, 1 H), 3.91-3.87 (m, 3 H), 3.81 (s, 3 H), 3.80
(s, 3 H), 3.79 (s, 3 H), 3.74-3.79 (m, 3 H), 3.64-3.61 (m, 1 H).

13

C NMR (125 MHz,

CDCl3): δ 159.50, 159.39, 133.88, 130.91, 130.83, 130.53, 129.97, 129.75, 129.45,
117.49, 114.07, 114.01, 97.69, 80.16, 75.12, 74.90, 74.62, 72.81, 72.41, 72.15, 68.05,
62.70, 55.51. [α]D25 = +35º (c 1.0, CHCl3). HR ESI MS: calcd. for C33H40O9Na [M+Na]+
m/z, 603.2570; found, 603.2549.
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Allyl 6-O-(tert-butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-Dmannopyranoside (1.170)

A solution of 1.169 (1.50 g, 2.58 mmol) and TBSCl (777 mg, 5.16 mmol) in pyridine (25
mL) was stirred under Ar overnight at rt. After concentration to remove most of the
pyridine, the residue was dissolved in CH2Cl2 and poured into water. The aqueous layer
was extracted twice with CH2Cl2 and the combined organic layers were washed with
saturated aqueous NaHCO3 and brine, then dried over Na2SO4 and concentrated in
vacuum. The resulting residue was purified by silica gel column chromatography to
obtain 1.170 (1.62 g, 88%) as a glassy syrup. 1H NMR (500 MHz, CDCl3): δ 7.29-7.27
(m, 4 H), 7.23-7.21 (m, 2 H), 6.87-6.84 (m, 6 H), 5.86-5.80 (m, 1 H), 5.20 (dd, J = 1.5,
17 Hz, 1 H), 5.13 (dd, J = 1.5, 10.5 Hz, 1 H), 4.83 (d, J = 10.5 Hz, 1 H), 4.66 (d, J = 12.5
Hz, 1 H), 4.59 (d, J = 12 Hz, 1 H), 4.56-4.52 (m, 3 H, includes 1-position), 4.12 (dd, J =
4.5, 13 Hz, 1 H), 3.91-3.80 (m, 4 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.80 (s, 3 H), 3.79-3.77
(m, 1 H), 3.73 (dd, J = 2.0, 3.5 Hz, 1 H), 3.57 (ddd, J = 2.0, 5.0, 9.0 Hz, 1 H), 0.89 (s, 9
H), 0.064 (s, 3 H), 0.058 (s, 3 H). 13C NMR (125 MHz, CDCl3): δ 159.41, 159.35, 134.20,
131.20, 131.09, 130.78, 129.86, 129.58, 129.48, 117.24, 114.00, 113.95, 113.90, 97.01,
80.21, 74.96, 74.90, 74.79, 73.55, 72.34, 72.05, 67.66, 63.09, 55.50, 26.16, -4.90, -5.04.
[α]D25 = +23º (c 1.0, CHCl3). HR ESI MS: calcd. for C39H54O9NaSi [M+Na]+ m/z,
717.3435; found, 717.3434.
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6-O-(tert-Butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-D-mannopyranose
(1.171)

To a solution of 1.170 (491 mg, 0.707 mmol) in CH2Cl2/AcOH (1:1, 8 mL) was added
H2O (5 drops), sodium acetate (373 mg, 4.50 mmol), and palladium chloride (248 mg,
1.41 mmol). After stirring under Ar at rt for 5 h, the reaction was concentrated down to a
volume of ~1 mL and diluted with EtOAc. After catalyst filtration through celite, the
organic layer was washed with saturated aqueous NaHCO3 and brine, then dried over
Na2SO4 and concentrated in vacuum. The residue was purified by silica gel column
chromatography to give an α,β-mixture of hemiacetal 1.171 (381 mg, 82%). 1H NMR
(500 MHz, CDCl3, signals of major isomer): δ 7.32-7.22 (m, 6 H), 6.90-6.85 (m, 6 H),
5.19 (dd, J = 2.0, 3.5 Hz, 1 H, 1-position), 4.85 (d, J = 11 Hz, 1 H), 4.68 (d, J = 12 Hz, 1
H), 4.62-4.55 (m, 4 H), 3.94-3.92 (m, 1 H), 3.87-3.78 (m, 13 H), 3.74 (dd, J = 2.0, 3.0 Hz,
1 H), 3.37 (d, J = 3.0 Hz, 1 H), 0.90 (s, 9 H), 0.070 (s, 3 H), 0.061 (s, 3 H).

13

C NMR

(125 MHz, CDCl3, all signals): δ 164.46, 164.38, 136.23, 136.10, 135.90, 134.96,
134.81, 134.60, 119.15, 119.05, 119.01, 118.96, 98.68, 97.91, 87.79, 84.60, 81.62,
80.17, 80.10, 79.94, 79.88, 79.53, 79.28, 78.59, 77.86, 77.44, 77.23, 77.13, 68.51,
67.88, 60.57, 60.54, 26.27, 26.20, -4.85, -5.03. HR ESI MS: calcd. for C36H50O9NaSi
[M+Na]+ m/z, 677.3122; found, 677.3103.

111
Phenyl O-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-2-O-allyl-3,4di-O-(p-methoxybenzyl)-1-thio-α-D-mannopyranoside (1.173)

DBU (5 drops) was added to a solution of hemiacetal 1.171 (735 mg, 1.26 mmol) and
trichloroacetonitrile (0.5 mL) in anhydrous CH2Cl2 (12 mL) stirring under an Ar
atmosphere at 0 ºC. After 20 min, the reaction mixture was concentrated in vacuum and
purified with a triethylamine-neutralized silica gel column to give 1.119 (706 mg, 77%).
A mixture of the resulting trichloroacetimidate 1.119 (706 mg, 0.97 mmol), acceptor
1.118 (413 mg, 0.75 mmol), and MS 4 Å (150 mg) in anhydrous CH2Cl2 (10 mL) was
stirred under an Ar atmosphere at rt for 1 h. After cooling to 0 ºC, TMSOTf (10 μl, 55
μmol) was added and the reaction was stirred for 5 min. Neutralization with
triethylamine was followed by filtration through celite to remove MS, concentration in
vacuum, and purification by silica gel column chromatography to give crude 1.172,
which was dissolved in anhydrous MeOH (10 mL) and treated with K2CO3 (to pH ~9).
After stirring for 1 h, the reaction was neutralized by Amberlyst H+ resin, filtered, and
concentrated in vacuum. The residue was purified by silica gel column chromatography
to afford α anomer 1.173 (530 mg, 66%, 2 steps) as a syrup. 1H NMR (500 MHz, CDCl3):
δ 7.45-7.43 (m, 2 H), 7.35-7.33 (m, 2 H), 7.28-7.25 (m, 5 H), 7.20-7.19 (m, 2 H), 7.087.06 (m, 2 H), 6.92-6.90 (m, 2 H), 6.85-6.81 (m, 10 H), 5.97-5.89 (m, 1 H), 5.52 (d, J =
1.5 Hz, 1 H, Man-I 1-position), 5.31 (dd, J = 1.5, 17 Hz, 1 H), 5.20 (dd, J = 1.5, 10.5 Hz,
1 H), 4.99 (d, J = 1.5 Hz, 1 H, Man-II 1-position), 4.85 (d, J = 11 Hz, 1 H), 4.74 (d, J = 10
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Hz, 1 H), 4.69-4.63 (m, 2 H), 4.61-4.54 (m, 3 H), 4.45 (d, J = 10.5 Hz, 1 H), 4.41 (d, J =
12 Hz, 1 H), 4.38 (d, J = 10 Hz, 1 H), 4.20-4.09 (m, 3 H), 4.05 (s, broad, 1 H), 3.93-3.86
(m, 3 H), 3.83 (s, 3 H), 3.81 (s, 3 H), 3.78 (s, 3 H), 3.77 (s, 3 H), 3.75 (s, 3 H), 3.84-3.75
(m, 3 H), 3.72-3.66 (m, 3 H), 3.59 (dd, J = 1.5, 10.5 Hz, 1 H), 2.41 (s, broad, 1 H).

13

C

NMR (125 MHz, CDCl3): δ 159.59, 159.57, 159.45, 159.38, 159.34, 135.02, 134.94,
131.15, 131.05, 130.80, 130.60, 130.44, 130.29, 129.90, 129.85, 129.81, 129.78,
129.75, 129.35, 127.43, 118.03, 114.16, 114.12, 114.03, 113.94, 113.84, 99.82, 85.96,
80.09, 79.64, 76.65, 75.11, 74.91, 74.65, 74.12, 73.15, 72.72, 72.13, 71.63, 71.51,
71.23, 68.61, 68.30, 66.71, 55.53, 55.51, 55.45. [α]D25 = +78º (c 1.0, CHCl3). HR ESI
MS: calcd. for C61H70O15NaS [M+Na]+ m/z, 1097.4333; found, 1097.4349.

Phenyl [6-O-(tert-butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-Dmannopyranosyl]-(1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→6)-2-O-allyl-3,4-di-O-(p-methoxybenzyl)-1-thio-α-D-mannopyranoside (1.115)

DBU (2 drops) was added to a solution of hemiacetal 1.171 (144 mg, 0.22 mmol) and
trichloroacetonitrile (0.3 mL) in anhydrous CH2Cl2 (3 mL) stirring under an Ar
atmosphere at 0 ºC. After 1 h, the reaction mixture was concentrated in vacuum and
purified with a triethylamine-neutralized silica gel column to give 1.120 (129 mg, 73%).
A mixture of the resulting trichloroacetimidate 1.120 (129 mg, 0.16 mmol), acceptor
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1.173 (121 mg, 0.11 mmol), and MS 4 Å (50 mg) in anhydrous Et2O (5 mL) was stirred
under an Ar atmosphere at rt for 1 h. After cooling to 0 ºC, TMSOTf (3 μl, 16 μmol) was
added and the reaction was stirred for 5 min. Neutralization with triethylamine was
followed by filtration through celite to remove MS, concentration in vacuum, and
purification by silica gel column chromatography to give α anomer 1.115 (145 mg, 76%)
as a syrup. 1H NMR (500 MHz, CDCl3) : δ 7.46-7.45 (m, 2 H), 7.34-7.32 (m, 2 H), 7.267.17 (m, 14 H), 7.15-7.10 (m, 3 H), 6.91-6.75 (m, 16 H), 5.95-5.87 (m, 1 H), 5.51 (d, J =
1.5 Hz, 1 H, Man-I 1-position), 5.30 (dd, J = 1.5, 17 Hz, 1 H), 5.23 (d, J = 1.0 Hz, 1 H,
Man-III 1-position), 5.18 (dd, J = 1.0, 10 Hz, 1 H), 4.85 (d, J = 10.5 Hz, 1 H), 4.82 (d, J =
2.0 Hz, 1 H, Man-II 1-position), 4.82 (d, J = 10.5 Hz, 1 H), 4.77 (d, J = 10.5 Hz, 1 H),
4.66 (d, J = 11.5 Hz, 1 H), 4.63 (d, J = 11.5 Hz, 1 H), 4.60 (d, J = 12 Hz, 1 H), 4.55 (d, J
= 10.5 Hz, 1 H), 4.51-4.47 (m, 2 H), 4.46 (d, J = 10.5 Hz, 1 H), 4.45 (d, J = 10.5 Hz, 1 H),
4.42-4.36 (m, 5 H), 4.22-4.15 (m, 2 H), 4.10-4.07 (m, 2 H), 3.96-3.91 (m, 3 H), 3.89-3.84
(m, 4 H), 3.83 (s, 3 H), 3.83-3.82 (m, 2 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.79-3.77 (m, 1
H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.74 (s, 3 H), 3.74-3.72 (m, 2 H), 3.69 (s, 3 H), 3.68 (s, 3
H), 3.66-3.63 (m, 2 H), 3.62-3.57 (m, 2 H), 0.88 (s, 9 H), 0.05 (s, 3 H), 0.04 (s, 3 H). 13C
NMR (125 MHz, CDCl3): δ 159.59, 159.45, 159.36, 159.32, 159.29, 159.09, 159.12,
159.15, 135.24, 134.94, 131.56, 131.27, 131.23, 131.07, 130.98, 130.89, 130.84,
130.64, 130.43, 129.89, 129.87, 129.81, 129.70, 129.61, 129.54, 129.38, 127.36,
118.05, 114.11, 114.05, 113.98, 113.93, 113.87, 113.84, 113.70, 99.50, 98.74, 86.16,
80.28, 80.08, 79.65, 76.65, 74.94, 74.85, 74.74, 74.69, 74.67, 74.59, 73.77, 73.08,
73.02, 72.46, 72.14, 72.08, 71.94, 71.66, 71.48, 69.14, 66.86, 62.93, 55.52, 55.48,
55.43, 55.41, 55.37, 55.32, 26.22, 18.59, -4.74, -4.98. The configurations of all three
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anomeric positions were established as α by coupled

13

C NMR JCH values (125 MHz):

99.50 (JCH = 171 Hz, Man-II), 98.74 (JCH = 171 Hz, Man-III), 86.16 (JCH = 167 Hz, Man-I).
[α]D25 = +37º (c 1.0, CHCl3). HR ESI MS: calcd. for C97H118O23NaSiS [M+Na]+ m/z,
1733.7452; found, 1733.7410.

(2-Cyanoethoxy)-(diisopropylamino)-(2,3-di-O-oleoyl-sn-glycerol)-phosphine
(1.179)
OCH2CH2CN
HO
OCO(CH2)7CH=CH(CH2)7CH3
OCO(CH2)7CH=CH(CH2)7CH3
1.178

(iPr)2N

P

N(iPr)2

diisopropylammonium
tetrazolide, CH2Cl2,
CH3CN

OCH2CH2CN
(iPr)2N

P

O

1.179

OCO(CH2)7CH=CH(CH2)7CH3
OCO(CH2)7CH=CH(CH2)7CH3

To a solution of known glycerolipid 1.178147 (516 mg, 0.83 mmol) and commercially
available bis(diisopropylamino)(2-cyanoethoxy)phosphine (375 mg, 1.24 mmol) in
anhydrous CH2Cl2/acetonitrile (2:1, 15 mL) was added diisopropylammonium tetrazolide
(142 mg, 0.83 mmol). After the reaction stirred at rt under Ar for 1 h, it was diluted with
CH2Cl2 and poured into saturated aqueous NaHCO3. The aqueous layer was extracted
3x with CH2Cl2, after which the combined organic layers were dried over Na2SO4 and
concentrated in vacuum. Purification using a triethylamine-neutralized silica gel column
gave a 1:1 diastereomeric (originating at phosphorus) mixture of phosphoramidite 1.179
(585 mg, 85%) as a white solid. 1H NMR (CDCl3, 400 MHz): δ 5.38-5.29 (m, 4 H), 5.215.15 (m, 1 H), 4.37-4.29 (m, 1 H), 4.19-4.12 (m, 1 H), 3.87-3.54 (m, 6 H), 2.63 (t, J = 7.0
Hz, 2 H), 2.33-2.28 (m, 4 H), 2.02-1.98 (m, 8 H), 1.65-1.58 (m, 4 H), 1.34-1.24 (m, 32 H),
1.17 (t, J = 8.0 Hz, 12 H), 0.87 (t, J= 8.0 Hz, 6 H). 31P NMR (CDCl3, 160 MHz): δ 150.64,
150.48.
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6-O-[2-Azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-D-glucopyranosyl]-1-O-[(2cyanoethoxy)-(2,3-di-O-oleoyl-sn-glycerol)-phosphono]-2,3,4,5-tetra-O-(pmethoxybenzyl)-myo-inositol (4)

To a solution of pseudodisaccharide 1.114 (50 mg, 41.6 μmol) and tetrazole (0.45 M
solution in acetonitrile, 0.92 mL, 0.416 mmol) stirring in anhydrous CH2Cl2-CH3CN (3:1,
8 mL) under Ar at rt was slowly added a solution of freshly prepared phosphoramidite
1.179 (171 mg in 1 mL dry CH2Cl2, 0.208 mmol). After the reaction stirred at rt under Ar
for 30 min, it was cooled to -40 ºC and treated with tert-butyl hydroperoxide (5.5 M
solution in decane, 151 μl, 0.832 mmol). The solution stirred for 1 h at -40 ºC, then
Me2S (125 μl, 1.66 mmol) was added and stirring continued for 1 h at -40 ºC. The
mixture was poured into saturated aqueous NaHCO3 and extracted 3x with CH2Cl2. The
combined organic layers were dried over Na2SO4 and concentrated in vacuum.
Purification by silica gel column chromatography gave the desired intermediate (quickly
characterized by MALDI-MS), which was then dissolved in anhydrous THF-CH3CN (1:1,
4 mL) and treated with Et3N•3HF (1 mL) under Ar at rt. After stirring for 5 days at rt, the
reaction was quenched by dropwise addition of saturated aqueous NaHCO3. The
mixture was extracted 3x with CH2Cl2, and the combined organic layer was dried over
Na2SO4, concentrated in vacuum, and purified by silica gel column chromatography to
give 1.182 (42 mg, 56%, 2 steps) as a ~1:1 mixture of diastereomers (originating at
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phosphorus). Preparative HPLC (Waters Nova-Pak Silica 6 μm, 300 x 19 mm, eluent
30% acetone in hexanes, 10 mL/min, isomer 1-tR = 14.3 min, isomer 2-tR = 15.2 min)
was used to separate the mixture, and isomer 1 was characterized and carried forward
to complete the synthesis. 1H NMR (500 MHz, CDCl3, isomer 1): δ 7.36-7.34 (m, 2 H),
7.33-7.31 (m, 2 H), 7.29-7.27 (m, 2 H), 7.22-7.20 (m, 2 H), 7.15-7.13 (m, 4 H), 6.90-6.83
(m, 8 H), 6.80-6.76 (m, 4 H), 5.40 (d, J = 3.5 Hz, 1 H, 1-position), 5.38-5.31 (m, 4 H),
5.23 (pent, J = 5.5 Hz, 1 H), 4.94 (d, J = 10.5 Hz, 1 H), 4.92 (d, J = 11 Hz, 1 H), 4.86 (d,
J = 10.5 Hz, 1 H), 4.83-4.78 (m, 2 H), 4.70-4.67 (m, 3 H), 4.62 (d, J = 10.5 Hz, 1 H),
4.61 (d, J = 11 Hz, 1 H), 4.43-4.32 (m, 5 H), 4.29-4.21 (m, 4 H), 4.17-4.12 (m, 1 H), 4.10
(dd, J = 6.0, 12 Hz, 1 H), 4.04-4.00 (m, 2 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H),
3.79 (s, 3 H), 3.78 (s, 3 H), 3.78-3.77 (m, 1 H), 3.76 (s, 3 H), 3.67 (dt, J = 3.0, 9.5 Hz, 1
H), 3.51 (dd, J = 2.0, 10 Hz, 1 H), 3.99 (t, J = 9.5 Hz, 1 H), 3.32-3.26 (m, 2 H), 3.18 (dd,
J = 3.5, 10 Hz, 1 H), 2.84-2.73 (m, 2 H), 2.29 (t, J = 7.5 Hz, 4 H), 2.10 (d, J = 4.0 Hz, 1
H), 2.04-2.00 (m, 8 H), 1.61-1.56 (m, 4 H), 1.33-1.27 (m, 36 H), 0.89 (t, J = 6.5 Hz, 1 H).
13

C NMR (CDCl3, 125 MHz): δ 173.38, 173.04, 159.69, 159.46, 159.41, 159.35, 159.29,

131.10, 130.98, 130.56, 130.53, 130.48, 130.24, 130.06, 129.96, 129.70, 129.53,
129.50, 129.29, 116.60, 114.22, 114.04, 113.96, 113.91, 113.88, 97.76, 81.48, 80.88,
80.86, 80.57, 78.56, 76.68, 75.68, 75.56, 75.11, 74.59, 74.52, 73.28, 72.78, 72.39,
69.97, 69.56, 69.51, 68.96, 66.39, 66.34, 62.71, 62.65, 62.61, 61.71, 55.51, 55.48,
34.31, 34.15, 32.14, 30.01, 29.99, 29.94, 29.77, 29.56, 29.48, 29.46, 29.41, 29.40,
29.34, 29.31, 27.47, 27.44, 25.03, 22.92, 19.91, 19.86, 14.36.

31

P NMR (CDCl3, 160

MHz): δ -1.42. [α]D25 = +24º (c 1.0, CHCl3). HR ESI MS: calcd. for C102H143N4O23NaP
[M+Na]+ m/z, 1845.9778; found, 1845.9757.
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Phenyl [6-O-(tert-butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-Dmannopyranosyl]-(1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→6)-3,4-di-O-(p-methoxybenzyl)-1-thio-α-D-mannopyranoside (1.183)
OPMB
O

TBSO
PMBO
PMBO
PMBO
PMBO
PMBO

O
O

O OAll
O
PMBO
PMBO
1.115 SPh

OPMB
O

TBSO
PMBO
PMBO
MgCl
Ti(OiPr)4, THF

PMBO
PMBO
PMBO

O
O

O OH
O
PMBO
PMBO
1.183 SPh

To a solution of 1.115 (56 mg, 32 μmol) in anhydrous THF (5 mL) was added
titanium(IV) isopropoxide (25 mg in 0.5 mL hexanes, 80 μmol). Cyclopentylmagnesium
chloride (2.0 M solution in THF, 160 μl) was added dropwise under an Ar atmosphere at
rt. After 2 h, saturated aqueous Na-K-tartrate was poured into the reaction, which was
stirred vigorously for 2 h. The mixture was extracted 3x with CH2Cl2, and then the
combined organic layer was washed with brine, dried over Na2SO4, and concentrated in
vacuum. The resulting residue was purified by silica gel column chromatography to
obtain 1.183 (45 mg, 82%) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.44-7.43 (m, 2 H),
7.32-7.30 (m, 2 H), 7.26-7.18 (m, 14 H), 7.15-7.11 (m, 3 H), 6.91-6.90 (m, 2 H), 6.876.75 (m, 14 H), 5.53 (d, J = 1.0 Hz, 1 H, Man-I 1-position), 5.24 (d, J = 1.5 Hz, 1 H,
Man-III 1-position), 4.83 (d, J = 2.0 Hz, 1 H), 4.82-4.80 (m, 2 H, includes Man-II 1position), 4.77 (d, J = 10.5 Hz, 1 H), 4.65 (s, 2 H), 4.59 (d, J = 12 Hz, 1 H), 4.55 (d, J =
10.5 Hz, 1 H), 4.50-4.44 (m, 4 H), 4.41-4.37 (m, 5 H), 4.25-4.22 (m, 2 H), 4.07 (t, J = 2.0
Hz, 1 H), 3.95-3.84 (m, 6 H), 3.83 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.82-3.79 (m, 2
H), 3.77 (s, 3 H), 3.76 (s, 3 H), 3.74 (s, 3 H), 3.74-3.72 (m, 3 H), 3.70 (s, 3 H), 3.68 (s, 3
H), 3.65-3.57 (m, 4 H), 2.72 (s, broad, 1 H), 0.88 (s, 9 H), 0.06 (s, 3 H), 0.05 (s, 3 H).
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C NMR (125 MHz, CDCl3): δ 159.78, 159.44, 159.33, 159.30, 159.20, 159.15, 131.50,

131.25, 131.16, 131.09, 130.91, 130.86, 130.65, 130.58, 129.96, 129.84, 129.81,
129.74, 129.64, 129.58, 129.56, 129.41, 127.42, 114.27, 114.05, 114.04, 113.94,
113.86, 113.84, 113.72, 99.54, 98.56, 87.57, 80.43, 79.96, 79.64, 74.98, 74.93, 74.85,
74.78, 74.59, 74.19, 73.74, 73.08, 72.89, 72.24, 72.10, 71.94, 71.52, 70.07, 69.15,
66.56, 62.94, 55.52, 55.49, 55.44, 55.41, 55.32, 29.95, 26.23, 18.61, -4.74, -4.97. [α]D25
= +58º (c 1.0, CHCl3). HR ESI MS: calcd. for C94H114O23NaSiS [M+Na]+ m/z, 1693.7139;
found, 1693.7136.

Phenyl [6-O-(tert-butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-Dmannopyranosyl]-(1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→6)-3,4-di-O-(p-methoxybenzyl)-2-O-triethylsilyl-1-thio-α-D-mannopyranoside
(1.184)
OPMB
O

TBSO
PMBO
PMBO
PMBO
PMBO
PMBO

O
O
O

PMBO
PMBO
1.183

OPMB
O

TBSO
PMBO
PMBO
TESOTf
OH
O
SPh

2,6-lutidine
CH2Cl2

PMBO
PMBO
PMBO

O
O

O OTES
O
PMBO
PMBO
1.184
SPh

TESOTf (6.5 μl, 29 μmol) was added slowly to a solution of 1.183 (15.8 mg, 9.45 μmol)
and 2,6-lutidine (4 μl, 33 μmol) in anhydrous CH2Cl2 (1 mL) stirring under Ar at 0 ºC.
After 2 h, saturated aqueous NaHCO3 was added to the reaction, which was then
extracted 3x with CH2Cl2. The combined organic layer was dried over Na2SO4,
concentrated in vacuum, and purified by silica gel column chromatography to afford
1.184 (15.2 mg, 90%) as a syrup. 1H NMR (500 MHz, CDCl3): δ 7.46-7.44 (m, 2 H),
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7.31-7.29 (m, 2 H), 7.26-7.15 (m, 14 H), 7.13-7.10 (m, 3 H), 6.88-6.84 (m, 4 H), 6.826.73 (m, 12 H), 5.31 (d, J = 2.0 Hz, 1 H, Man-I 1-position), 5.24 (d, J = 1.5 Hz, 1 H,
Man-III 1-position), 4.83-4.80 (m, 3 H, includes Man-II 1-position), 4.76 (d, J = 10.5 Hz,
1 H), 4.68 (d, J = 11 Hz, 1 H), 4.60 (d, J = 11.5 Hz, 1 H), 4.59 (d, J = 11 Hz, 1 H), 4.54
(d, J = 10.5 Hz, 1 H), 4.48 (s, 2 H), 4.45 (d, J = 10 Hz, 1 H), 4.40-4.33 (m, 5 H), 4.28 (t,
J = 2.0 Hz, 1 H), 4.19 (ddd, J = 1.0, 3.0, 9.0 Hz, 1 H), 4.07 (t, J = 2.5 Hz, 1 H), 3.92 (t, J
= 9.5 Hz, 1 H), 3.91-3.84 (m, 4 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.80-3.77
(m, 2 H), 3.75-3.71 (m, 12 H), 3.70 (s, 3 H), 3.66 (s, 3 H), 3.68-3.63 (m, 3 H), 3.58 (dd, J
= 2.0, 11 Hz, 1 H), 3.55 (dd, J = 1.5, 11.5 Hz, 1 H), 0.94 (t, J = 8.0 Hz, 9 H), 0.88 (s, 9
H), 0.60 (dq, J = 2.0, 8.0 Hz, 6 H), 0.06 (s, 3 H), 0.05 (s, 3 H).

13

C NMR (125 MHz,

CDCl3): δ 159.43, 159.40, 159.31, 159.29, 159.19, 159.16, 159.15, 135.24, 131.54,
131.34, 131.27, 131.26, 130.97, 130.88, 130.81, 130.69, 130.59, 129.76, 129.73,
129.57, 129.53, 129.36, 127.30, 114.03, 113.94, 113.85, 113.82, 113.69, 99.33, 98.73,
89.70, 80.68, 80.44, 79.66, 74.91, 74.85, 74.76, 74.65, 74.62, 74.54, 73.79, 73.06,
72.99, 72.45, 72.20, 72.13, 72.08, 71.91, 71.47, 71.45, 68.98, 67.01, 62.95, 55.50,
55.48, 55.47, 55.45, 55.42, 55.39, 55.29, 29.94, 26.21, 18.59, 7.12, 5.26, -4.76, -4.99.
[α]D25 = +28º (c 1.0, CHCl3). HR ESI MS: calcd. for C100H128O23NaSi2S [M+Na]+ m/z,
1807.8003; found, 1807.7996.
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[6-O-(tert-Butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-3,4-di-O-(pmethoxybenzyl)-2-O-triethylsilyl-D-mannopyranose (1.185)
OPMB
O

TBSO
PMBO
PMBO
PMBO
PMBO
PMBO

O
O
O

PMBO
PMBO
1.184

OPMB
O

TBSO
PMBO
PMBO
NIS, AgOTf, TTBP
OTES
O

CH2Cl2,H2O

SPh

PMBO
PMBO
PMBO

O
O

O OTES
O
PMBO
PMBO
OH
1.185

To a mixture of 1.184 (15.0 mg, 8.4 μmol), 2,4,6-tri-tert-butylpyrimidine (8.3 mg, 33.6
μmol), and N-iodosuccinimide (3.8 mg, 16.8 μmol) in wet CH2Cl2 (1 mL) at 0 ºC was
added silver triflate (4.3 mg, 16.8 μmol). After stirring for 30 min, saturated aqueous
Na2S2O3 was added and the mixture was stirred for an additional 30 min while warming
to rt. The reaction was extracted 3x with CH2Cl2, and the combined organic layer was
dried over Na2SO4, concentrated in vacuum, and purified by silica gel column
chromatography to afford hemiacetal 1.185 (10.5 mg, 74%) as a syrup. 1H NMR (500
MHz, CDCl3): δ 7.28-7.16 (m, 14 H), 7.09-7.08 (m, 2 H), 6.86-6.76 (m, 16 H), 5.17 (s,
broad, 1 H, Man-III 1-position), 4.90 (s, broad, 1 H), 4.83-4.81 (m 2 H), 4.78-4.76 (d, J =
11 Hz, 1 H), 4.68-4.63 (m, 2 H), 4.58-4.49 (m, 5 H), 4.48-4.34 (m, 8 H), 4.08 (t, J = 1.0
Hz, 1 H), 3.99 (t, J = 1.0 Hz, 1 H), 3.95-3.90 (m, 2 H), 3.87-3.83 (m, 5 H), 3.82-3.80 (m,
6 H), 3.79-3.77 (m, 4 H), 3.76-3.74 (m, 8 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.71 (s, 3 H),
3.69-3.63 (m, 5 H), 3.61-3.56 (m, 4 H), 0.96-0.87 (m, 18 H), 0.61-0.56 (dq, J = 1.5, 7.5
Hz, 6 H), 0.02 (s, 3 H), 0.01 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 159.49, 159.43,

159.41, 159.34, 159.26, 159.20, 131.22, 131.12, 130.92, 130.87, 130.73, 130.59,
129.92, 129.75, 129.59, 129.51, 129.50, 114.06, 113.95, 113.89, 113.85, 113.75, 99.32,
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97.96, 95.25, 80.07, 79.62, 75.29, 75.08, 74.89, 74.78, 74.47, 73.58, 73.10, 72.69,
72.33, 72.13, 72.11, 72.06, 71.68, 70.43, 69.67, 68.59, 63.09, 55.49, 55.45, 55.43,
55.37, 31.85, 29.96, 26.25, 22.91, 18.67, 14.37, 11.68, 7.16, 5.24, -4.75, -4.92. HR ESI
MS: calcd. for C94H124O24NaSi2 [M+Na]+ m/z, 1715.7919; found, 1715.7977.

6-O-{[6-O-(tert-Butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-Dmannopyranosyl]-(1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→6)-[3,4-di-O-(p-methoxybenzyl)-2-O-triethylsilyl-α-D-mannopyranosyl]-(1→4)[2-azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2cyanoethoxy)-(2,3-di-O-oleoyl-sn-glycerol)-phosphono]-2,3,4,5-tetra-O-(pmethoxybenzyl)-myo-inositol (1.187)
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O
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NCH2CH2CO P O
O
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OCOR
OCOR

R = -(CH2)7CH=CH(CH2)7CH3

DBU (1 drop) was added to a solution of hemiacetal 1.185 (52 mg, 31 μmol) and
trichloroacetonitrile (0.5 mL) in anhydrous CH2Cl2 (5 mL) stirring under an Ar
atmosphere at 0 ºC. After 1 h, the reaction mixture was concentrated in vacuum and
purified with a triethylamine-neutralized silica gel column to give 1.186 (49 mg, 88%). A
mixture of the resulting trichloroacetimidate 1.186 (33.3 mg, 18.0 μmol), acceptor 1.182
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(11.0 mg, 6.0 μmol), and MS 4 Å (10 mg) in anhydrous CH2Cl2 (400 μl) was stirred
under an Ar atmosphere at rt for 1 h. After cooling to 0 ºC, TMSOTf (0.36 M solution in
anhydrous CH2Cl2, 10 μl) was added and the reaction was stirred for 10 min. Saturated
aqueous NaHCO3 and CH2Cl2 were then added, and the resulting mixture was passed
through celite to remove MS. After extraction of the aqueous layer with CH2Cl2 3x, the
combined organic phase was dried over Na2SO4, concentrated in vacuum, and purified
by silica gel column chromatography to give α-pseudopentasaccharide 1.187 (11.5 mg,
64%) as a syrup. 1H NMR (500 MHz, CDCl3, resolved signals): δ 7.31-7.04 (m, 28 H),
6.89-6.70 (m, 28 H), 5.43 (d, J = 3.5 Hz, 1 H, GlcN3 1-position), 5.40-5.34 (m, 4 H), 5.21
(m, 2 H, includes Man-III 1-position, glyceride CH), 4.91 (d, J = 11.5 Hz, 1 H), 4.86-4.84
(m, 2 H), 4.81-4.72 (m, 6 H, includes Man-II 1-position), 4.70 (d, J = 9.5 Hz, 1 H), 4.65
(d, J = 12 Hz, 1 H), 4.60-4.53 (m, 4 H), 4.04 (s, broad, 1 H), 3.55 (dd, J = 4.0, 11 Hz, 1
H), 3.49 (dd, J = 2.0, 12.5 Hz, 1 H), 3.40-3.34 (m, 2 H), 3.21 (dd, J = 4.0, 10 Hz, 1 H),
2.76-2.68 (m, 2 H), 2.28 (t, J = 7.5 Hz, 4 H), 2.06-1.98 (m, 8 H), 0.49-0.40 (m, 6 H), 0.05
(s, 3 H), 0.04 (s, 3 H). 13C NMR (CDCl3, 125 MHz): δ 173.35, 173.00, 159.42, 159.39,
159.37, 159.33, 159.25, 159.19, 159.17, 159.15, 159.13, 159.09, 131.67, 131.32,
131.28, 131.13, 131.06, 130.96, 130.90, 130.77, 130.70, 130.61, 130.52, 130.42,
130.24, 129.95, 129.70, 129.66, 129.57, 129.47, 129.23, 129.07, 116.56, 114.10,
114.03, 113.90, 113.82, 113.79, 113.64, 99.84, 98.79, 97.76, 81.39, 80.71, 80.66, 80.56,
79.65, 79.00, 76.66, 75.53, 75.39, 75.05, 74.83, 74.79, 74.70, 74.60, 74.38, 73.72,
73.34, 73.09, 72.93, 72.79, 72.51, 72.36, 72.20, 72.10, 71.82, 71.24, 70.54, 69.59,
69.54, 69.02, 68.65, 68.40, 67.30, 66.55, 66.36, 66.33, 66.11, 64.56, 63.23, 62.64,
61.72, 55.49, 55.44, 55.33, 55.30, 55.25, 55.22, 34.30, 34.14, 32.14, 30.00, 29.97,

123
29.94, 29.76, 29.56, 29.54, 29.45, 29.40, 29.34, 29.29, 27.46, 27.43, 26.20, 25.02,
22.91, 19.84, 19.78, 18.56, 14.34, 7.17, 5.17, -4.74, -5.03.

31

P NMR (CDCl3, 160 MHz):

δ -1.31. [α]D25 = +10º (c 0.5, CHCl3). HR ESI MS: calcd. for C196H265N4O46NaSi2P
[M+Na]+ m/z, 3520.7694; found, 3520.7732. Note: One of the mannose 1-O-positions
was suppressed in the NMR spectra for this compound, but was present after the next
transformation (see information for compound 1.188 below).

6-O-{[2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-tri-O-(pmethoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-α-Dmannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-Dglucopyranosyl]} -1-O-[(2-cyanoethoxy)-(2,3-di-O-oleoyl-sn-glycerol)-phosphono]2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.188)

Compound 1.187 (6.0 mg, 1.7 μmol) was dissolved in anhydrous THF-CH3CN (1:1, 600
μl) and treated with Et3N•3HF (300 μl) under Ar at rt (TLC showed that selectivity for
removal of the primary TBS ether was not substantial). After stirring overnight at rt, the
reaction was quenched by dropwise addition of saturated aqueous NaHCO3. The
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aqueous layer was extracted 3x with CH2Cl2, and the combined organic layer was dried
over

Na2SO4,

concentrated

in

vacuum,

and

purified

by

silica

gel

column

chromatography to give 1.188 (4.0 mg, 70%). 1H NMR (500 MHz, CDCl3, resolved
signals): δ 7.34-7.09 (m, 28 H), 6.89-6.71 (m, 28 H), 5.40 (d, J = 4.0 Hz, 1 H, GlcN3 1position), 5.32-5.38 (m, 4 H), 5.23-5.25 (m, 2 H, includes Man-III 1-O-position, glyceride
CH), 5.15 (s, 1 H, Man-I 1 position), 4.98 (s, 1 H, Man-II 1 position), 4.92 (d, J = 11 Hz,
1 H), 4.90 (d, J = 9 Hz, 1 H), 4.84-4.74 (m, 5 H), 4.69-4.60 (m, 5 H), 3.54-3.48 (m, 4 H),
3.38 (t, J = 9.5 Hz, 1 H), 3.27 (d, J = 10 Hz, 1 H), 3.18-3.16 (m, 2 H), 2.82-2.72 (m, 2 H),
2.29 (t, J = 7.5 Hz, 4 H), 2.06-1.98 (m, 8 H).

13

C NMR (CDCl3, 125 MHz): δ 173.34,

172.99, 159.63, 159.47, 159.45, 159.42, 159.39, 159.37, 159.21, 159.15, 131.16,
131.07, 131.06, 131.04, 130.97, 130.70, 130.66, 130.56, 130.49, 130.36, 130.23,
130.11, 129.94, 129.86, 129.78, 129.73, 129.70, 129.67, 129.51, 129.41, 129.25,
129.17, 116.55, 114.17, 114.09, 114.06, 114.05, 113.93, 113.88, 113.84, 113.82,
101.80, 99.63, 99.51, 97.92, 81.44, 80.74, 80.62, 79.50, 79.43, 76.65, 75.56, 75.22,
75.17, 75.08, 74.93, 74.82, 74.71, 74.19, 74.13, 73.63, 73.16, 72.94, 72.89, 72.78,
72.44, 72.03, 71.96, 71.90, 71.71, 70.04, 69.54, 69.19, 68.88, 68.40, 66.41, 65.50,
63.20, 62.69, 61.73, 55.49, 55.46, 55.42, 55.40, 55.37, 55.32, 55.27, 55.23, 34.31,
34.15, 32.13, 30.00, 29.93, 29.75, 29.55, 29.54, 29.45, 29.40, 29.34, 29.30, 27.46,
27.43, 25.03, 22.91, 19.90, 19.83, 14.33. Configurations of anomeric positions were
established as α by coupled

13

C NMR JCH values (125 MHz): 101.80 (JCH = 176 Hz,

Man-1), 99.66 (JCH = 175 Hz, Man-1), 99.54 (JCH = 170 Hz, Man-1), 97.90 (JCH = 177 Hz,
GlcN3-1).
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P NMR (CDCl3, 160 MHz): δ -1.27. HR ESI MS: calcd. for

C184H237N4O46NaP [M+Na]+ m/z, 3292.5964; found, 3292.6030.
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(2-Cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethoxy](diisopropylamino)-phosphine (1.189)
OCH2CH2CN
HO

NHFmoc

(iPr)2N

P

N(iPr) 2

diispropylammonium
tetrzolide, CH2Cl2,
CH3CN

OCH2CH2CN
P
OCH2CH2NHFmoc
(iPr) 2N
1.189

To a solution of N-Fmoc-ethanolamine (38 mg, 132 μmol) and commercially available
bis(diisopropylamino)(2-cyanoethoxy)phosphine (84 μl, 264 μmol) in anhydrous CH2Cl2CH3CN (2:1, 3 mL) was added diisopropylammonium tetrazolide (24 mg, 135 μmol).
After the reaction stirred at rt under Ar for 1 h, it was diluted with CH2Cl2 and poured into
saturated aqueous NaHCO3. The aqueous layer was extracted 3x with CH2Cl2, after
which the combined organic layers were dried over Na2SO4 and concentrated in
vacuum. Purification using a triethylamine-neutralized silica gel column gave
phosphoramidite 1.189 (59 mg, 92%) as a white solid.

1

H NMR (CDCl3, 400

MHz): δ 7.78 (m, 2 H), 7.62-7.61 (m, 2 H), 7.43-7.40 (m, 2 H), 7.34-7.31 (m, 2 H), 5.27
(s, broad, 1 H), 4.42 (d, J = 7.0 Hz, 2 H), 4.24 (t, J = 7.0 Hz, 1 H), 3.90-3.84 (m, 1 H),
3.82-3.58 (m, 5 H), 3.44 (q, J = 5.0 Hz, 2 H), 2.61 (t, J = 6.5 Hz, 2 H), 1.20 (t, J = 8.0 Hz,
12 H).

13

C NMR (CDCl3, 125 MHz): δ 156.65, 144.21, 141.55, 127.92, 127.28, 125.30,

120.21, 117.90, 66.91, 63.06, 62.93, 58.69, 58.53, 47.79, 43.41, 43.31, 42.41, 24.92,
24.87, 24.81, 20.64, 20.58. 31P NMR (CDCl3, 160 MHz): δ 149.65.
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6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-αD-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-Dglucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-oleoyl-sn-glycerol)-phosphono]2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.190)

To a solution of pseudopentasaccharide diol 1.188 (2.70 mg, 0.82 μmol) stirring in
anhydrous CH2Cl2-CH3CN (3:1, 1 mL) under Ar at rt was added a solution of freshly
prepared phosphoramidite 1.189 (4.0 mg in 200 μl dry CH2Cl2, 8.2 μmol) and tetrazole
(0.45 M solution in acetonitrile, 36 μl, 16.4 μmol). After stirring at rt under Ar for 1 h, TLC
showed conversion to one major spot with a small amount of starting material remaining.
The reaction was quenched by cooling to -40 ºC and adding tert-butyl hydroperoxide
(5.5 M solution in decane, 6 μl, 32.8 μmol). The solution stirred for 1 h at -40 ºC, then
Me2S (4.9 μl, 65.6 μmol) was added and stirring continued for 1 h at -40 ºC. After
passage through celite to remove MS, the mixture was poured into saturated aqueous
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NaHCO3 and extracted 3x with CH2Cl2. The combined organic layers were dried over
Na2SO4 and concentrated in vacuum. Purification by silica gel column chromatography
afforded unreacted starting material (0.49 mg) and crude 1.188. The latter was further
purified with a Sephadex LH-20 size exclusion column (CHCl3/MeOH 5:1) to provide
1.190 as a diastereomeric mixture (1.51 mg, 50%, 61% based on recovered starting
material). 1H NMR (500 MHz, CDCl3, resolved signals): δ 7.66-7.65 (m, 2 H), 7.50-7.49
(m, 2 H), 5.31 (s, 1 H, GlcN3 1-position), 5.27 (s, 4 H), 5.14 (m, 2 H, includes Man-III 1position, glyceride CH), 4.94 (s, 1 H, Man-I 1-position), 4.90 (s, 1 H, Man-II 1-position),
2.66 (m, 2 H), 2.19 (m, 4 H), 1.93 (m, 8 H).
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P NMR (CDCl3, 160 MHz): δ -1.48, -2.27.

HR ESI MS: calcd. for C204H264N8O51P2 [M+2NH4]2+ m/z, 1851.8893; found, 1851.8940.
MALDI TOF MS (positive mode): calcd. for C204H256N6O51NaP2 [M+Na]+ m/z, 3690.7;
found, 3690.9. Regiochemistry was established by comparing the chemical shifts of the
Man-I 2-O-position protons from the starting material (1.188) and the product, which
was aided by COSY NMR spectroscopy. The analysis suggested that the Man-I 2-Oposition proton did not shift downfield, as would be expected if that site had been
phosphorylated.
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6-O-{[6-O-[(2-Aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→2)-(α-Dmannopyranosyl)-(1→6)-(α-D-mannopyranosyl)-(1→4)-(2-amino-2-deoxy-α-Dglucopyranosyl)}-1-O-[(2,3-di-O-oleoyl-sn-glycerol)-phosphono]-myo-inositol
(1.109)

To a solution of 1.190 (1.28 mg, 0.35 μmol) in CH2Cl2 (400 μl) was added acetic acid (1
drop) and zinc powder (1 mg). After stirring for 2 h, MALDI TOF MS showed complete
reduction of the azide [MALDI TOF MS (positive mode): calcd. for C206H258N4O51NaP2
[M+Na]+ m/z, 3664.7; found, 3664.7]. The mixture was filtered and condensed in
vacuum to remove acetic acid, and the resulting residue was re-dissolved in CH2Cl2
(300 μl) and treated with DBU (1 μl). The solution stirred for 1 h, after which MALDI TOF
MS confirmed removal of the Fmoc and cyanoethyl protecting groups [MALDI TOF MS
(positive mode): calcd. for C183H240N2O49Na3P2 [M-2H+3Na]+ m/z, 3380.6; found,
3380.9]. Then, 20% TFA in CH2Cl2 (300 μl) was added directly to the reaction, giving a
final concentration of ~10% TFA. After stirring for 30 min, the reaction was coevaporated with toluene 5 times. Purification of the crude product by Sephadex LH-20
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size exclusion chromatography (CHCl3/MeOH/H2O 3:3:1) gave 1.109 (0.46 mg, 81%).
1

H NMR (500 MHz, CDCl3/CD3OD/D2O 3:3:1, anomeric region): δ 5.28 (1 H, GlcNH2-1),

5.25 (4 H, lipid sp2-CH), 5.18 (1 H, glyceride CH), 5.09 (1 H, Man-1), 5.00 (1 H, Man-1),
4.88 (1 H, Man-1).
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P NMR (CDCl3, 160 MHz): δ 4.29, 3.63. MALDI TOF MS (negative

mode): calcd. for C71H129N2O35P2 [M-H]- m/z, 1631.8; found, 1632.1. MALDI TOF MS
(positive mode): calcd. for C71H128N2O35Na3P2 [M-2H+3Na]+ m/z, 1699.8; found, 1700.4.

6-O-{[6-O-[(2-Aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→2)-(α-Dmannopyranosyl)-(1→6)-[2-O-[(2-aminoethyl)-phosphono]-α-D-mannopyranosyl](1→4)-(2-amino-2-deoxy-α-D-glucopyranosyl)}-1-O-[(2,3-di-O-oleoyl-sn-glycerol)phosphono]-myo-inositol (1.110)

A mixture of 1.191 (microscale quantity sufficient for characterization by MALDI TOF
MS), freshly prepared phosphoramidite 1.189 (3.0 mg, 6.2 μmol, large excess), and MS
4 Å (5 mg) was stirred in anhydrous CH2Cl2 (200 μl) under Ar at rt for 1 h. Tetrazole
(0.45 M solution in acetonitrile, 28 μl, 12.4 μmol) was added and the reaction stirred
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overnight at rt. The mixture was cooled to -40 ºC and treated with tert-butyl
hydroperoxide (5.5 M solution in decane, 4.5 μl, 24.8 μmol). The solution stirred for 1 h
at -40 ºC, then Me2S (3.7 μl, 49.6 μmol) was added and stirring continued for 1 h at -40
ºC. After passage through celite to remove MS, saturated aqueous NaHCO3 was added
and then the mixture was extracted 3x with CH2Cl2. The combined organic layers were
dried over Na2SO4 and concentrated in vacuum. The crude material was passed
through a Sephadex LH-20 size exclusion column (CHCl3/MeOH 5:1) to provide the
diphosphorylated GPI intermediate, which was taken directly to the three-step global
deprotection. To a solution of the intermediate in CH2Cl2 (200 μl) was added acetic acid
(1 drop) and zinc powder (1 mg). After stirring for 2 h, the mixture was filtered and
condensed in vacuum to remove acetic acid, and the resulting residue was re-dissolved
in CH2Cl2 (150 μl) and treated with DBU (1 μl). The solution stirred for 1 h, then 20%
TFA in CH2Cl2 (150 μl) was added directly to the reaction, giving a final concentration of
~10% TFA. After stirring for 30 min, the reaction was co-evaporated with toluene 5
times to give 1.110 (isolated yield not obtained). MALDI TOF MS (negative mode): calcd.
for C73H135N3O38P [M-H]- m/z, 1754.8; found, 1755.0.
P

(2-Cyanoethoxy)-(diisopropylamino)-(2,3-di-O-stearyl-sn-glycerol)-phosphine
(1.192)

To a solution of known glycerolipid 1.208156 (1.04 g, 1.66 mmol) and commercially
available bis(diisopropylamino)(2-cyanoethoxy)phosphine (970 mg, 0.32 mmol) in
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anhydrous CH2Cl2/acetonitrile (3:1, 12 mL) was added diisopropylammonium tetrazolide
(266 mg, 1.66 mmol). After the reaction stirred at rt under Ar for 1 h, it was diluted with
CH2Cl2 and poured into saturated aqueous NaHCO3. The aqueous layer was extracted
3x with CH2Cl2, after which the combined organic layers were dried over Na2SO4 and
concentrated in vacuum. Purification using a triethylamine-neutralized silica gel column
gave a 1:1 diastereomeric (originating at phosphorus) mixture of phosphoramidite 1.192
(1.25 g, 90%) as a white solid. 1H NMR (CDCl3, 400 MHz): δ 5.21-5.16 (m, 1 H), 4.374.30 (m, 1 H), 4.20-4.13 (m, 1 H), 3.89-3.48 (m, 6 H), 2.63 (t, J = 6.4 Hz, 2 H), 2.33-2.28
(m, 4 H), 1.65-1.58 (m, 4 H), 1.34-1.24 (m, 56 H), 1.17 (t, J = 7.2 Hz, 12 H), 0.87 (t, J=
7.2 Hz, 6 H). 31P NMR (CDCl3, 160 MHz): δ 150.64, 150.48.

6-O-[2-Azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-D-glucopyranosyl]-1-O-[(2cyanoethoxy)-(2,3-di-O-stearyl-sn-glycerol)-phosphono]-2,3,4,5-tetra-O-(pmethoxybenzyl)-myo-inositol (1.195)

To a solution of pseudodisaccharide 1.114 (150 mg, 125 μmol) and tetrazole (0.45 M
solution in acetonitrile, 1.66 mL, 0.75 mmol) stirring in anhydrous CH2Cl2-CH3CN (3:1, 8
mL) under Ar at rt was slowly added a solution of freshly prepared phosphoramidite
1.192 (326 mg in 1 mL dry CH2Cl2, 375 μmol). After the reaction stirred at rt under Ar for
20 min, it was cooled to 0 ºC and treated with tert-butyl hydroperoxide (5.5 M solution in
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decane, 151 μl, 0.832 mmol). The solution stirred for 1 h at while warming to rt, then
diluted with CH2Cl2. The mixture was poured into saturated aqueous NaHCO3 and
extracted 3x with CH2Cl2. The combined organic layers were dried over Na2SO4 and
concentrated in vacuum. Purification by silica gel column chromatography gave the
desired intermediate (quickly characterized by MALDI-MS), which was then dissolved in
anhydrous THF-CH3CN (1:1, 4 mL) and treated with Et3N•3HF (2 mL) under Ar at rt.
After stirring for 7 days at rt, the reaction was quenched by dropwise addition of
saturated aqueous NaHCO3. The mixture was extracted 3x with CH2Cl2, and the
combined organic layer was dried over Na2SO4, concentrated in vacuum, and purified
by silica gel column chromatography to give 1.195 (124 mg, 54%, 2 steps) as a ~1:1
mixture of diastereomers (originating at phosphorus). Preparative HPLC (Waters NovaPak Silica 6 μm, 300 x 19 mm, eluent 30% acetone in hexanes, 10 mL/min, isomer 1tR = 18.4 min, isomer 2-tR = 19.6 min) was used to separate the mixture, and isomer 1
was characterized and carried forward to complete the synthesis. 1H NMR (500 MHz,
CDCl3, isomer 1): δ 7.36-7.34 (m, 2 H), 7.33-7.31 (m, 2 H), 7.29-7.27 (m, 2 H), 7.227.20 (m, 2 H), 7.15-7.13 (m, 4 H), 6.90-6.83 (m, 8 H), 6.80-6.76 (m, 4 H), 5.40 (d, J =
4.0 Hz, 1 H, 1-position), 5.23 (pent, J = 5.5 Hz, 1 H), 4.94 (d, J = 10.5 Hz, 1 H), 4.92 (d,
J = 11 Hz, 1 H), 4.86 (d, J = 10 Hz, 1 H), 4.83-4.78 (m, 2 H), 4.70-4.67 (m, 3 H), 4.62 (d,
J = 10.5 Hz, 1 H), 4.61 (d, J = 11 Hz, 1 H), 4.43-4.32 (m, 5 H), 4.29-4.21 (m, 4 H), 4.174.12 (m, 1 H), 4.10 (dd, J = 6.0, 12 Hz, 1 H), 4.04-4.00 (m, 2 H), 3.82 (s, 3 H), 3.81 (s, 3
H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.78-3.77 (m, 1 H), 3.76 (s, 3 H), 3.67 (dt, J
= 3.0, 10 Hz, 1 H), 3.51 (dd, J = 1.5, 9.5 Hz, 1 H), 3.40 (t, J = 9.0 Hz, 1 H), 3.33-3.26 (m,
2 H), 3.18 (dd, J = 3.5, 10.5 Hz, 1 H), 2.84-2.73 (m, 2 H), 2.29 (t, J = 7.5 Hz, 4 H), 2.09
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(d, J = 4.0 Hz, 1 H), 1.61-1.56 (m, 4 H), 1.32-1.26 (m, 56 H), 0.89 (t, J = 6.5 Hz, 1 H).
13

C NMR (CDCl3, 125 MHz): δ 173.41, 173.06, 159.69, 159.43, 159.41, 159.35, 159.29,

131.11, 130.98, 130.57, 130.52, 130.49, 130.24, 130.06, 129.70, 129.53, 129.50,
129.29, 116.60, 114.21, 114.04, 113.96, 113.90, 113.88, 97.77, 81.48, 80.86, 80.57,
78.57, 76.67, 75.69, 75.57, 75.11, 74.59, 73.28, 72.78, 72.40, 69.96, 69.56, 69.53,
68.97, 66.37, 66.35, 62.70, 62.64, 62.62, 61.71, 55.50, 55.47, 55.45, 34.33, 34.18,
32.16, 29.96, 29.93, 29.92, 29.90, 29.78, 29.76, 29.61, 29.58, 29.56, 29.38, 29.35,
25.05, 22.93, 14.36.
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P NMR (CDCl3, 160 MHz): δ -1.42. [α]D25 = +26º (c 1.0, CHCl3).

HR ESI MS: calcd. for C102H147N4O23NaP [M+Na]+ m/z, 1850.0091; found, 1850.0048.

[6-O-(tert-Butyldimethylsilyl)-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl](1→2)-[3,4,6-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-2-O-allyl-3,4-diO-(p-methoxybenzyl)-D-mannopyranose (1.209)
OPMB
O

TBSO
PMBO
PMBO
PMBO
PMBO
PMBO

O
O
O

PMBO
PMBO
1.115
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O
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O
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O
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O
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OH
1.209

To a solution of 1.115 (85 mg, 49.6 μmol) and 2,4,6-tri-tert-butylpyrimidine (62 mg, 248
μmol) in CH2Cl2 (2.0 mL) at -60 ºC was added silver triflate (51 mg in 1.0 mL Et2O, 199
μmol). Then, pTolSCl (12 μl, 59.5 μmol) was added directly to the mixture to preactivate the substrate. After stirring for 1 min, acetone-H2O (10:1, 105 μl) was added
and the reaction was warmed to rt gradually and stirred for 2 h. After quenching with
triethylamine and concentration in vacuum, the resulting residue was redissolved in
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CH2Cl2 and filtered to remove solids. The filtrate was then washed with water, dried over
Na2SO4, concentrated, and purified by silica gel column chromatography to afford
unreacted starting material 1.115 (15 mg) and hemiacetal 1.209 (40 mg, 50% yield,
68% BRSM). The desired product, an anomeric mixture, was quickly characterized by
1

H NMR and HR ESI MS (see Appendix A for spectra). HR ESI MS: calcd. for

C91H114O24NaSi [M+Na]+ m/z, 1641.7367; found, 1641.7310. We thank Prof. Xuefei
Huang of Michigan State University for providing p-TolSCl.

6-O-{[2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-tri-O-(pmethoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[2-O-allyl-3,4-di-O-(pmethoxybenzyl)-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(pmethoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-oleoyl-snglycerol)-phosphono]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.198)

DBU (1 drop) was added to a solution of hemiacetal 1.209 (36 mg, 22.2 μmol) and
trichloroacetonitrile (0.25 mL) in anhydrous CH2Cl2 (2 mL) stirring under an Ar
atmosphere at 0 ºC. After 1 h, the reaction mixture was concentrated in vacuum and
purified with a triethylamine-neutralized silica gel column to give 1.196 (36 mg, 92%). A

135
mixture of the resulting trichloroacetimidate 1.196 (36 mg, 20.4 μmol), acceptor 1.195
(23 mg, 12.6 μmol), and MS 4 Å (10 mg) in anhydrous Et2O (0.5 mL) was stirred under
an Ar atmosphere at rt for 1 h. After cooling to 0 ºC, TMSOTf (0.5 μl, 0.1 equiv) was
added and the reaction was stirred for 5 min. Saturated aqueous NaHCO3 and Et2O
were then added, and the resulting mixture was passed through celite to remove MS.
After extraction of the aqueous layer with Et2O 3x, the combined organic phase was
dried over Na2SO4, concentrated in vacuum, and taken directly to the next step. Thus,
crude intermediate 1.197 was dissolved in anhydrous THF-CH3CN (1:1, 2 mL) and
treated with Et3N•3HF (0.5 mL) under Ar at rt. After stirring overnight, the reaction was
quenched by dropwise addition of saturated aqueous NaHCO3. The aqueous layer was
extracted 3x with Et2O, and the combined organic layer was dried over Na2SO4,
concentrated in vacuum, and purified by silica gel column chromatography to give 1.198
(35 mg, 83%, 2 steps) as a syrup. 1H NMR (500 MHz, CDCl3, resolved signals): δ 5.675.75 (m, 1 H), 5.42 (d, J = 4.0 Hz, 1 H, GlcN3 1-position), 5.23 (pent, J = 4.5 Hz, 1 H),
5.20 (s, 1 H, Man-III 1-position), 5.13 (dd, J = 2.0, 17.5 Hz, 1 H), 5.08 (d, J = 1.5 Hz, 1 H,
Man-I 1-position), 4.99 (dd, J = 2.0, 10.5 Hz, 1 H), 4.94-4.89 (m, 4 H), 4.85-4.79 (m, 5 H,
includes Man-II 1-position), 4.74 (d, J = 10.5 Hz, 1 H), 4.69-4.59 (m, 8 H), 4.55-4.47 (m,
9 H), 4.45-4.40 (m, 8 H), 4.37-4.21 (m, 14 H), 4.15-4.09 (m, 4 H), 4.07-4.04 (m, 1 H),
4.01 (t, J = 9.0 Hz, 1 H), 3.92 (t, J = 9.5 Hz, 1 H), 3.87-3.84 (m, 5 H), 3.53-3.48 (m, 4 H),
3.42-3.37 (m, 6 H), 3.33-3.31 (m, 1 H), 3.25 (dd, J = 3.5, 11 Hz, 1 H), 3.20 (dd, J = 3.5,
10 Hz, 1 H), 2.80-2.70 (m, 2 H), 2.82 (t, J = 8.0 Hz, 4 H), 1.60-1.54 (m, 4 H), 1.31-1.25
(m, 56 H), 0.89 (t, J = 7.0 Hz, 6 H).

13

C NMR (CDCl3, 125 MHz): δ 173.40, 173.05,

159.43, 159.37, 159.32, 159.29, 159.23, 159.13, 135.49, 131.15, 131.06, 130.99,
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130.93, 130.73, 130.59, 130.49, 130.32, 130.18, 129.77, 129.72, 129.622, 129.52,
129.41, 129.28, 129.25, 129.15, 128.77, 116.58, 116.47, 114.10, 114.07, 114.04,
113.98, 113.93, 113.83, 101.09, 99.79 (2 overlapping signals confirmed by HMQC),
97.94, 81.42, 80.76, 80.62, 79.82, 79.85, 79.51, 79.26, 76.61, 76.26, 75.60, 75.25,
75.21, 75.09, 74.99, 74.83, 74.78, 74.62, 74.57, 74.25, 73.48, 73.12, 73.09, 73.00,
72.78, 72.35, 72.05, 72.02, 71.94, 71.86, 71.65, 70.16, 69.58, 69.42, 69.09, 68.47,
66.40, 62.96, 62.67, 62.64, 62.54, 61.72, 55.46, 55.33, 55.31, 55.26, 55.23, 34.33,
34.18, 32.17, 29.96, 29.91, 29.77, 29.61, 29.58, 29.56, 29.38, 29.35, 25.05, 22.93,
19.89, 19.83, 14.36. Configurations of anomeric positions were established as α by
coupled

13

C NMR JCH values (125 MHz): 101.09 (JCH = 167 Hz, Man-1), 99.79 (JCH =

174 Hz, Man-1), 99.79 (JCH = 174 Hz, Man-1), 97.94 (JCH = 177 Hz, GlcN3-1).

31

P NMR

(CDCl3, 160 MHz): δ -1.38. [α]D25 = +32º (c 1.0, CHCl3). HR ESI MS: calcd. for
C187H245N4O46NaP [M+Na]+ m/z, 3336.6590; found, 3336.6597.
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6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[2-O-allyl-3,4-di-O-(pmethoxybenzyl)-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(pmethoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-stearyl-snglycerol)-phosphono]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.199)

To a solution of pseudopentasaccharide alcohol 1.198 (32 mg, 9.7 μmol) stirring in
anhydrous CH2Cl2 (1 mL) under Ar at rt was added a solution of freshly prepared
phosphoramidite 1.189 (23 mg in dry CH2Cl2, 48 μmol) and tetrazole (0.45 M solution in
acetonitrile, 216 μl, 97 μmol). After stirring at rt under Ar for 1 h, the reaction was cooled
to -40 ºC and treated with tert-butyl hydroperoxide (5.5 M solution in decane, 53 μl, 291
μmol). The solution stirred for 1 h at -40 ºC, then Me2S (43 μl, 582 μmol) was added and
stirring continued for 1 h at -40 ºC. The mixture was poured into saturated aqueous
NaHCO3 and extracted 3x with CH2Cl2. The combined organic layers were dried over
Na2SO4 and concentrated in vacuum. Purification by silica gel column chromatography
afforded 1.199 as a ~1:1 diastereomeric mixture (29 mg, 81%). Preparative HPLC
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(Waters Nova-Pak Silica 6 μm, 300 x 19 mm, eluent 35% acetone in hexanes, 10
mL/min, isomer 1-tR = 14.6 min, isomer 2-tR = 15.7 min) was used to separate the
mixture facilitate characterization.

1

H NMR (500 MHz, CDCl3, isomer 1): δ 7.74 (d, J =

7.5 Hz, 2 H), 7.58 (d, J = 7.0 Hz, 1 H), 7.39-7.36 (m, 2 H), 7.32-7.28 (m), 7.11 (m), 7.067.04 (m, 2 H), 6.88-6.72 (m), 5.75-5.67 (m, 1 H), 5.53 (t, J = 7.0 Hz, 1 H), 5.42 (d, J =
3.5 Hz, 1 H, GlcN3 1-position), 5.23 (pent, J = 4.5 Hz, 1 H), 5.20 (s, 1 H, Man-III 1position), 5.15-5.12 (m, 5 H, includes Man-I 1-position), 5.00 (d, J = 10.5 Hz, 1 H), 4.934.89 (m, 2 H), 4.86-4.77 (m, 5 H, includes Man-II 1-position), 4.73 (d, J = 10.5 Hz, 1 H),
4.69-4.56 (m, 8 H), 4.52-4.47 (m, 6 H), 4.45-4.36 (m, 9 H), 4.33-4.21 (m, 17 H), 4.194.05 (m, 8 H), 3.02-4.93 (m, 3 H), 3.91-3.86 (m, 7 H), 3.82 (s, 3 H), 3.80-3.79 (m, 3 H),
3.78 (s, 3 H), 3.77 (s, 3 H), 3.76 (s, 6 H), 3.74 (s, 12 H), 3.73 (s, 3 H), 3.72-3.69 (m, 4 H),
3.65 (s, 3 H), 3.64 (s, 3 H), 3.62 (s, 3 H), 3.59-3.49 (m, 5 H), 3.45 (s, 1 H), 3.41 (s, 3 H),
3.39-3.37 (m, 3 H), 3.34-3.32 (m, 2 H), 3.27 (dd, J = 4.0, 10.5 Hz, 1 H), 3.22 (dd, J = 3.5,
10 Hz, 1 H), 2.77-2.69 (m, 2 H), 2.27 (m), 2.05 (m), 1.32-1.22 (m), 0.89 (t, J = 6.5 Hz, 6
H).

13

C NMR (CDCl3, 125 MHz): δ 173.40, 173.05, 159.45, 159.38, 159.32, 159.26,

159.20, 156.62, 144.21, 141.49, 135.47, 135.44, 131.19, 131.09, 131.04, 130.94,
130.89, 130.81, 130.67, 130.63, 130.52, 130.49, 130.36, 130.17, 129.84, 129.77,
129.72, 129.64, 129.61, 129.52, 129.48, 129.27, 128.77, 127.88, 127.32, 125.43,
125.27, 120.13, 117.19, 116.65, 116.44, 114.10, 114.07, 114.04, 113.99, 113.92,
113.87, 113.80, 113.78, 100.95, 99.67, 99.56, 97.92, 81.43, 80.61, 79.85, 79.57, 77.73,
76.65, 76.25, 75.57, 75.08, 75.02, 74.92, 74.81, 74.79, 74.59, 74.49, 74.25, 73.44,
73.11, 73.08, 72.79, 72.56, 72.43, 72.16, 71.99, 71.94, 71.86, 71.37, 71.34, 70.09,
69.59, 69.55, 68.96, 68.56, 68.48, 68.21, 67.36, 67.28, 67.10, 66.68, 66.39, 66.35,
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63.00, 62.71, 62.68, 62.32, 62.28, 61.74, 55.45, 55.34, 55.30, 55.27, 55.24, 47.39,
41.54, 34.33, 34.18, 32.44, 32.17, 29.95, 29.91, 29.77, 29.60, 29.55, 29.38, 29.3426.63,
25.85, 25.05, 23.66, 22.93, 19.88, 19.83, 19.36, 19.31, 14.35.
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P NMR (CDCl3, 160

MHz): δ -0.32, -1.25. [α]D25 = +6º (c 0.25, CHCl3). HR ESI MS: calcd. for
C207H268N7O51NaP2 [M+NH4]+ m/z, 3729.8068; found, 3729.7986.

6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-αD-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(p-methoxybenzyl)-α-Dglucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-stearyl-sn-glycerol)-phosphono]2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.200)

A solution of [Ir(COD)(PMePh2)2]PF6 (9.0 mg, 11 μmol) in anhydrous THF (0.5 mL) was
stirred under H2 at rt until the color turned from red to colorless to pale yellow (10 min).
After the H2 atmosphere was exchanged with Ar, 1.99 (27 mg, 7.3 μmol, solution in 0.5
mL THF) was added slowly. After 2 h, the reaction was concentrated in vacuum, then
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dissolved in acetone/H2O (9:1, 1 mL) and treated with HgCl2 (6 mg, 22 μmol) and HgO
(0.2 mg, 0.7 μmol). Note: The isomerization reaction cannot be monitored by TLC; we
took small aliquots of the reaction forward to treatment with Hg(II), then checked MALDI
MS to determine if the isomerization was proceeding. The mixture was stirred at rt
under an Ar atmosphere for 2 h, then concentrated and purified by silica gel column
chromatography to give 1.200 (24 mg, 90%), which was taken directly to the next step
after characterization by mass spectrometry. MALDI TOF MS (positive mode): calcd. for
C204H260N6O51NaP2 [M+Na]+ m/z, 3694.7; found, 3695.0.
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6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-2O-succinyl-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(pmethoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-stearyl-snglycerol)-phosphono]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.201)
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To a mixture of 1.200 (12 mg, 3.2 μmol) and molecular sieves (~10 mg) in CH2Cl2 were
added succinic anhydride (3.2 mg, 32 μmol) and DMAP (4.0 mg, 32 μmol) at rt under Ar.
After stirring for 6 h, additional succinic anhydride (3.2 mg, 32 μmol) and DMAP (4.0 mg,
32 μmol) were added. The reaction was stirred overnight, treated with AcOH,
concentrated, and purified by silica gel column chromatography to afford 1.201 (8.1 mg,
67%).

1

H NMR (500 MHz, CDCl3, mixture of 2 diastereomers from previous

phosphorylation reaction): See Appendix A.
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P NMR (CDCl3, 160 MHz): δ -2.05, -2.36.

MALDI TOF MS (positive mode): calcd. for C208H264N6O54Na1P2 [M+Na]+ m/z, 3794.7;
found, 3794.1.
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6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-2O-propargylsuccinamide-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O(p-methoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-stearylsn-glycerol)-phosphono]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.202)

To a solution of 1.201 (2.0 mg, 0.53 μmol) in CH2Cl2 stirring under an Ar atmosphere at
rt was added HOBt (solution in CH2Cl2/DMF, total 0.17 mg, 1.2 μmol) and EDCI
(solution in CH2Cl2, total 0.23 mg, 1.2 μmol). After stirring for 15 min, propargylamine
(solution in CH2Cl2, total 0.05 mg, 0.83 μmol) was added. The reaction was stirred
overnight, treated with 1 drop AcOH, concentrated, and purified by silica gel column
chromatography to afford 1.202 (1.5 mg, 75%). 1H NMR (500 MHz, CDCl3, mixture of 2
diastereomers): See Appendix A. HR ESI MS: calcd. for C211H267N7O53Na2P2 [M+2Na]2+
m/z, 1927.3944; found, 1927.3900.
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6-O-{[6-O-[(2-Aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→2)-(α-Dmannopyranosyl)-(1→6)-(2-O-propargylsuccinamide-α-D-mannopyranosyl)-(1→4)(2-amino-2-deoxy-α-D-glucopyranosyl)}-1-O-[(2,3-di-O-stearyl-sn-glycerol)phosphono]-myo-inositol (1.111)
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To a solution of 1.202 (1.02 mg, 0.26 μmol) in CH2Cl2 (250 μl) was added acetic acid (1
drop) and zinc powder (1 mg). After stirring for 1 h, MALDI TOF MS showed complete
reduction of the azide [MALDI TOF MS (positive mode): calcd. for C211H269N5O53NaP2
[M+Na]+ m/z, 3805.8; found, 3805.2]. The mixture was filtered and condensed in
vacuum to remove acetic acid, and the resulting residue was re-dissolved in CH2Cl2
(250 μl) and treated with DBU (1 μl). The solution stirred for 1 h, after which MALDI TOF
MS confirmed removal of the Fmoc and cyanoethyl protecting groups [MALDI TOF MS
(positive mode): calcd. for C190H251N2O51Na3P2 [M-2H+3Na]+ m/z, 3521.6; found,
3522.2]. Then, 20% TFA in CH2Cl2 (250 μl) was added directly to the reaction, giving a
final concentration of ~10% TFA. After stirring for 30 min, the reaction was coevaporated with toluene 5 times. Purification of the crude product by Sephadex LH-20
size exclusion chromatography (CHCl3/MeOH/H2O 3:3:1) gave 1.111 (0.40 mg, 85%).
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1

H NMR (500 MHz, CDCl3/CD3OD/D2O 3:3:1, anomeric region): δ 5.39 (1 H, GlcNH2-1),

5.35 (2 H), 5.27 (1 H, glyceride CH), 5.18 (1 H, Man-1), 5.11 (1 H, Man-1), 4.97 (1 H,
Man-1).
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P NMR (CDCl3, 160 MHz): δ -0.38, -0.35. MALDI TOF MS (positive mode):

calcd. for C78H139N3O37Na3P2 [M-2H+3Na]+ m/z, 1840.8; found, 1841.4.

6-O-{[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]phosphono]-2,3,4-tri-O-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-triO-(p-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(p-methoxybenzyl)-2O-biotinylsuccinamide-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(pmethoxybenzyl)-α-D-glucopyranosyl]}-1-O-[(2-cyanoethoxy)-(2,3-di-O-stearyl-snglycerol)-phosphono]-2,3,4,5-tetra-O-(p-methoxybenzyl)-myo-inositol (1.204)

To a solution of 1.201 (1.8 mg, 0.48 μmol) in CH2Cl2 stirring under an Ar atmosphere at
rt was added HOBt (solution in CH2Cl2/DMF, total 0.13 mg, 0.96 μmol) and EDCI
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(solution in CH2Cl2, total 0.18 mg, 0.96 μmol). After stirring for 15 min, PEG3-biotinamine (solution in CH2Cl2, total 0.25 mg, 0.63 μmol) was added. The reaction was
stirred overnight, treated with 1 drop AcOH, concentrated, and purified by silica gel
column chromatography to afford 1.204 (1.4 mg, 70%). MALDI TOF MS: calcd. for
C226H296N10O58NaP2S [M+Na]+ m/z, 4195.0; found, 4195.1.

6-O-{[6-O-[(2-Aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→2)-(α-Dmannopyranosyl)-(1→6)-(2-O-biotinylsuccinamide-α-D-mannopyranosyl)-(1→4)(2-amino-2-deoxy-α-D-glucopyranosyl)}-1-O-[(2,3-di-O-stearyl-sn-glycerol)phosphono]-myo-inositol (1.112)
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To a solution of 1.204 (0.53 mg, 0.13 μmol) in CH2Cl2 (250 μl) was added acetic acid (1
drop) and zinc powder (1 mg). After stirring for 1 h, MALDI TOF MS showed complete
reduction of the azide [MALDI TOF MS (positive mode): calcd. for C226H298N8O58NaP2S
[M+Na]+ m/z, 4169.0; found, 4169.1]. The mixture was filtered and condensed in
vacuum to remove acetic acid, and the resulting residue was re-dissolved in CH2Cl2
(250 μl) and treated with DBU (1 μl). The solution stirred for 1 h, after which MALDI TOF
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MS confirmed removal of the Fmoc and cyanoethyl protecting groups [MALDI TOF MS
(positive mode): calcd. for C205H280N6O56Na3P2S [M-2H+3Na]+ m/z, 3884.8; found,
3884.7]. Then, 20% TFA in CH2Cl2 (250 μl) was added directly to the reaction, giving a
final concentration of ~10% TFA. After stirring for 30 min, the reaction was coevaporated with toluene 5 times. Purification of the crude product by Sephadex LH-20
size exclusion chromatography (CHCl3/MeOH/H2O 3:3:1) gave 1.112. MALDI TOF MS
(positive mode): calcd. for C93H171N6O42P2 [M+H]+ m/z, 2138.0; found, 2138.5. Also
observed in the MALDI TOF MS spectrum (in Appendix A) are several other species
corresponding to the desired compound with varying phosphate counterions. The
isolated yield of this target could not be calculated due to decomposition of the 2-Oester bond (see section 1.4), although the initial MALDI TOF MS analysis showed a
virtually quantitative reaction.
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CHAPTER 2
SYNTHESIS AND STRUCTURAL STUDIES OF
CD52 PEPTIDES AND GLYCOPEPTIDES
2.1 Introduction
According to a 1999 analysis of the SWISS-PROT protein database, over half of
all proteins may be glycosylated.1 The two primary modes of protein glycosylation are
N- and O-glycosylation, which occur at asparagine (Asn) and serine (Ser)/threonine
(Thr) residues, respectively. The cellular functions of N-linked glycosylation in
euokaryotes have been extensively studied and include molecular recognition, immune
response, modulation of protein function, protein folding, and protein stabilization.2 The
N-glycan, an oligosaccharide that is covalently linked to asparagine in the consensus
sequence Asn-X-Ser/Thr (where X is any amino acid except proline), has the ability to
affect protein structure and, consequently, activity.3-5 This observation has provided the
impetus to design studies that combine synthesis and spectroscopic analysis to probe
the effects of N-glycosylation on protein conformation and function.5-10 Such studies
require access to pure and structurally defined samples, a task made challenging by
microheterogeneity in biosynthetic glycoproteins, which generally exist as complex
mixtures of glycoforms. However, advances in carbohydrate and peptide synthesis have
enabled chemists to obtain sufficient quantities of homogeneous glycopeptides and
small glycoproteins for comparative structural analyses.11-13 The following introductory
sections will include brief overviews of the process of N-glycosylation, its effects on
protein structure, its role in the bioactivity of the CD52 antigen, and synthetic methods
for obtaining glycosylated peptides/proteins for structural studies. Finally, our work in
this area involving the CD52 antigen will be discussed in detail.
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2.1.1 Protein N-Glycosylation
Asparagine glycosylation is a ubiquitous co-translational protein modification that
occurs in eukaryotic and some prokaryotic systems, and is characterized by the
attachment of an oligosaccharide to Asn through a β-glycosylamide linkage.14 As
mentioned above, N-glycosylation may only occur at the consensus tripeptide sequence
Asn-X-Ser/Thr (where X is any amino acid except proline). However, the presence of
this motif does not necessitate that the site will be glycosylated, for reasons that remain
unclear.
N-glycans can be separated into three general classes that include highmannose-type, hybrid-type, and complex-type structures, each of which can be attained
through a common biosynthetic pathway (Figure 2.1).15 N-glycosylation is initiated by
the

oligosaccharyl

transferase-mediated

attachment

of

a

dolichol-linked

tetradecasaccharide (Glc3Man9GlcNAc2, Figure 2.2) to the Asn amide nitrogen of a
growing polypeptide chain during protein synthesis. This oligosaccharide then
undergoes enzymatic modification in the ER, including glucose trimming by
glucosidases I and II, a process that plays a vital role in protein folding and quality
control.16

After

the

protein

has

been

correctly

folded,

additional

mannose

trimming/modification occurs to form high-mannose type structures. In mammals, highmannose type structures may then be converted to hybrid-type or complex-type Nglycans by subsequent addition/trimming of sugars such as glucose, galactose, fucose,
sialic acid, and others. Primitive unicellular organisms do not contain the biosynthetic
tools necessary to form hybrid- or complex-type glycans, but utilize the early stages of
the N-glycosylation process to aid in protein folding.
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Figure 2.1. The N-glycosylation pathway

Figure 2.2. The Glc3Man9GlcNAc2 tetradecasaccharide N-glycan donor
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2.1.2 Effects of N-Glycosylation on Protein Structure
Protein glycosylation is the most prevalent co- and post-translational modification,
and understanding its effects on protein structure and function is crucial to the study of
biological systems. Glycoproteins are expressed throughout the cell and are involved in
many diverse and vital functions, but their structural analysis – specifically, determining
what structural implications glycosylation has on the 3D structure of a protein – is quite
complicated for several reasons.
The first roadblock to glycopeptide/glycoprotein characterization is accessing a
sufficient amount of pure sample, which, depending on the analytical technique, can
range from microgram to milligram quantities. In the vast majority of cases, these
molecules cannot be isolated from natural sources in a sufficient quantity, and thus
researchers have turned to expression systems and chemical synthesis/semi-synthesis.
Although the former technique is useful for obtaining large quantities of sample, it does
not produce natively glycosylated proteins. In addition, expressed glycoproteins are
usually formed as complex heterogeneous mixtures due to the phenomenon of
microheterogeneity. Therefore, chemical synthesis (covered in section 2.1.4) and semisynthesis, although costly and time-consuming, have become the best route to pure and
structurally well-defined glycopeptides and small glycoproteins.
Even after an acceptably pure sample is available in sufficient quantity, structural
analysis can be a daunting prospect. X-ray crystallography, the powerful standard for
protein structure determination, is a difficult task due to the flexible and dynamic nature
of carbohydrates. In fact, even though well over half of proteins are estimated to be
glycosylated,17 only 3% of structures in the Protein Data Bank18 contain glycoprotein

170
chains.10 Furthermore, most of this small fraction of solved structures required some
type of glycan modification or truncation to achieve acceptable crystal formation. As a
result, the glycan and peptide chain are analyzed separately for most glycoproteins, and
thus no truly accurate representation of the 3D structure can be generated. To
overcome these limitations, NMR spectroscopy has become the primary tool for the
analysis of glycosylated proteins. The techniques used for this purpose, which have
been reviewed in detail,10 mostly rely on 2D NMR spectroscopy, specifically nuclear
Overhauser effect correlation spectroscopy (NOESY), in combination with molecular
modeling and other methods. Circular dichroism (CD) is another method that is useful
for identifying common protein structural motifs such as the α-helix or β-sheet, and is
also useful for quickly contrasting conformational changes in related peptide/protein
derivatives.
Several hallmark examples demonstrate how these techniques have been used
to determine glycoprotein structure and how covalently linked carbohydrates can affect
structure and function. While very few glycoproteins have been characterized by X-ray
crystallography, the simian immunodeficiency virus (SIV, closely related to HIV)
envelope glycoprotein gp120, which enlists N-glycans to assist in virus attachment to
host cells and to evade immune detection, was characterized with its glycans intact.19-20
This important achievement has helped scientists to rationally design carbohydratebased vaccine candidates for HIV that have shown some promise.21 In the case of the
human T-cell specific surface glycoprotein CD2, which is a key component of immune
stimulation, NMR structural determination was enabled by expressing a sample that
was uniformly

15

N-isotopically labeled.22 These studies led to the conclusion that the N-
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glycan in CD2 was responsible for stabilizing the protein, which could unfold or
aggregate without carbohydrate present.
More pertinent to our research was work done by Imperiali and co-workers, in
which synthetic peptides and glycopeptides were analyzed by NMR spectroscopy to
determine what effect N-glycans had on the secondary/tertiary structure of a relatively
small peptide.6-7 Their molecule of interest was a short peptide sequence from the
influenza A virus envelope glycoprotein hemagglutinin (HA), which is involved in host
cell recognition and infection.21 The authors synthesized a non-glycosylated
nonapeptide as well as a glycosylated version carrying an N-linked chitobiose
disaccharide [β-D-GlcNAc(1→4)β-D-GlcNAc] group, which is present in the core of all
N-linked glycans. By determining the structures of these synthetic compounds using 2D
NMR spectroscopy, it was discovered that a conformational switch occurred upon
glycosylation of the peptide. In fact, the free peptide exhibited an “Asx” turn
conformation that is important for the N-glycosylation process, whereas the
glycopeptide exhibited a Type I β-turn conformation, which is present in the natively
folded HA glycoprotein. Therefore, N-glycosylation triggered a structural change from an
open conformation to a more compact conformation in the HA model system.

2.1.3 Structure and Function of the Human CD52 Antigen
Our interest in the effect of N-glycosylation on protein structure lies in the human
CD52 antigen, a GPI-anchored glycopeptide that is expressed on lymophocyte and
sperm cells.23-25 Although both lymphocyte and sperm CD52 share an identical 12
amino acid peptide, structural variations in their GPI anchor and N-linked glycan lead to
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distinct biological functions, with the former playing a role in the human immune system
and the latter being involved in the human reproductive process.24,26 Lymphocyte CD52
antibodies have been used to treat immune-related diseases such as leukaemia,27
whereas sperm CD52-specific antibodies have been isolated from infertile women and
suggest the potential for immunocontraceptive development.28-29
Structurally, the two forms of CD52 have the same remarkably short peptide and
exhibit one N-glycosylation site at the Asn3 residue, to which complex-type glycans are
linked (Figure 2.3).24-25 Interestingly, the makeup of the N-linked glycans is one of the
main structural differences between the two forms. For example, bi- and tri-antennary Nglycans, peripheral fucosylation, and the α(2→3)-linkage of sialic acid residues are
unique features of sperm CD52 and are therefore termed “male-specific modifications”
of the antigen.26 In addition, certain modifications of the CD52 GPI anchor have been
observed. For instance, lymphocyte CD52 bears an additional α–mannose unit at the
Man-III 2-O-position and its phospholipid is composed of a diacylglycerolipid, which is in
contrast to the monoalkylglycerolipid found in sperm CD52.26 The structural differences
of the N-glycans/GPI between sperm and lymphocyte CD52 seem to have a critical
influence on their bioactivity. Sperm CD52-specific antibodies bind to the N-glycan of
the antigen and may inhibit sperm-egg binding.28-29 Lymphocyte CD52 antibodies,
however, recognize a sequence of the peptide chain,27 suggesting a possible difference
in peptide structure between the two forms of CD52 and therefore the potential for
conformational change induced by N-glycosylation or GPI anchoring.
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Figure 2.3. Structural comparison of lymphocyte and sperm CD52

2.1.4 Chemical Synthesis of N-Linked Glycopeptides
As a result of advances in peptide and carbohydrate synthesis, the preparation of
glycopeptides and even some small glycoproteins is now a fairly straightforward
process. While the preparation of glycopeptides/glycoproteins using various strategies
has been reviewed extensively elsewhere,11,30 this section will briefly focus on methods
for the chemical synthesis of N-linked glycopeptides, which are the topic of this research.
Although chemical synthesis of N-linked glycopeptides is relatively costly and laborious,
it is currently the best option available for accessing significant quantities of
homogeneous and structurally well-defined samples.
Synthesis of an N-linked glycopeptide almost universally begins with the
preparation of a custom glycosylated asparagine derivative that can subsequently be
used in peptide chain elongation to eventually form the desired structure (Scheme 2.1).
First, a glycosyl amine carrying the desired suitably protected N-glycan must be
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prepared, usually by reduction of a glycosyl azide that was synthesized using
conventional regio/stereoselective oligosaccharide techniques. Alternatively, treatment
of unprotected N-acetylglucosamine reducing sugars with saturated ammonium
bicarbonate is useful for converting oligosaccharides obtained from natural sources
directly in glycosyl amines. The newly formed glycosyl amine is then reacted with a
protected aspartic acid derivative in the presence of a coupling reagent (e.g.
EDCI/HOBt) to effect a condensation reaction, thus forming a glycosyl asparagine
building block that can be subjected to peptide chain elongation and eventually global
deprotection to afford the desired glycopeptide.

Scheme 2.1. Glycosyl amine formation and application to glycopeptide synthesis

Several strategies have been developed for applying a protected glycosyl
asparagine building block to peptide chain elongation. Perhaps the most obvious is
solution phase synthesis, in which the glycosyl asparagine can be elaborated at the Cand/or N-terminus by cycles of selective deprotection/coupling or by convergent
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coupling to a larger peptide fragment. Kunz, a pioneer in the field, employed this
methodology in conjunction with a divergent-convergent assembly in the synthesis of a
divalent Lewisx antigen (Scheme 2.2).31 Through a series of solution phase reactions,
per-O-acetyl-protected glycosyl asparagine derivative 2.1 was diverted to intermediates
2.2 and 2.3, which were set up for coupling with EDCI and HOBt. The resulting fully
protected glycopeptide 2.4, which contained two N-glycans, was then elongated at the
C-terminus and deprotected to give the divalent glycopeptide 2.5. While successful, the
solution phase strategy requires purification at each step, thus increasing lab work and
cost while decreasing the overall efficiency of a synthesis dramatically.
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A major development in the area of glycopeptide synthesis was the application of
the solid phase peptide synthesis (SPPS) strategy, which was originally developed by
Merrifield in the 1960s.32 SPPS involves the stepwise elongation of a growing peptide
chain that is anchored at the C-terminus carboxyl group to insoluble polymeric beads
via a cleavable linker. Thus, the desired product remains attached to the solid support
throughout the process, allowing impurities to be easily washed away after each step.
SPPS has become the clear standard for peptide and glycopeptide synthesis due to its
speed, ease of use, high yields, availability on automated synthesizers, and the ability to
prepare relatively large peptide fragments (maximum ~50-70 amino acid residues,
depending on the sequence). SPPS can be easily adapted to glycopeptide synthesis by
employing custom glycosyl asparagine building blocks in place of standard amino acids
at the desired position. In addition, SPPS offers a substantial degree of flexibility so that
any target glycopeptide, regardless of protecting/functional groups used, should be
accessible. For example, The N-protecting group can be either Boc, which is removed
with TFA, or Fmoc, which is removed with the relatively weak base piperidine. For
glycopeptide SPPS, Fmoc protection is typically used so that glycosidic bonds are not
repeatedly subjected to the acidic conditions required for Boc removal. In addition, the
available linkers, which bridge the peptide chain and the solid support, are chemically
diverse, so that the peptide may be cleaved from the resin under various conditions. For
instance, linkers exist that are cleaved under strongly acidic conditions (95% TFA,
example: Wang resin), weakly acidic conditions (1% TFA or AcOH, example: 2chlorotrityl resin), or neutral conditions (palladium catalysis, example: HYCRAM resin).
Because the incorporation of glycans to the SPPS process incurs various
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considerations about sterics, protecting group tactics, and functional group lability, the
flexibility of SPPS is very useful in planning a synthesis. Scheme 2.3 depicts a standard
glycopeptide synthesis using Fmoc-SPPS. Starting from a pre-loaded resin, the desired
number of Fmoc-SPPS cycles involving Fmoc deprotection and amino acid coupling are
carried out to give solid-supported peptide 2.7. Then, using a minimal amount of the
valuable glycosyl asparagine building block 2.8, the N-glycan is added to the desired
position of the growing peptide chain to give an intermediate of type 2.9. Additional
cycles of Fmoc-SPPS are then carried out to form the remainder of the peptide, after
which cleavage from the resin, global deprotection, and HPLC purification provided the
desired glycopeptide 2.10.
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Scheme 2.3. A typical glycopeptide synthesis using Fmoc-SPPS

In addition to the solution and solid phase synthesis methods described above,
our group previously developed a third option specifically for application to glycopeptide
synthesis called “solution phase synthesis with solid phase work-up.”33-34 In this method,
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glycosyl asparagines using unprotected oligosaccharide chains were employed in
peptide coupling reactions. The polar N-glycans acted as phase tags, such that work-up
of the reaction mixtures by addition of cold diethyl ether precipitated the desired product
out of the NMP solution in excellent yield and purity. Like SPPS, this strategy negated
the need for intermediate purification. Moreover, final deprotection of the glycan, which
can sometimes be problematic for certain structures, was bypassed. Using this method,
Guo synthesized several targets, including hydrogenation-sensitive glycopeptide 2.11
(tyrosine residues can be affected) and tetravalent glycopeptide 2.12 bearing four
vicinal oligosaccharide chains (Figure 2.4). Although not widely applied, this method is a
viable alternative to solution phase synthesis and SPPS.

Figure 2.4. Glycopeptides synthesized using Guo’s “solution phase synthesis with solid
phase work-up” method
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2.2 Results and Discussion
2.2.1 Background and Project Design
As laid out in section 2.1.3, the CD52 antigen exists in two distinct functional
forms, sperm and lymphocyte CD52, despite the fact that both species have an identical
primary amino acid sequence. As a result, it is possible that variations in the N-glycan or
GPI anchor or both induce conformational changes in the peptide that lead to
contrasting biological functions. I felt that this presented an excellent opportunity for
probing the effects of glycosylation on peptide structure in a serviceable model system.
To explore this interesting question, I set out to compare the structures of nonglycosylated CD52 peptides to their glycosylated counterparts to determine what effect
a model N-glycan might have on the conformation of the CD52 peptide backbone. For
this purpose, I prepared the natural and N-terminal acetylated CD52 peptides 2.13 and
2.14 (Figure 2.5), as well as glycopeptides 2.15 and 2.16-2.17, which contained a

Figure 2.5. Target CD52 peptides and glycopeptides
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disaccharide

β-D-GlcNAc(1→4)-β-D-GlcNAc

and

a

fucose-containing

branched

trisaccharide β-D-GlcNAc(1→4)[α-L-Fuc(1→6)]-β-D-GlcNAc, respectively, using FmocSPPS. Next, CD was used to examine the solution structures of the synthetic targets
and determine whether CD52 can form any specific secondary/tertiary structure and
whether Asn-N-glycosylation or N-terminal acetylation could result in any significant
secondary/tertiary structure changes.

2.2.2 Synthesis of Peptides 2.13 and 2.14
The straightforward preparation of peptides 2.13 and 2.14 was carried out using
standard Fmoc-SPPS on an automatic peptide synthesizer. Commercially available Serloaded resin and Fmoc-protected amino acids were used to synthesize the target
peptide on a 0.1 mmol scale (84% yield based on weight). A portion of the resin-bound
peptide was N-acetylated, and another portion was left unaltered at the N-terminus.
Concomitant release of the peptides from the solid support and deprotection of the
amino acid side chains was accomplished using a 95% TFA aqueous solution
containing 2.5% triethylsilane. Purification of the products by reverse phase (RP)-HPLC
gave the desired peptides 2.13 and 2.14. All spectroscopic data gathered for 2.13 were
in agreement with previously reported values,35 and 2.14 was positively characterized
using NMR spectroscopy and MS.

2.2.3 Synthesis of Glycopeptides 2.15-2.17
The most widely adopted method for glycopeptide synthesis is solid phase
synthesis. However, due to the acid lability of O-glycosidic bonds, particularly the
fucosidic linkage,36 and the potential for strong base-induced β-elimination or amino
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acid epimerization,37 care must be taken in the selection of protecting groups and
overall synthetic strategy. Thus, partially or fully benzyl-protected oligosaccharideasparagine conjugates were used in the target syntheses to facilitate late-stage
deprotection under mild conditions, and measures were taken to ensure that acid
sensitive functionalities would remain intact throughout each synthesis.
The primary challenge of synthesizing 2.16 and 2.17 is the α-fucosidic linkage,
which is particularly acid sensitive when it is fully benzylated.36 Although acyl-protected
fucosides are more stable to acidic conditions,38 protection of the 2-O-position by an
acyl group, which has the neighboring group participation effect, must be avoided to
achieve α–fucosylation. Our group developed the “solution-phase synthesis with solidphase workup” strategy, which employs unprotected carbohydrate and peptide building
blocks,33-34 to address the problem in an earlier synthesis of 2.17.39 During this study, it
was observed that an unprotected fucoside intermediate could withstand treatment with
20% TFA, which is strong enough to deprotect peptide side chains. Based on these
results, our group developed a strategy for solid phase glycopeptide synthesis that is
compatible with all glycosidic bonds.40-41 I therefore made use of the 2-chlorotrityl resin,
a hyper acid sensitive support that can release fully protected peptides upon treatment
with 10% acetic acid, as the solid phase support in my synthesis of the target
compounds.
Perbenzylated disaccharide-Asn conjugate 2.24 was chosen as the glycosyl
amino acid to be employed in Fmoc-SPPS en route to glycopeptide 2.15 (Scheme 2.4).
Starting from D-glucosamine hydrochloride, reported methods were used to arrive at
2.18,42-43 which was deacetylated and then benzylated to afford thioglycoside 2.19.
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Glycosylation of acceptor 2.2044 by donor 2.19 was promoted by NIS and TfOH to give
disaccharide 2.21 in 75% yield. After phthalimide removal and subsequent N-acetylation
to afford 2.22, Lindlar’s catalyst was used to reduce the anomeric azide under a H2
atmosphere to give a glycosyl amine, which immediately underwent amide bond
formation using the active ester Fmoc-Asp(OBt)-OtBu to furnish 2.23. Finally, treatment
of the product with 20% TFA to remove the C-terminal tert-butyl ester protecting group
resulted in the desired disaccharide-Asn conjugate 2.24.

Scheme 2.4. Synthesis of disaccharide-Asn conjugate 2.24

With glycosyl amino acid 2.24 in hand, solid phase construction of glycopeptide
2.15 commenced (Scheme 2.5). The preparation of resin-linked nonapeptide 2.25 was
carried out on an automated peptide synthesizer using standard Fmoc-SPPS chemistry
starting from Ser-loaded 2-chlorotrityl resin. Coupling of the reactive benzotriazole (Bt)
ester of 2.24 with peptide 2.25 was completed manually. In this case, only 1.5
equivalents of the valuable intermediate 2.24 were used in the synthesis. The mixture of
2.25 and the active ester of 2.24 was shaken under an Ar atmosphere overnight to give
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2.26. The subsequent peptide chain elongation and N-terminal acetylation followed to
afford resin-bound glycopeptide 2.27. Release of the glycopeptide from the solid
support was achieved with 10% acetic acid. Finally, the resultant glycopeptide was
deprotected in two steps, including palladium-catalyzed N-glycan debenzylation and the
amino acid side chain deprotection using 20% TFA to produce the target glycopeptide
2.15, which was purified by RP-HPLC.

Scheme 2.5. Solid phase synthesis of glycopeptide 2.15

Partially benzylated trisaccharide-Asn conjugate 2.36 was chosen as the
glycosylated asparagine to be employed in Fmoc-SPPS en route to glycopeptides 2.16
and 2.17 (Scheme 2.6). Previous studies suggested that the remaining free hydroxyl
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groups in 2.26 would remain inert during the peptide elongation process.33 Glycosyl
azide 2.34 was previously prepared by Shao et al,39 while a slightly shorter pathway
leading to 2.34 was developed in the work presented herein. Starting from Dglucosamine, p-methoxy benzylidene acetal 2.2845 was synthesized in four steps. 3-OBenzylation of this intermediate followed by regioselective acetal ring opening gave
glycosyl acceptor 2.29 in 71% yield over two steps. The resultant PMB group on the 6O-position could be easily and selectively removed later under mild conditions.

Scheme 2.6. Synthesis of trisaccharide-Asn conjugate 2.36

Alcohol 2.29 underwent glycosylation with glycosyl bromide 2.3046 in the
presence of AgOTf. The disaccharide product contained a small quantity of an
inseparable impurity, so full characterization of the product was completed after acidic
removal of the PMB group, which proceeded to give β-disaccharide 2.31 in 69% over
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two steps. The resulting alcohol 2.31 was fucosylated by 2.3247 stereoselectively
according to the conditions (CuBr2/Bu4NBr) set forth by Lemieux et al.48 The
transformation from 2.33 to 2.34 was achieved in a 3 step sequence, including removal
of the N-phthalimido and O-acetyl groups, acetylation, and then O-deacetylation. ODeacetylation at this stage was preferential due to potential complications in late-stage
basic deprotection, and, as mentioned above, the free hydroxyl groups would remain
inert throughout the remainder of the synthesis. Next, Lindlar’s catalyst and a H2
atmosphere were employed to reduce the anomeric azide and produce a glycosyl
amine, which underwent amide bond formation with the active ester Fmoc-Asp(OBt)OAll to furnish 2.35. In contrast to the previous trisaccharide-Asn conjugate,39 in which
the carboxylic group was protected by a tert-butyl group, an allyl group was used to
protect the carboxylic group in 2.35. The allyl ester could be deprotected without acid,
thus allowing fucose to remain benzylated. Indeed, treatment of 2.35 with Pd(PPh3)4
and N-methylaniline resulted in the desired trisaccharide-Asn conjugate 2.36, which was
subsequently used in Fmoc-SPPS.
Fmoc-SPPS construction of glycopeptides 2.16 and 2.17 (Scheme 2.7) began
with the manual coupling of the benzotriazole active ester of glycosyl-Asn conjugate
2.36

to

the

2-chlorotrityl-resin

anchored

nonapeptide

2.25.

The

resulting

glycodecapeptide 2.37 was then elongated at the N-terminus by manual Fmoc-SPPS to
give fully protected, resin-bound glycopeptide 2.38. Both the natural and N-terminal
acetylated trisaccharide glycopeptides, 2.16 and 2.17, were accessible from 2.38.
Glycopeptide 2.16 was obtained via cleavage of 2.38 from the solid support followed by
palladium catalyzed N-glycan debenzylation and TFA-mediated side chain deprotection
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as described above. Care was taken during debenzylation of to use aldehyde-free
solvents to prevent N-terminal methylation via reductive amination. After the benzyl
protecting groups were removed, the fucosidic linkage became stable to 20% TFA
treatment, which was used to achieve amino acid side chain deprotection. Glycopeptide
2.17 was afforded by first carrying out solid phase N-terminal acetylation, then
completing the same protocols of glycopeptide release and global deprotection
described for 2.16. Purification by RP-HPLC gave the desired glycopeptides 2.16 and
2.17. Characterization of 2.16 was carried out using NMR and MS, while all
spectroscopic data gathered for 2.17 were in agreement with previously reported
values.39

Scheme 2.7. Solid phase synthesis of glycopeptides 2.16 and 2.17.
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2.2.4 CD Structural Studies
CD studies were performed by Yu-Cheng Chang. The aqueous solution
conformations of the synthetic CD52 peptides and glycopeptides 2.13-2.17 were studied
using CD spectroscopy, which has previously been used to probe the effects of
glycosylation on peptide structure.49-51 The CD spectra of 2.13, 2.14, 2.15, 2.16, and
2.17 are very similar with peak minima at 196, 201, 201, 198, and 200 nm, respectively
(Figure 2.6). These features are suggestive of random coil conformations for all
derivatives as clearly described in the literature.49,52 It was thus concluded that, in this
case, neither N-glycosylation nor N-terminal acetylation led to any noticeable ordered
secondary conformation of the CD52 peptide backbone, and thus further conformational
studied by NMR spectroscopy were not pursued.

Figure 2.6. CD spectra of 2.13-2.17 in H2O at room temperature

188
2.3 Conclusions
The free peptide of the human CD52 antigen and four N-terminal acetylated or
Asn-glycosylated derivatives or both (2.13-2.17) were synthesized by SPPS. Benzylated
glycosyl asparagine conjugates were employed as building blocks in the solid phase
synthesis of glycopeptides. To avoid strong acid treatment that may affect the αfucosidic bond, 2-chlorotrityl resin, which is particularly acid-labile, was used as the solid
phase support so that the glycopeptides could be released under mildly acidic
conditions compatible with all glycosidic linkages. CD structural studies of the synthetic
peptides and glycopeptides led us to conclude that neither N-glycosylation nor Nterminal acetylation had a noticeable influence on the random coil conformation of the
CD52 peptide, even though the fucose-containing branched trisaccharide is relatively
sterically hindered. I believe that this is probably a result of the unique structure and
properties of the CD52 peptide, as it is extremely short and hydrophilic. However, the
conformation of the CD52 antigen when it contains larger, natural N-glycans or when it
is GPI-anchored onto the cell surface is still unknown.

2.4 Future Work
This work focused on the synthesis and structural comparison of several CD52
derivatives containing highly truncated N-glycans. Although Imperiali and co-workers
observed a conformational change by addition of a simple disaccharide,6-7 in our case
glycosylation with model carbohydrates did not incur any changes according to CD.
Thus, one potential future pathway for this work would be to synthesize CD52
glycopeptides bearing more natural N-glycans, as shown in Figure 2.3, although the
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complexity of the synthetic work would increase by multitudes. Another possible future
project would involve structural analysis of GPI-anchored CD52 peptides and
glycopeptides to determine whether attachment of a GPI anchor induces conformational
changes. Again, synthesis would be a demanding task for such a project, although our
group has extensive experience in GPI synthesis. Finally, the target molecules of this
research could be analyzed in detail by 2D NMR to determine whether any subtle
change in conformation was imparted by glycosylation, which would require a heavy
investment of time and resources.

2.5 Experimental
General Methods
1

H NMR spectra were recorded at 400 or 500 MHz with chemical shifts reported in ppm

(δ) downfield from tetramethylsilane (TMS) or relative to CHCl3 (7.26 ppm) unless
otherwise noted. The coupling constants (J) are reported in hertz (Hz). Thin layer
chromatography (TLC) was performed on silica gel GF254 plates with detection by UV or
charring with a 5% H2SO4 in EtOH solution. Molecular sieves 4 Å (4 Å MS) were dried in
high vacuum at 170-180 oC for 6-10 h immediately before use. Anhydrous solvents
were obtained from a solvent purification system, while commercial anhydrous reagents
were used without further purification. Automated peptide synthesis was carried out on
an Applied Biosystems 433A peptide synthesizer using fresh reagents and solvents
purchased from Applied Biosystems. 2,5-Dihydroxybenzoic acid (DHB) was used as the
MALDI TOF MS matrix, and samples were dissolved in either H2O-CH3CN (1:1)
containing 1% TFA or CH2Cl2-MeOH (1:1) for unprotected and fully protected
compounds, respectively.
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Preparation of Compounds
CD52 Peptide 2.14
H2N
AcHN

O

O
N
H

HO
H
N

O
O

O
N
H
NH2

O
H
N
O
HO

O
N
H

OH
H
N

O
N
H

O
H2N

O

OH
H
N
O

O
N
H
OH

OH
N
O

HO
O
N
H

OH
O

2.14

The resin-bound, fully protected precursor of CD52 peptide 2.1335 was subjected to
acetylation conditions (pyr-Ac2O 2:1) for 4 h. After the resin was washed thoroughly and
filtered, the desired N-terminal acetylated peptide 2.14 was released by treatment with
95% aqueous TFA containing 2.5% Et3SiH as the cation scavenger. After precipitation
by cold ether and lyophilization, 2.14 was purified by RP-HPLC (Supelco Discovery C18,
250 x 10 mm, eluent 5% CH3CN in H2O, 2 mL/min, Rt = 14.9 min). 1H NMR (500 MHz,
D2O, DHO at δ 4.79 as reference): δ 4.72 (t, J = 7.0 Hz, 1 H), 4.54-4.43 (m, 4 H), 4.414.39 (m, 3 H), 4.35-4.31 (m, 2 H), 4.25 (dd, J = 5.0, 6.5 Hz, 1 H), 3.73-3.94 (m, 11 H),
2.95 (dd, J = 6.5, 17 Hz, 1 H), 2.87 (dd, J = 6.0, 15.5 Hz, 1 H), 2.85 (dd, J = 7.0, 17.0 Hz,
1 H), 2.77 (dd, J = 8.0, 15.5 Hz, 1 H), 2.40-2.29 (m, 5 H), 2.21-2.08 (m, 2 H), 2.07 (s, 3
H), 2.05-1.96 (m, 5 H), 1.22 (d, J = 2.0 Hz, 3 H), 1.20 (d, J = 1.5 Hz, 3 H). ESI MS:
[M+Na]+ calcd for C47H75N15O25Na, 1272.4932; found: m/z 1272.4956.
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p-Methylphenyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-Dglucopyranoside (2.19)

After 2.18 (5.00 g, 9.23 mmol) was treated with NaOMe in methanol (0.05 M, 40 mL) at
rt for 2 h, the solution was neutralized to pH 6-7 by amberlyst H+ resin. After filtration of
the resin, the filtrate was concentrated to afford a white powder that was directly used
for the next step. To a solution of the triol intermediate (3.00 g, 7.22 mmol) in DMF (60
mL) was added tetrabutylammonium iodide (TBAI, 300 mg, 0.76 mmol) and benzyl
bromide (5.71 mL, 45.9 mmol). The solution was cooled to 0 °C and then NaH (60%
dispersion in mineral oil, 1.6 g, 40.0 mmol) was added slowly. The reaction mixture was
stirred at 0 °C for 1 h and then stirred at rt overnight. The reaction was quenched with
aqueous NH4Cl and extracted with CH2Cl2. The organic phase was washed with
aqueous NH4Cl and brine, then dried over Na2SO4 and filtered. The solvent was
evaporated and the crude product was purified by silica gel chromatography to give
2.19 as white foam (2.9 g, 59%). 1H NMR (400 MHz, CDCl3): δ 7.90-7.60 (m, 4 H), 7.427.26 (m, 10 H), 7.04-6.82 (m, 5 H), 5.51 (d, 1 H), 4.76-4.90 (m, 2 H), 4.74-4.56 (m, 3 H),
4.50-4.36 (m, 2 H), 4.26 (t, 1 H), 3.90-3.66 (m, 4 H), 2.29 (s, 3 H). ESI MS: [M+Na]+
calcd for C42H39NO6NaS, 708.2; found: m/z 708.4.
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O-(-3,4,6-tri-O-Benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→4)-3,6-di-Obenzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl Azide (2.21)

To a solution of 2.19 (1.0 g, 1.46 mmol) and 2.20 (514 mg, 1.00 mmol) in anhydrous
CH2Cl2 (50 mL) was added 4 Å MS under an Ar atmosphere. The reaction was cooled
to -30 °C, and NIS (520 mg, 2.31 mmol) was added. TfOH (41 µL, 0.46 mmol) was then
added dropwise over a 5 min period. The reaction mixture was stirred for 20 min, and
was then filtered through celite. The filtrate was washed with aqueous NaHCO3,
Na2S2O3, and brine solution. The organic layer was dried over Na2SO4, filtered, and
concentrated to give yellowish oil. Silica gel chromatography yielded 2.21 (800 mg, 75%)
of as clear syrup. NMR data were consistent with literature-reported values.53 MALDI
TOF MS: [M-N2+Na]+ calcd for C63H57N3O12Na, 1070.4; found: m/z 1070.2; [M+Na]+
calcd for C63H57N5O12Na, 1098.4; found: m/z 1098.2.

O-(2-Acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl)-(1→4)-2acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranosyl Azide (2.22)

After a mixture of 2.21 (200 mg, 0.19 mmol), ethylenediamine (1 mL), and 1-butanol (5
mL) was stirred at 90 °C overnight, it was concentrated to dryness under vacuum. The
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resulting residue was dissolved in Ac2O/pyridine (1:2, 3 mL) and stirred overnight at rt.
After the reaction mixture was diluted with EtOAc (50 mL), the solution was washed with
saturated NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated under
vacuum. The residue was purified by silica gel chromatography to give 2.22 as white
foam (156 mg, 91%). NMR data were consistent with literature-reported values.53
MALDI TOFMS: [M-N2+Na]+ calcd for C51H57N3O10Na, 894.4; found: m/z 895.0; [M+Na]+
calcd for C51H57N5O10Na, 922.4; found: m/z 922.8.

Nα-(9-Fluorenylmethoxycarbonyl)-Nγ-[2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-Dglucopyranosyl)-(1→4)-2-acetamido-3,6-di-O-benzyl-2-deoxy-β-Dglucopyranosyl]-L-asparagine tert-Butyl Ester (2.23)

To a solution of Fmoc-Asp-OtBu in CH2Cl2 (10 mL) and NMP (1 mL) was subsequently
added HOBt and DCC. The mixture was stirred at rt for 1 h to give the active ester.
Meanwhile, a mixture of 2.22 and Lindlar’s catalyst in CH2Cl2/MeOH was stirred at rt for
2.5 h under an H2 atmosphere. After filtration through celite and concentration in
vacuum, the resulting residue was dissolved in CH2Cl2 (2 mL), and then the freshly
prepared active ester solution was added (precipitated DCU was filtered off before
addition). The mixture was stirred at rt overnight, concentrated, and purified directly by
silica gel chromatography to give 2.23 as white foam (70%). 1H NMR (500 MHz,
CD3OD-CDCl3 1:5): δ 7.71 (d, 2 H, J = 8.0 Hz), 7.56 (d, 2 H, J = 7.5 Hz), 7.40-7.06 (m,
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32 H), 4.79-4.67 (m, 4 H), 4.61-4.53 (m, 3 H), 4.51 (d, 1 H, J = 10.5 Hz), 4.42 (t, 1 H, J =
5 Hz), 4.40-4.31 (m, 5 H), 4.23 (t, 1 H, J = 7.5 Hz), 4.16 (t, 1 H, J = 7.0 Hz), 4.04 (t, 1 H,
J = 7.0 Hz), 3.96 (t, 1 H, J = 8.5 Hz), 3.84 (t, 1 H, J = 10.0 Hz), 3.64-3.49 (m, 7 H), 3.493.41 (m, 2 H), 3.28-3.23 (m, 1 H), 2.77 (ddd, 2 H, J =16 Hz, 3.5 Hz), 1.78 (s, 3 H), 1.73
(s, 3 H), 1.37 (s, 9 H). MALDI TOF MS: [M +Na]+ calcd for C74H82N4O15Na, 1289.6;
found: m/z 1289.9.

Nα-(9-Fluorenylmethoxycarbonyl)-Nγ-[2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-Dglucopyranosyl)-(1→4)-2-acetamido-3,6-di-O-benzyl-2-deoxy-β-Dglucopyranosyl]-L-asparagine (2.24)

To a solution of 2.23 (55 mg, 43 μmol) in CH2Cl2 (4 mL) was added triethylsilane (0.25
mL) and TFA (1 mL). After the mixture was stirred for 2.5 h at rt, Et3N was added to
quench the reaction, which was then concentrated and subjected to silica gel
chromatography to give 2.24 as white foam (50 mg, 96%). 1H NMR (400 MHz, CD3ODCDCl3 1:5): δ 7.76 (d, J = 7.2 Hz, 2 H), 7.63 (d, J = 7.2 Hz, 2 H), 7.37-7.16 (m, 32 H),
5.71 (d, J = 2.4 Hz, 1 H), 4.78-4.52 (m, 9H), 4.49-4.44 (4 H), 4.39-4.31 (m, 2 H), 4.264.16 (m, 3 H), 3.93-3.73 (m, 6 H), 3.66-3.53 (m, 5 H), 3.37 (s, broad, 1 H), 2.86 (dd, J =
5.6, 16.4 Hz, 1 H), 2.76 (dd, J = 7.2, 15.2 Hz, 1 H), 2.04 (s, 3 H), 1.86 (s, 3 H). MALDI
TOF MS: [M+Na]+ calcd for C70H74N4O15Na, 1233.5; found: m/z 1233.4.
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Resin-Bound Glycopeptide 2.25

Ser-loaded 2-chlorotrityl resin (417 mg, 0.25 mmol) was subjected to eight cycles of
Fmoc-SPPS on an automated peptide synthesizer to prepare resin-bound nonapeptide
2.25 (661 mg, 93% by weight) using HBTU-DIEA as the condensation reagent and 20%
piperidine as the deprotection reagent. The product was then used in the SPPS
construction of glycopeptides 2.15, 2.16, and 2.17.

CD52 Glycopeptide 2.15

A solution of glycosyl amino acid 2.24 (37 mg, 30 μmol), HOBt (8 mg, 60 μmol), and
DCC (12 mg, 60 μmol) in NMP (1 mL) was stirred at rt for 1 h and then transferred to a
SPPS vessel containing resin-bound nonapeptide 2.25 (56 mg, 20 μmol). The mixture
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was shaken at rt overnight under an Ar atmosphere, after which the resin was filtered off
and washed thoroughly with NMP to give solid supported glycopeptide 2.26. After Fmoc
removal with 20% piperidine in NMP, the resin was subjected to two manual FmocSPPS cycles using the benzotriazole active esters of Fmoc-Gln(Trt)-OH and Fmoc-GlyOH to afford the desired peptide sequence. After final Fmoc deprotection and Nterminal acetylation of half of the sample with Ac2O to give 2.27, the resin was treated
with CH2Cl2/AcOH/TFE (8:1:1) at rt for 2 h to release the glycopeptide. The resin was
filtered off and the cleavage mixture was diluted with hexanes and concentrated under
vacuum to give a white solid (13 mg, 42% based on 2.25). To the resulting fully
protected glycopeptide (13 mg, 4 μmol) was added solvent CH2Cl2-MeOH (1:1, 1 mL),
10% Pd/C (13 mg), and a H2 atmosphere. After MALDI MS showed complete reaction,
the catalyst was filtered off and the solvent was evaporated to get the debenzylated
product (8 mg, 78% based on previous step), which was treated with 20% TFA in
CH2Cl2 (1 mL) at rt for 2.5 h. After co-evaporation with toluene and thorough washing of
the residue with diethyl ether, the product 2.15 was lyophilized and then purified by RPHPLC (Supelco Discovery C18, 250 x 10 mm, eluent 2.0% i-PrOH in H2O, 2 mL/min, Rt
= 16.1 min, 2.2 mg, 42% based on previous yield given). 1H NMR (500 MHz, D2O, DHO
at δ 4.79 as reference): δ 5.05 (d, J = 10.0 Hz, 1 H), 4.69 (t, J = 7.0 Hz, 1 H), 4.61 (d, J
= 8.0 Hz, 1 H), 4.55 (t, J = 5.0 Hz, 1 H), 4.51 (t, J = 5.0 Hz, 1 H), 4.47-4.40 (m, 4 H),
4.37-4.32 (m, 2 H), 4.28-4.26 (m, 2 H), 4.01-3.81 (m, 15 H), 3.78-3.74 (m, 4 H), 3.693.64 (m, 2 H), 3.60-3.55 (m, 2 H), 3.52-3.49 (m, 2 H), 2.89 (dd, J = 6.0, 16. Hz, 1 H),
2.77 (dd, J = 7.5, 15.0 Hz, 2 H), 2.69 (dd, J = 6.5, 16.0 Hz, 1 H), 2.42-2.30 (m, 5 H),
2.22-2.11 (m, 2 H), 2.08 (s, 6 H), 2.06-2.04 (m, 2 H), 2.02 (s, 3 H), 2.01-1.99 (m, 2 H),
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1.24 (s, 3 H), 1.23 (s, 3 H). ESI MS: [M+2H]2+ calcd for C63H103N17O35, 828.8401; found:
m/z 828.8364.

3-O-Benzyl-2-deoxy-6-O-(para-methoxybenzyl)-2-phthalimido-β-D-glucopyranosyl
Azide (2.29)

To a solution of 2.28 (2.20 g, 4.86 mmol) in DMF (15 mL) at 0 ºC was added NaH (60%
dispersion in mineral oil, 1.24 g, 7.27 mmol). After stirring for 30 min, benzyl bromide
(0.86 mL, 7.27 mmol) was added to the reaction mixture, which was stirred at rt
overnight. After quenching excess NaH with MeOH, the reaction was concentrated
under vacuum to remove most of the DMF, then diluted with EtOAc and washed with
saturated NaHCO3, brine, dried over Na2SO4, and concentrated under vacuum.
Purification by silica gel chromatography gave the benzylated intermediate (2.11 g, 3.9
mmol, 80%), which was then dissolved in THF and cooled to 0 ºC. To this solution was
added MS 4 Å (1.0 g), NaBH3CN (2.4 g, 39 mmol), and 1.0 M HCl in dry Et2O (to pH 12). After 1 h, MS were filtered off, and the filtrate was diluted with EtOAc. The organic
layer was washed with cold NaHCO3 and brine, then dried over Na2SO4, filtered, and
concentrated under vacuum. Silica gel chromatography gave 2.29 as colorless syrup
(1.9 g, 89%). 1H NMR (500 MHz, CDCl3): δ 7.83-7.71 (m, 4 H), 7.29 (d, J = 8.5 Hz, 2 H),
7.04-6.89 (m, 7 H), 5.36 (d, J = 9.5 Hz, 1 H), 4.75 (d, J = 12.0 Hz, 1 H), 4.59 (d, J = 12.0
Hz, 1 H), 4.53 (d, J = 11.5 Hz, 2 H), 4.26 (dd, J = 8.5, 10.5 Hz, 1 H), 4.08 (dd, J = 9.5,
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10.5 Hz, 1 H), 3.85-3.81 (m, 2 H), 3.82 (s, 3 H) 3.79-3.70 (m, 2 H). ESI MS: [M+Na]+
calcd for C29H28N4O7Na, 567.1832; found: m/z 567.1856.

O-(2-Deoxy-2-acetamido-β-D-glucopyranosyl)-(1→4)-[O-2,3,4-tri-O-benzyl-αfucopyranosyl)-(1→6)]-3-O-benzyl-2-deoxy-2-acetamido-β-D-glucopyranosyl
Azide (2.31)

To a solution of 2,3,4-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl acetate
(75 mg, 0.15 mmol) in CH2Cl2 (2 mL) was added 33% HBr in HOAc (100 μL) at 0 ºC.
After being stirred at rt for 5 h, the reaction mixture was washed with saturated aqueous
NaHCO3 and brine, dried over Na2SO4, and concentrated under vacuum to give
glycosyl bromide 2.30 as syrup that was directly used in the glycosylation reaction. After
a mixture of 2.30 (all product acquired from bromination), 2.29 (40 mg, 0.07 mmol), and
MS 4 Å (50 mg) in dry CH2Cl2 (2 mL) was stirred at rt for 1 h, it was cooled to -50 ºC. To
this mixture was added AgOTf (38 mg, 0.15 mmol). The reaction was then warmed to rt
and stirred for 3 h, at which point the MS were filtered off, and the resulting filtrate was
washed with NaHCO3 and brine, then dried over Na2SO4 and concentrated under
vacuum. The residue was not fully separable by silica gel chromatography, as another
compound co-eluted with the desired disaccharide. Thus, to a solution of the
intermediate in CH2Cl2 (4 mL) was added TFA (0.2 mL) and Et3SiH (0.5 mL). After the
reaction stirred for 2.5 h, it was quenched with Et3N, concentrated, and purified by silica
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gel chromatography to give pure 2.31 (43 mg, 69% yield over two steps). Spectroscopic
data of 2.31 were identical to literature-reported values.39

Nα-(9-Fluorenylmethoxycarbonyl)-Nγ-[2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-Dglucopyranosyl)-(1→4)-[O-2,3,4-tri-O-benzyl-α-fucopyranosyl)-(1→6)]-3-O-benzyl2-deoxy-2-acetamido-β-D-glucopyranosyl]-L-asparagine Allyl Ester (2.35)

Glycosyl azide 2.34 (127 mg, 0.133 mmol) was dissolved in a mixture of CH2Cl2 (1 mL)
and MeOH (3 mL). Lindlar’s catalyst (127 mg) was then added and the reaction was
stirred under a H2 atmosphere at rt for 3 h. After filtration of the catalyst by silica gel, the
reaction was concentrated under vacuum to give the glycosyl amine intermediate.
Meanwhile, to a solution of Fmoc-Asp(OH)-OAll (79 mg, 0.20 mmol) in CH2Cl2 (3 mL)
and NMP (0.1 mL) was added DCC (49 mg, 0.24 mmol) and HOBt (32 mg, 0.24 mmol).
After stirring for 1 h, DCU was filtered off and the active ester solution was directly
transferred to a solution of the glycosyl amine in CH2Cl2 (1 mL). The reaction was stirred
at rt under an Ar atmosphere overnight, then concentrated and purified by silica gel
chromatography to give the glycosyl-Asn conjugate 2.35 (122 mg, 72%). 1H NMR (400
MHz, CDCl3-CD3OD 3:1): δ 7.56 (d, J = 8.0 Hz, 2 H), 7.40 (d, J = 7.2 Hz, 2 H), 7.217.05 (m, 24 H), 5.72-5.65 (m, 1 H), 5.11 (d, J = 16.8 Hz, 1 H), 5.02 (d, J = 10.4 Hz, 1 H),
4.77 (d, J = 11.6 Hz, 1 H), 4.72 (d, J = 11.2 Hz, 1 H), 4.68-4.55 (m, 4 H), 4.44-4.40 (m, 6
H), 4.23 (dd, J = 7.6, 10.8 Hz, 1 H), 4.04-3.99 (m, 2 H), 3.87-3.84 (m, 2 H), 3.74 (dd, J =
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3.2, 9.6 Hz, 1 H), 3.71-3.66 (m, 4 H), 3.62-3.56 (m, 5 H), 3.35-3.27 (m, 4 H), 3.13-3.07
(m, 4 H), 2.62 (dd, J = 6.0, 16.4 Hz, 1 H) 2.49 (dd, J = 4.0, 16.4 Hz, 1 H), 1.77 (s, 3 H),
1.67 (s, 3 H), 0.95 (d, J = 6.4 Hz, 3 H). ESI MS: [M+Na]+ calcd for C72H82N4O19Na,
1329.5414; found: m/z 1329.5471.

Nα-(9-Fluorenylmethoxycarbonyl)-Nγ-[2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-Dglucopyranosyl)-(1→4)-[O-2,3,4-tri-O-benzyl-α-fucopyranosyl)-(1→6)]-3-O-benzyl2-deoxy-2-acetamido-β-D-glucopyranosyl]-L-asparagine (2.36)

To a solution of 2.35 (77 mg, 0.058 mmol) in CH2Cl2/MeOH (1:1, 2 mL) was added Nmethylaniline (100 μL) and Pd(PPh3)4 (12 mg, 0.01 mmol). The reaction mixture was
stirred overnight at rt, then concentrated under vacuum and purified by silica gel
chromatography to give 2.36 (57 mg, 78%). 1H NMR (500 MHz, CD3OD, δ 4.78 as
reference): δ 7.69 (d, J = 7.2 Hz, 2 H), 7.55-7.52 (m, 2 H), 7.29-7.15 (m, 24 H), 4.98 (d,
J = 11.6 Hz, 1 H), 4.90 (d, J = 10.0 Hz, 1 H), 4.84 (d, J = 2.4 Hz, 1 H), 4.71-4.66 (m, 4
H), 4.61 (d, J = 8.8 Hz, 1H), 4.54 (d, J = 10.4 Hz, 1 H), 4.47 (d, J = 11.2 Hz, 1 H), 4.244.23 (m, 3 H), 4.11 (t, J = 6.4 Hz, 1 H), 4.01 (d, J = 5.6 Hz, 1 H), 3.90-3.81 (m, 4 H),
3.78-3.68 (m, 5 H), 3.53 (t, J = 9.6 Hz, 1 H), 3.47-3.42 (m, 2 H), 3.38 (t, J = 9.8 Hz, 1 H),
3.31-3.28 (m, 3 H), 3.19-1.17 (m, 1 H), 2.65 (s, broad, 2 H), 1.91 (s, 3 H), 1.84 (s, 3 H),
1.05 (d, J = 5.6 Hz, 3 H). ESI MS: [M+Na]+ calcd for C69H78N4O19Na, 1289.5116; found:
m/z 1289.5158.
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CD52 Glycopeptide 2.16

A solution of glycosyl amino acid 2.36 (51 mg, 40 μmol), HOBt (12 mg, 90 μmol), and
DCC (18 mg, 90 μmol) in NMP (1 mL) was stirred at rt for 1 h and then transferred to a
SPPS vessel containing resin-bound nonapeptide 2.25 (56 mg, 20 μmol). The mixture
was shaken at rt overnight under an Ar atmosphere, after which the resin was filtered off
and washed thoroughly with NMP to give resin supported glycopeptide 2.37. After Fmoc
removal with 20% piperidine in NMP, the resin was subjected to two manual FmocSPPS cycles using the benzotriazole active esters of Fmoc-Gln(Trt)-OH and Fmoc-GlyOH to give the desired peptide sequence. After final Fmoc deprotection to give 2.38,
half of the resin was treated with CH2Cl2/AcOH/TFE (8:1:1) at rt for 2 h to release the
glycopeptide. The resin was filtered off and the cleavage mixture was diluted with
hexanes and concentrated under vacuum to give a white solid (13 mg, 43% based on
2.25). To the resulting fully protected glycopeptide (13 mg, 4.3 μmol) was added
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CH2Cl2-MeOH (1:1, 1 mL), 10% Pd/C (13 mg), and a H2 atmosphere (MeOH used in the
debenzylation was refluxed with NaBH4 for several hours and then distilled to reduce
any formaldehyde present and thus prevent N-methylation via reductive amination).
After MALDI MS showed complete reaction, the catalyst was filtered off and the solvent
was evaporated to get the debenzylated product (10 mg, 87% based on previous step),
which was treated with 20% TFA in CH2Cl2 (1 mL) at rt for 2.5 h. After co-evaporation
with toluene and thorough washing of the residue with diethyl ether, the product 2.16
was lyophilized and then purified by RP-HPLC (Supelco Discovery C18, 250 x 10 mm,
eluent 1.5% i-PrOH in H2O, 2 mL/min, Rt = 17.9 min, 2.1 mg, 31% based on previous
yield given). 1H NMR (500 MHz, D2O, DHO at δ 4.79 as reference): δ 5.05 (d, J = 10.0
Hz, 1 H), 4.90 (d, J = 4.0 Hz, 1 H), 4.67 (d, J = 8.5 Hz, 1 H), 4.54 (t, J = 5.5 Hz, 1 H),
4.53-4.51 (m, 1 H), 4.49-4.44 (m, 2 H), 4.43-4.40 (m, 2 H), 4.37-4.32 (m, 2 H), 4.27 (t, J
= 6.0 Hz, 1 H), 4.14 (dd, J = 6.5, 13.0 Hz, 1 H), 3.95-3.86 (m, 11 H), 3.85-3.74 (m, 8 H),
3.70-3.68 (m, 2 H), 3.57 (t, J = 8.5 Hz, 1 H), 3.53-3.46 (m, 2 H), 2.90 (dd, J = 5.0, 16.5
Hz, 1 H), 2.86-2.77 (m, 3 H), 2.42-2.37 (m, 4 H), 2.35-2.32 (m, 1 H), 2.21-2.17 (m, 1 H),
2.12-2.10 (m, 1 H), 2.09 (s, 3 H), 2.08-2.04 (m, 2 H), 2.03 (s, 3 H), 2.02-2.00 (m, 2 H),
1.24-1.20 (m, 9 H). MALDI TOF MS: [M+Na]+ calcd for C67H109N17O38Na, 1782.7; found:
m/z 1782.6.
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CD52 Glycopeptide 2.17
BnO

OBn
O

HO
HO
HO

OBn

O
O
BnO
NHAc

O

NH2
Gly
Trt Gln
HN
O

H
N

NHAc O

O
C

Asp-Thr-Ser-Gln-Thr-Ser-Ser-Pro-Ser-2ClTrt
tBu tBu tBu Trt tBu tBu tBu
tBu
2.38
Ac2O, MeOH
CH2Cl2/AcOH/TFE (8:1:1)
Pd-C, H2, CH2Cl2/MeOH
20% TFA, Et3SiH, CH2Cl2
2.17

2.17 was prepared according to the procedure described for the synthesis of 2.16. The
half of resin-bound glycopeptide 2.38 (10 μmol) remaining from the synthesis of 2.16
was treated with Ac2O-MeOH (1:2, 1 mL) at rt for 4 h. The resin was then treated with
CH2Cl2/AcOH/TFE (8:1:1) at rt for 2 h to release the glycopeptide. The resin was filtered
off and the cleavage mixture was diluted with hexanes and concentrated under vacuum
to give a white solid (12 mg, 40% based on 2.25). The remaining deprotection steps
were carried out according to the protocol described for 2.16 to arrive at 2.17, which
was purified by RP-HPLC (Supelco Discovery C18, 250 x 10 mm, eluent 1.5% i-PrOH in
H2O, 2 mL/min, Rt = 17.9 min, 1.9 mg, 28% based on previous yield given).
Spectroscopic data of 2.17 were consistent with literature-reported values.39

Circular Dichroism Spectroscopy
CD spectra of all derivatives were recorded on a Chirascan circular dichroism
spectrometer equipped with a water bath to control the temperature at 25 °C. The
solutions of 2.13, 2.14, 2.15, 2.16, and 2.17 were prepared from dry samples in ddH2O
to give concentrations of 6.6 × 10-2, 3.2 × 10-2, 1.6 × 10-2, 4.2 × 10-2, and 1.8 × 10-2 mM,
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respectively. The molar ellipticity was normalized using the equation

ε=θ/(32.98 × C),

in which θ is the CD absorbance of each peptide analog. The molar ellipticities of 2.13,
2.14, 2.15, 2.16, and 2.17 were normalized from concentrations of 6.6 × 10-2, 3.2 × 10-2,
8.0 × 10-2, 6.2 × 10-2, and 9.2 × 10-2 mM, respectively. Each curve represents the
average of five scans.
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Appendix A: Selected Characterization Data From Chapter 1
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HPLC chromatogram for purification of (±)-9
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HPLC chromatogram for purification of (-)-1.129
Conditions: Waters Nova-Pak Silica 6 μm, 300 x 19 mm
eluent 25% EtOAc in hexanes, 10 ml/min
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Conditions: Waters Nova-Pak Silica 6 μ m, 300 x 19 mm
eluent 20% EtOAc in hexanes, 10 ml/min
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HPLC chromatogram for separation of diastereomers of 1.182
Conditions: Waters Nova-Pak Silica 6 μm, 300 x 19 mm
eluent 30% acetone in hexanes, 10 ml/min
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Doubly charged species: calcd. For C204H264N8O51P2 [M+2NH4]2+ m/z, 1851.8893;
found, 1851.8940.
Mass: 1851.8940
Calculated mass: 1851.8893
ppm error: +2.8ppm
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Appendix B: Selected Characterization Data From Chapter 2

[M+Na] +

307

308

[M+Li]+

[M+Na]+

[M+K] +

309

[M+Na] +

[M-N 2+Na] +

310

OBn
BnO
BnO

O

OBn

O
O
N3
BnO
NHAc 2.22 NHAc

[M-N 2+Na] +

[M+Na] +

OBn
BnO
BnO

O

OBn

O
O
N3
BnO
NHAc 2.22 NHAc

311

312

[M+Na] +

[M-H+2Na] +

313

[M+H+Na] 2+

[M+2H] 2+

[M+2Na] 2+

314

315

[M+Na] +

316

[M+Na] +

317

[M+Na] +

318

[M+Na] +

[M-H+2Na] +

[M-2H+3Na] +

319

320
ABSTRACT
SYNTHESIS OF FUNCTIONALIZED GPI ANCHORS
AND RELATED GLYCOCONJUGATES
by
BENJAMIN M. SWARTS
March, 2010
Advisor:

Zhongwu Guo, B.S, Ph. D.

Major:

Chemistry (Organic)

Degree:

Doctor of Philosophy

This dissertation is divided into two chapters describing the background,
significance, and synthesis of GPI anchors and GPI-anchored molecules. GPI
anchors are a class of complex glycolipids with the primary purpose of attaching
cell surface proteins/glycoproteins to the cell membrane. The first chapter is
focused on the synthesis of functionalized GPI anchors, and begins with an
introductory look at the discovery, structure, biosynthesis, and biological
functions of GPIs. Then, after surveying progress and achievements in GPI
synthesis, including discussion about current strategic shortcomings in the field
that prevent the chemical synthesis of various GPI derivatives, our approach to
accessing uniquely functionalized GPI anchors is described. By employing the
para-methoxybenzyl group for global hydroxyl protection, rather than traditional
benzyl- or acyl-based protection, several functionalized GPI anchors were
synthesized, including GPIs bearing unsaturated lipid chains, an alkynecontaining ‘clickable’ GPI anchor, and a biotinylated GPI anchor.
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In the second chapter, the topic is shifted from the GPI itself to a GPIanchored molecule, namely the human CD52 antigen, which is a 12-amino acid
glycopeptide containing a single N-glycosylation site, to which complex glycans
are attached. This glycoconjugate exists in two distinct functional forms, including
lymphocyte and sperm CD52, which are involved in the human immune and
reproductive systems, respectively. The contrasting biological functions arise
from structural differences in their N-glycan and GPI anchor, raising the topic of
how

N-glycosylation

and

GPI-anchorage

affect

peptide

structure,

and

consequently, activity. To probe this question, we synthesized several CD52
peptides and glycopeptides and compared their conformational profiles using
circular dichroism. This work, as well as brief introductions to N-glycosylation, the
CD52 antigen, and chemical synthesis of glycopeptides are discussed the
second chapter.
Both chapters contain extensive experimental details for the preparation of
all unknown compounds. Appendices A and B provide selected characterization
data, including NMR, MS, and HPLC chromatograms, for chapters 1 and 2,
respectively.
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